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Zusammenfassung 
Biologisch aktive Peptide sind kurze Polymere von einer Länge von bis zu 100 Aminosäuren. 
Sie finden Anwendung in vielen Bereichen der Medizin, von Wirkstoffen gegen Krebs, 
antimikrobiellen Medikamenten bis hin zum Einsatz in der Immuntherapie. Limitierende 
Faktoren für die gängige Nutzung sind jedoch ihre metabolische Instabilität und strukturelle 
Flexibilität, sowie die für Impfstoffe erforderliche Immunogenität. In dieser Studie wurden 
verschiedene, bereits beschriebene, Strategien zur Modifizierung eines Peptids des 
Haemagglutinin Noose Epitop (HNE) des Masernvirus kombiniert, um dessen Stabilität 
gegenüber Peptidasen und die Immunogenität zu erhöhen. 
 
Epitop-Peptide mit substituierten Aminosäuren wurden mit Kernspinresonanzspektroskopie 
untersucht. Die Strukturen einiger Peptide wurden berechnet und die Ergebnisse lieferten 
Informationen über Anforderungen an die Peptidstruktur zur Aufrechterhaltung der 
Antigenität mit HNE-spezifischen Antikörpern. Durch Anwendung dieser Methoden wurden 
die jeweiligen Strategien zur Erhöhung der Biostabilität und Immunogenizität des HNE-
Peptid Modells angepasst. 
 
Die Resultate zeigten, dass HNE-Peptide eine C-terminale α-Helix formen und dass Lys387 
eine wichtige Rolle in der Antigenität spielt. Ausserdem kann der flexible N-terminale 
Bereich einiger substituierten Peptide das Binden von Antikörpern behindern, wenn das 
Peptid unabhängig von den Einschränkungen des Wildtyp-Proteins ist. Der Vergleich unserer 
Peptidstrukturen mit den kürzlich publizierten Röntgenkristallographiestrukturen vom 
Haemagglutinin-Protein vertieften unser Verständnis der Antigenität und bestätigten 
gleichzeitig die strukturelle Ähnlichkeit des Epitops im Protein und der freien HNE-Peptide. 
In den Stabilitäts-Untersuchungen wurden veränderte Peptide mit einer erhöhten Stabilität 
gegenüber Peptidasen in Serum und Intestinalflüssigkeit erfolgreich synthetisiert. Diese 
Peptide mit einer Vielzahl von verschiedenen ausgetauschten Aminosäuren in der Sequenz 
oder Änderungen an den Peptid-Enden, reagierten weiterhin mit Epitop-spezifischen 
Antikörpern. Diese Peptide bewahrten ihre Immunogenität und die induzierten Antikörper 
konnten mit dem Wiltyp-HNE-Peptid als auch mit dem nativen Haemagglutinin-Protein 
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kreuzreagieren, allerdings in geringerem Maße. Trotz ihrer erhöhten Stabilität konnten diese 
Peptide keine bessere Immunantwort hervorrufen. 
Neben den Substitutionen und terminalen Änderungen in der Peptidsequenz, wurden ein 
zyklisiertes und ein gerüstgebundenes HNE-Peptid analysiert. Eine erhöhte Biostabilität und 
eine aufrechterhaltene Antigenität und Immunogenität wurden bestätigt, jedoch erkannten die 
induzierten Antikörper das Wildtyp-Peptid und -Protein nicht. 
 
Zusammenfassend zeigten die Ergebnisse dass es möglich ist die Stabilität von HNE-Peptiden 
deutlich zu erhöhen, aber dass es erhebliche Unterschiede zwischen Antigenität und 
kreuzreagierender Immunogenität gibt, ein bekanntes Problem von kurzen Peptide. Der 
Austausch von Aminosäuren muss bedacht gewählt warden, um die korrekte strukturelle 
Ausrichtung von kurzen Peptiden in Lösung oder in Gerüstkomplexen und somit ihre 
kreuzreagierende Immunogenität zu gewährleisten. 
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Abstract 
Abstract 
Biologically active peptides, short polymers of less than 100 amino acids, are of great 
importance in several fields of medicine, from anticancer and antimicrobial drugs to 
immunotherapy. Their widespread use is however limited by several key problems such as 
their metabolic instability and their conformational flexibility. The use of peptides in vaccines 
faces the additional challenging need for immunogenicity. In this study several previously 
described strategies were combined to modify a peptide of the Haemagglutinin Noose Epitope 
(HNE) of measles virus, to improve its stability against peptidases and increase its 
immunogenicity. 
 
Epitope-peptides with amino acid substitutions were analysed by nuclear magnetic resonance 
spectroscopy. The structures of several of these peptides were resolved and the results 
provided information on the conformational requirements for antigenicity with antibodies 
targeting the HNE. These tools have guided the efforts to enhance biostability and 
immunogenicity of the HNE-peptide model. 
 
The results showed that HNE-peptides form a C-terminal α-helix and that Lys387 plays a 
crucial role in antigenicity. In addition a flexible N-terminal region in several substituted 
HNE-peptides can disrupt antibody binding, when the peptide is removed from the constraints 
of the wild-type protein. Comparisons of these peptide structures with recently published 
crystallography structures of the wild-type Haemagglutinin protein have further increased the 
understanding of the antigenicity and confirmed the structural similarities between the epitope 
in the protein and the shorter free HNE-peptides. 
In the stabilisation studies modified peptides with an increased resistance towards peptidases 
in serum and intestinal fluid were successfully synthesised. These peptides, with a number of 
substitutions in the epitope sequence and modified flanking regions, retained their reactivity 
with HNE-specific antibodies. The peptides were also immunogenic and antibodies raised 
against them were capable of crossreacting with the wild-type HNE-peptide and the native 
Haemagglutinin protein, but with lower reactivity. Despite their increased stability these 
peptides did not induce a better immune response. 
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Additionally to substitutions and additions in the peptide sequence, a scaffold-bound and a 
backbone cyclised HNE-peptide were analysed and their increased stability and conserved 
immunogenicity was demonstrated. However, the induced antibodies failed to crossreact with 
the wild-type peptide and protein. 
 
In conclusion the results showed that the stability of HNE-peptides can be significantly 
increased, but that there is a discrepancy between antigenicity and crossreactive 
immunogenicity that is inherent to these small peptides. Residue changes need to be carefully 
selected to guarantee the correct conformational arrangement of short peptides in solution or 
in constructs and thus their crossreactive immunogenicity. 
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Chapter 1: Introduction 
1. Peptides as therapeutic agents and their role in vaccination 
1.1. Therapeutic peptides 
The therapeutic potential of peptides has been known for 40 years (Freidinger 2003). The 
clinical application of these biologically active peptides, short polymers of less than 50 or 100 
amino acids in length, has been hampered by several key problems such as their metabolic 
instability and their conformational flexibility (Adessi and Soto 2002; Lien and Lowman 
2003; Hans et al. 2006; Sato et al. 2006). Extensive peptide-based research has affected many 
fields of medicine and biology. 
 
Antimicrobial/antibacterial 
 
The current status of antibacterial peptides has been recently reviewed (Lien and Lowman 
2003; Marr et al. 2006). Antimicrobial peptides are part of the innate immune system of 
higher organism, for example magainins, a family of peptides with antibacterial and 
antifungal properties, have been isolated from the skin of the African clawed frog (Xenopus 
laevis) (Zasloff 1987). More than 600 peptides able to recruit elements of the innate immune 
system and capable of killing microorganisms including Gram-negative and Gram-positive 
bacteria, viruses and funghi, have been described. The common features of these peptides are 
a cationic charge and an induced amphiphilic conformation since half of the residues are 
hydrophobic (Powers and Hancock 2003). Molecular dynamics simulations have elucidated 
the mode of action of antimicrobial peptides: they form a pore in the phospholipid membrane, 
which is permeable to both water and lipids (Leontiadou et al. 2006). The main advantage of 
these antimicrobial peptides is their activity against methicillin-resistant Staphylococcus 
aureus and multi-drug resistant Pseudomonas aeruginosa (Zhang et al. 2005). In addition 
there is only a remote possibility of development of complete resistance against these peptides 
due to their mode of action on the membrane and possibly multiple other targets (Marr et al. 
2006). 
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Anti-cancer drugs 
 
Peptides have various potential uses in the treatment of cancers to increase the effectiveness 
of current anti-cancer treatments and to lower their considerable side-effects. Peptides can act 
by enhancing cellular uptake and drug targeting, as well as acting as antigens in cancer 
vaccines (Lien and Lowman 2003). The latter are further described in the Immunotherapy 
section below. 
Matrix metalloproteases (MMP) are capable of degrading the extracellular matrix and are 
thought to play a role in tumour metastasis as high MMP levels are often linked to poor 
prognosis (Stetler-Stevenson et al. 1993; Birkedal-Hansen 1995; Murray et al. 1998; Leeman 
et al. 2002). Koivunen and colleagues have reported the synthesis of cyclic peptides with 
selective inhibitor activity against MMP-2 and MMP-9, and potent antitumour activity 
(Koivunen et al. 1999). 
The group of Freidinger has developed a peptide-cytotoxic drug specifically targeting prostate 
tumours. Prostate specific antigen (PSA) is a protease only produced in prostate epithelium 
and metastasised cells of prostate cancer. Antibody levels induced against circulating PSA are 
used as prostate cancer marker. The peptide component of the drug is a PSA-specific substrate 
and the proteolytic cleavage releases the cytotoxic agent in the close environment of prostate 
cancer cell, thus increasing drug targeting (Freidinger 2003). 
 
1.2. Immunotherapy and the concept of subunit vaccines 
Immunotherapy and more specifically subunit vaccines is the most interesting field of 
peptide-research relating to this work. Traditionally most vaccines are based on whole 
microorganism or virus antigens, either in killed or attenuated form delivered by injection. 
With increasing knowledge of the targets of the immune response, there has been a shift away 
from these classical vaccines towards subunit vaccines. These are reduced to a limited set of 
microbial or viral proteins or even to the smallest immunogenic part of a protein which can 
induce a precisely directed immune response against the infectious pathogen (Purcell et al. 
2007). These minimal regions are called epitopes and in this work, an epitope of the measles 
virus is used as a model (Figure 1). 
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Figure 1: From whole virus to peptide-epitope 
Reductionist approach to vaccine design. Starting from whole measles virus, moving to immunogenic surface 
Haemagglutinin protein to give an immunogenic Haemagglutinin Noose Epitope peptide, capable of inducing a 
crossreactive immune response. 
 
For these synthetic vaccines to mount an effective immune response they need to incorporate 
two different antigenic epitopes: the T cell epitope (TCE) needs to be processed and presented 
by antigen presenting cells (APC) via the major histocompatibility complex (MHCI and 
MHCII) to activate the cell mediated cytotoxic response and combat intracellular infectious 
pathogens. The B cell epitope (BCE) binds to preformed cell receptors and with the help of T 
helper cells (TH) leads to clonal expansion and maturation of antibody secreting B cells 
(Purcell et al. 2007). Even when only an antibody response against a BCE is desired, a TCE is 
still required to induce an effective humoral response (Hans et al. 2006). 
The identification of antigenic determinant amino acid sequences are the prerequisite for the 
successful development of a synthetic vaccine. The methods employed to indentify these 
sequences are described in detail elsewhere (Zauner et al. 2001; Hans et al. 2006) and in the 
context of this work, priority is given to the selection of BCEs. Whereas TCEs are purely 
sequence dependent, the antibody reactive BCEs are related to the structure of the native 
antigen. These structural recognition patterns are usually located at the solvent exposed sites 
of the native proteins and can be formed by continuous amino acid residues, i.e. by sequential 
residues in the primary amino acid sequence, or by discontinuous sequences. These 
discontinuous BCEs are spatial arrangements of residues which are not closely located in the 
primary sequence, but brought together by the folding of protein chains into the secondary 
and tertiary structure, stabilised by disulfide bonds or non covalent interactions (Zauner et al. 
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2001). These epitopes are much more difficult to recreate synthetically, nevertheless this has 
been possible in the case of foot and mouth disease virus (FMDV) epitopes (Villen et al. 
2004). Continuous BCEs can be indentified by PEPSCAN, a method by which a library of 
synthetic peptides with overlapping sequences are screened for their reactivity with sera from 
mice immunised with the infectious pathogen (Hans et al. 2006). This method cannot be 
applied to discontinuous BCEs and thus the identification of these BCEs is more problematic 
(Zauner et al. 2001). 
 
1.3. Use of synthetic peptide-based vaccines in immunotherapy 
There has been extensive research into peptide-based vaccines, but given the long time 
required for the development of these therapeutic vaccines and the only recent advances in the 
field, these synthetic vaccines are only expected to hit the market in the near future. 
 
Cancer therapy 
 
As noted above, peptides can be used in cancer therapy to enhance drug targeting. Another 
attractive possibility is vaccination against cancers. The strategy of anti-cancer vaccination is 
based on the observation that cancerous cells express cell surface antigens not present on 
healthy cells. These tumour associated antigens can be used to develop synthetic peptide-
based vaccines that specifically target cancer cells and by upregulating the cytotoxic immune 
response, can effectively combat tumours (Sahin et al. 1997). Vaccines against a multitude of 
cancers including cervical, lung, breast, colorectal, leukaemia and melanoma cancer, are 
currently in development and have been reviewed elsewhere (Hans et al. 2006; Pietersz et al. 
2006). 
 
Allergies and other diseases 
 
Larché has reviewed the recent advances in immunotherapy for allergic diseases where 
peptide therapy showed promising results in preclinical studies against cat allergens, insect 
venoms and autoimmune diseases and has lead to first clinical studies in humans (Larché 
2007). There has also been an increased interest in vaccination against Alzheimer, a disease 
characterised by the deposition of extracellular β-amyloid (Aβ)-containing plaques. Human 
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clinical trials with Aβ42 containing peptide-vaccines were effective in reducing plaque 
formation but had to be prematurely halted because of severe side-effects. New refined 
peptides vaccines are currently undergoing clinical trials (Hawkes and McLaurin 2007). 
 
Viral infections 
 
The second biggest research area of peptide-based vaccines after anti-cancer vaccines is the 
vaccination against viruses, further advancing our understanding peptide/immune system 
interactions. Examples of peptide-vaccines in development include peptide-epitopes of the 
surface glycoprotein of human respiratory syncytial virus (Beck et al. 2007), influenza, herpes 
simplex virus (Purcell et al. 2007), human papilloma virus and of course several peptide-
epitopes from the surface proteins (gp120 and gp41) of HIV (Hans et al. 2006). 
Even though no peptide-based vaccine has yet been licensed for the human market, the 
feasibility and proof of concept have been confirmed by the successful vaccination of swine 
against FMDV (Wang et al. 2002). The peptide used in this vaccine is based on an epitope of 
the VP1 protein (Bittle et al. 1982) and short synthetic peptides of this region were found to 
induce neutralising antibodies against all seven serotypes of FMDV (Francis et al. 1990). 
 
1.4. Advantages and disadvantages of peptides-based vaccines 
Synthetic peptide-based vaccines offer a number of significant advantages over conventional 
vaccines, which are based on whole organisms, cells or viruses and are heterogeneous 
mixtures of chemicals and biological materials. These can cause important side-effects and 
there is concern about  the risk of reversion to virulent forms of live attenuated virus vaccines 
(Johnson 1999; Greensfelder 2000). In addition not all pathogens can be modified by these 
classical procedures (Zauner et al. 2001; Purcell et al. 2007). The controlled chemical 
synthesis of peptides eliminates the risk of infectious diseases and side-effects thus increasing 
safety. The use of several peptides of the same epitope or several epitopes of the same 
pathogen can potentially bypass genetic restriction arising from mutations in different virus 
strains (Table 1).  
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Table 1: Advantages and drawbacks of peptide-based vaccines adapted from Purcell (2007)and Hans (2006) 
 
Advantages Disadvantages 
 
Absence of infectious material 
 
Low chemical stability of native peptides 
Homogeneous and chemically pure Low conformational stability 
Economically large scale synthesis Poor immunogenicity of simple peptides 
Freeze-dried storage (avoids need for cold-chain) Need for T cell stimulation 
No risk of reversion to virulent strain  
(live attenuated viruses) 
Limited availability of carriers and adjuvants 
HLA restrictions for T cell epitopes 
No risk of genetic integration 
(DNA-Vaccines) 
 
Multiple epitopes of one or more pathogens  
Stabilisation by amino acid modification  
Improved quality control  
 
The development of peptide-based vaccines is hampered by three main interconnected factors: 
poor immunogenicity, chemical and metabolic instability. While the low immunogenicity of 
peptides is in fact a favourable and desirable aspect in the context of peptide drugs, it is the 
pivotal factor in peptide-vaccine design. The poor immunogenicity of peptides is a result of 
their chemical and conformational instability. Short peptides are rapidly removed from the 
circulating system by renal clearance and their in vivo stability is reduced by proteolytic 
degradation. Amino- and carboxyexopeptidases cleave single amino acids, dipeptides or 
tripeptides from the N- and C-termini, respectively, and endopeptidases cleave peptide bonds 
within the peptide sequence. Proteases do not cut peptides with discrete secondary structure 
without unwinding and reverting them to random coils that fit into their β-strand preferring 
active site (Tyndall and Fairlie 1999; Fairlie et al. 2000). Short peptides rarely display a 
defined secondary structure in solution. It is estimated that the longer peptides are, the more 
likely they are to fold into complex structures, burying a number of residues and thus 
increasing the stability towards proteolytic enzymes (Hans et al. 2006). Using this approach 
conformationally restricted epitopes appear to induce better immune responses than the linear 
epitopes (Kaumaya et al. 1992; Sundaram et al. 2004; Dakappagari et al. 2005). The relative 
influence of purely chemical stability and conformational stability becomes blurred as each 
one influences the other. 
In addition to the above listed concrete disadvantages there are doubts that a rational design of 
peptide-vaccines based purely on epitopes and the corresponding contact residues, is 
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achievable. This theory focuses on the relationship between peptide antigenicity, i.e. its ability 
to specifically interact with the antibody paratope, and crossreactive immunogenicity, i.e. the 
ability of the peptide to induce an immune response capable of recognising the parent protein. 
It is feasible to modify a peptide-epitope to increase binding to a monoclonal antibody that 
specifically recognises the epitope’s native parent protein. While this reductionist approach 
down to purely chemical interactions, is possible with respect to antigenicity, the situation 
with immunogenicity is however different since it relies on complex interactions between 
various parts of the immune system. A neutralising antibody can trap a flexible peptide-
epitope in a conformation corresponding to the structure of the native protein. Such an 
engineered peptide is unlikely to induce crossreactive antibodies against the parent protein, 
since its many possible conformations are recognised by a multitude of B cells. The affinity 
maturation is not limited to a single stable conformation but targets a variety of structures, 
thus weakening the specific response (Van Regenmortel 1999, 2001b, 2001a; Dormitzer et al. 
2008). 
Despite these warranted doubts and conceptual difficulties, synthetic peptides mimicking 
BCEs of FMDV and canine parvovirus have been successfully used for vaccinating the 
respective animals (Langeveld et al. 1994; Wang et al. 2002). Also peptide-epitopes of 
measles were shown to induce neutralising and protective antibodies (Obeid et al. 1995; 
Atabani et al. 1997; Putz et al. 2004). 
 
1.5. Engineering peptide-based vaccines – Stabilisation of peptides 
Several strategies have been developed to enhance the metabolic and conformational stability 
of peptides with the aim of improving immunogenicity (Figure 2). Cocktails of purified 
proteases generally do not mimic the complex metabolic behaviour of peptides in vitro and 
the use of homogenates, plasma or serum are more appropriate to investigate the stability of 
peptides (Adessi and Soto 2002). The thought is that the more stable a peptide is, the more 
persistently it can be presented and processed, thus increasing its immunogenicity (Delamarre 
et al. 2006). There are numerous strategies to improve the stability, conformation and 
immunogenicity of peptides-vaccines and only the most relevant will be described here. For a 
complete and extensive list of modifications the reader is referred to recent reviews (Adessi 
and Soto 2002; Webb et al. 2003; Werle and Bernkop-Schnurch 2006; Purcell et al. 2007) 
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Figure 2: Common peptide modifications to increase proteolytic stability 
The location of modifications introduced into linear peptides are illustrated. X and Y represent any chemical 
group or atom. R1, R2 and R3 denote sidechains of natural amino acids. Figure adapted from (Adessi and Soto 
2002) 
 
 
Chemical modifications 
 
Chemically modified peptides can be divided into three groups, depending on the importance 
of the changes to the original sequence and chemistry: (i) modified peptides are peptide 
derivatives with only small modifications which conserve the peptide bonds and the chemical 
nature of peptides. (ii) Pseudopeptides contain mostly peptide bond modifications and 
replacements. (iii) Peptide mimetics are organic molecules that mimic the activity of peptides 
but contain no peptide bonds. In line with the modifications applied in this study the focus 
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will be mainly on modified peptides. The two other groups are reviewed elsewhere (Adessi 
and Soto 2002).  
 
N- and C-terminal modifications 
 
Natural L-amino acid peptides with free N- and C- termini are rapidly degraded in serum. The 
stability of many neuropeptides is known to be dependent on acetylation and amidation, and 
some hormones and peptides are naturally end-protected. These termini modifications have 
been widely employed to block exopeptidase activity and to increase peptide drug 
biostabilities. Mallière and colleagues found that terminal acetylation or amidation of a 13 
residue peptide increased its stability compared to non-modified peptide and that the 
combination of the two modifications further stabilised these peptides (Maillère et al. 1995). 
A similar improvement was achieved in a pentapeptide (Heavner et al. 1986) and by 
alkylation of N-terminal amide (Marschütz et al. 2002). Terminal conjugation with 
polyethylene glycol (PEG) increases the overall size of peptides, decreases renal clearance 
and also protects peptides against exopeptidase degradation, however the lowered 
immunogenicity of some conjugated peptides make this modification only attractive for 
peptide drugs and not for peptide-vaccines (He et al. 1999; Werle and Bernkop-Schnurch 
2006). 
 
Cyclisation 
 
Cyclisation of peptides can function as chemical and/or conformational stabilisation. The 
conformational stability is increased by constraining the peptide in a conformation potentially 
more closely related to the native protein (Putz et al. 2003b). Cyclised peptides can be formed 
either by combining the terminal residues of a peptide sequence or by sidechain-sidechain 
linkage of residues within the sequence. Cyclisation can be achieved by reducing cysteines 
sidechains, by the formation of ester, ether or thioether bridges, and terminal residues can be 
backbone cyclised to give an additional peptide bond. The effects of cyclisation on peptides 
have been reviewed (Adessi and Soto 2002; Werle and Bernkop-Schnurch 2006) and 
cyclisation is an accepted method for reducing proteolytic cleavage and prolonging 
biostability (Clark et al. 2005). Tugyi and colleagues compared the biostabilities of thioether, 
peptide bond and disulfide cyclised peptides compared to their linear analogue and found 
them to decrease in stability as listed (Tugyi et al. 2005a). It should be noted that cyclisation 
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does not always lead to more reactive analogues of linear peptides, as has been shown by the 
cyclisation of a Herpes simplex virus epitope (Schlosser et al. 2003) and anthopleurin A 
epitope (Gould et al. 1992).  
 
Amino acid substitution 
 
Another strategy to improve the biostability of peptides is the replacement of susceptible 
amino acid residues. The substitution residue can be another natural amino acid with a 
chemically similar sidechain or a modified natural amino acid, in order to change the 
recognition site of proteases yet preserve the activity or antigenicity and immunogenicity of 
the peptide (Adessi and Soto 2002). For example methylated Lys in histones are known to 
play an important role in gene regulation and signal transduction (Morgunkova and Barlev 
2006; Paik et al. 2007) and have been shown to increase the stability of microbial peptides 
(Na et al. 2007). Alternatively substitutions with non-natural amino acids such as D-isomers 
and β-amino acids are also known to increase the biological stability of peptides, though their 
chirality and backbone elongation can lead to loss of activity or antigenicity. In the context of 
peptide-based vaccines, the need for conserved antigenicity and structural similarity with the 
parent protein precludes substitution of critical contact residues with D-amino acids. But 
substitution of non-conserved or flanking residues is an interesting approach. Powell and 
colleagues increased the biostability of several peptides by replacing the L-amino acid 
residues at both termini with their respective D-isomers (Powell et al. 1993). D-amino acids 
substitutions of terminal residues of antimicrobial peptides have also increased the proteolytic 
stability in serum and selected proteases without affecting the antimicrobial activity (Hong et 
al. 1999; Hamamoto et al. 2002). Manea and colleagues added D-amino acids and β-amino 
acids as non native flanking regions to a plaque specific β-amyloid epitope and observed the 
same antigenicity than native epitope (Manea et al. 2008). Substitution of flanking residues 
with D-amino acids in an epitope of mucin glycoprotein (MUC2) improved the stability of 
peptides in serum and lysosome homogenates, while preserving antigenicity (Tugyi et al. 
2005b). 
 
In addition to the above, some more extensive modifications have been employed in the 
design of pseudopeptides. Amide bond reduction from the natural amide (CO-NH) to a 
aminomethyl (CH2-NH) in a glycoprotein TCE of lymphocytic choriomeningitis virus, 
substantially increases stability of this peptide in vivo and maintains MHC binding (Stemmer 
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et al. 1999). Recently Reuter and colleagues synthesised a series of retro-inverse peptides 
based on chicken ovalbumin BCEs. Simultaneous reversion of chirality and sequence (Chorev 
et al. 1979), lead to a peptide that is structurally more related to its L-amino acid parent 
peptide than the D-analogue. These peptides displayed an increased stability in murine 
intestinal fluid compared to the natural peptides. Immunisation with these retro-inverse 
peptides induced similar anti-peptide antibody titres than their normal analogues, but failed to 
crossreact with the native ovalbumin protein (Reuter 2008). 
 
Conformational stability 
 
Conformational stability can be increased by conjugating the flexible peptide-epitope to a 
scaffold. Steroids have emerged as an attractive scaffold system due to their rigidity and the 
possibility of variable functionalisation (Barry et al. 1999; Salunke et al. 2006) and bile acids 
have attracted a lot of attention for peptide-conjugation (Kramer et al. 1997). Such a steroidal 
bile acid conjugate incorporating the HNE peptide was synthesised in a collaboration between 
our laboratory and the University of Ghent by Cathy Bodé (Bodé et al.; Bodé 2007; Bodé et 
al. 2007). 
 
1.6. Increasing the immunogenicity of peptides 
As mentioned before, peptides are only poorly immunogenic due to their size related inherent 
flexibility and the low biostability. Besides increasing the chemical and conformational 
stability, the immunogenicity of peptides can be increased by several mechanisms. 
 
Conjugation to carrier proteins 
 
There are suggestions that conjugating labile peptides to poorly digestible carrier proteins can 
partially protect them from proteolytic cleavage (Delamarre et al. 2006). Coupling of atrial 
natriuretic peptide to human serum albumin has been shown to increase it’s stability (Léger et 
al. 2003). Reuter and colleagues have increased the stability of ovalbumin derived peptides in 
muine intestinal fluid by coupling them to cholera toxin B (Reuter 2008). Peptides can be 
conjugated to a large variety of molecules to increase their immunogenicity, for animal 
experiments protein carriers such as bovine serum albumin (BSA), keyhole limpet 
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hemocyanin (KLH), tetanus toxoid (TT) and diphtheria toxoid (DT) are often used. (Zauner et 
al. 2001; Lien and Lowman 2003). These carrier proteins can also supply TCE, which are 
essential for a immunological memory (Zauner et al. 2001). 
 
Oligomerisation 
 
Branching several peptides onto a central polylysine core, via α and ε amino groups, form so-
called multiple antigen peptides (MAP) which can overcome the ineffectiveness of single 
linear peptides to induce an immune response (Tam 1996). Alternatively peptides can be 
assembled into linear chimeric constructs. Branched polyepitope constructs have been shown 
to induce higher antibody titres than carrier-conjugated peptides, with a significantly reduced 
response against the carrier molecule (Hudecz 2001). These MAP also allow the coupling of 
various peptides of the same epitope and peptides of different epitopes of the same or various 
pathogens, thus potentially overcoming the genetic variability of some pathogens such as HIV 
(Hewer and Meyer 2005). 
 
Adjuvants 
 
Adjuvants are substances that trigger or enhance an immune response of antigens that would 
under normal circumstances only be poorly immunogenic. As vaccine development moves 
away from killed or attenuated whole pathogens towards increasingly pure antigens, with 
poorer immunogenicity, there is an increasing and vital need for adjuvants to help elicit 
clinically relevant immune responses. Over the past decades there has been a large expansion 
in the search of new adjuvant (Table 2), yet despite this, only few adjuvants, including Alum 
(aluminium salts) and MF59 (a squalene based oil in water formulation) are currently licensed 
for human use because of stringent regulations. Immunopotentiating reconstituted influenza 
virosomes (IRIVs) incorporate peptides or proteins on the surface of influenza virus like 
particles. A hepatitis A vaccine using this adjuvant has been recently licensed for human use 
(Gluck 1999; Moreno et al. 2001; Westerfeld and Zurbriggen 2005). Alum was first used in 
1926 and has dominated the adjuvant market ever since (Glenny et al. 1926). Even though 
there have been a number of new adjuvants that proved to be as effective as or even more than 
Alum, they were deemed unsuitable for human use due to local and systemic toxicity. The 
most notable examples are Freund’s adjuvant (Freund et al. 1937) and lipopolysaccharide 
(LPS) (Johnson et al. 1956). Freund’s adjuvant is a water in mineral oil emulsion (incomplete 
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Freund’s adjuvant) that can be complemented with heat-killed mycobacteria (complete 
Freund’s adjuvant) and has been routinely used in veterinary medicine and experimental 
immunology for decades because of its very strong adjuvanticity and ease of use. Tolerance 
issues have lead to the development of several substitutes (O'Hagen 2000). 
 
 
Table 2: Short overview of current adjuvant classes 
 
Adjuvant family Adjuvant example References 
 
Mineral salts 
 
Aluminium hydroxide 
 
(Glenny et al. 1926) 
 Aluminium phosphate (Gupta and Siber 1994) 
 Calcium phosphate (He et al. 2000) 
Bacterial products Cholera toxin B subunit (Holmgren et al. 1993) 
 CpG oligonucleotides (Harandi 2004; Agger et al. 2006) 
 E. coli heat-labile enterotoxin 
non-toxic variants LTK63 LTR72 
(Partidos et al. 1996; Giuliani et al. 
1998; Tierney et al. 2003) 
 Monophosphoryl Lipid A (Schneerson et al. 1991) 
 Muramyl dipeptide (MDP) (Cohen et al. 1996) 
Emulsions Freund adjuvant (Freund et al. 1937) 
 Montanide (Aucouturier et al. 2002; Halassy et 
al. 2006) 
 MF59 (Granoff et al. 1997) 
Microparticles virosomes (Gluck 1999; Moreno et al. 2001) 
 ISCOMS (Sjolander et al. 1997) 
Surface-active reagents Saponins (QUIL-A, QS-21) (Dalsgaard 1984; Jackson and 
Opdebeeck 1995; Wong et al. 
1999; Boyaka et al. 2001) 
Cytokines Interleukins (Lynch et al. 2003) 
 Interferons (Odean et al. 1990) 
 
 
 
 
The ideal adjuvant should be non toxic, non immunogenic, generate a depot at the site of 
inoculation, slowly release the antigen, target antigen presenting cells, etc. (O'Hagen 2000; 
Zauner et al. 2001). By differently stimulating Th1 and Th2 T-helper cells, adjuvants can 
modulate the immune response of the host. Despite the increased knowledge of the immune 
system and the use of adjuvants for decades, their mechanisms of actions are still very poorly 
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understood. The family of toll like receptors (TLRs) has emerged as a key element of the 
reactivity of adjuvants (Seya et al. 2006), suggesting that adjuvants activate the innate 
immune response. Several adjuvants are known to act as TLR activators or ligands such as 
unmethylated CpGs and LPS, and initiate a Th1 mediated immune response. Though Alum, 
which stimulates a Th2 response, does not exercise its function through TLRs (Schnare et al. 
2001). Until recently it was also thought that Alum exerted its adjuvant function by depot 
effect , but this has since been disputed (Gupta et al. 1996). 
 
The choice of adjuvants depends on the antigen, the desired immune response and the route of 
inoculation. With the large variety of adjuvants currently in development or clinical trials, this 
choice is not simple. A description of the current adjuvants in development goes beyond the 
scope of this thesis and the reader is referred to recent reviews on adjuvants (Powell and 
Newman 1995; O'Hagen 2000; Vogel 2000; Zauner et al. 2001; Aguilar and Rodriguez 2007; 
Del Giudice and Rappuoli 2007). In an effort to further increase their adjuvanticity, many of 
these adjuvants have been combined and these mixtures of two or more adjuvants are 
reviewed elsewhere (Fraser et al. 2007). 
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2. Measles virus epitopes as models for peptide-subunit vaccines 
2.1. Family and history 
Despite the availability of an effective vaccine, measles, caused by the measles virus (MV), 
remains one of the most important causes of childhood mortality and morbidity worldwide 
with around 200,000 deaths and 20 million infected annually particularly in the developing 
world (WHO 2008). MV is a morbillivirus of the family of paramyxoviridae, which includes 
peste des petits ruminants, dolphin and porpoise morbillivirus, canine and phocoid distemper 
virus. The close phylogenetic relation to rinderpest virus suggests an ancestral virus evolving 
during the early stages of colonisation with close proximity of humans and cattle (Norrby et 
al. 1992). Measles transmission studies in island populations suggests that the critical 
community size is 300,000 to 500,000 (Keeling 1997); population sizes of this magnitude 
were first reached in ancient Egypt and Sumaria around 3000 BC (Griffin 2007). Measles was 
first precisely described by Abu Becr, an Arab physician of the 9th century also known as 
Rhazes of Baghdad (Rhazes 1748; Redd et al. 1999) and has caused millions of deaths over 
the last thousands of years, making it one of the most important human infectious diseases 
(Griffin 2007). 
In the 16th century the disease, together with smallpox, played an important role in the 
conquest of the Americas, disseminating the native Indian population and facilitating the 
colonisation (McNeill 1976). Humans are the only natural reservoir of MV (Griffin 2007). 
The first isolate of MV, the Edmonston strain, was cultured by Enders and Peebles in 1954 
from the blood of an infected child, David Edmonston (Enders and Peebles 1954) 
2.2. Disease and complications 
MV is transmitted from infected persons to susceptible individuals by aerosols or respiratory 
droplets and enters the organism via the respiratory route, where it infects and replicates in the 
epithelial cells. 10-14 days after measles infection the first non specific symptoms of measles 
disease appear: fever, cough, coryza and conjunctivitis. Following the 2-3 day prodrome 
period, the characteristic maculopapular rash starts on the face and behind the ears and then 
spreads centrifugally to the trunk and extremities. The rash lasts for 3-4 days and coincides 
with the immune response, clearance of virus and clinical recovery. Recovery from natural 
 19
Chapter 1: Introduction 
measles infection is accompanied by a lifelong immunity and hence measles is considered a 
childhood disease since older members of a community are protected through previous 
exposure to the virus (Ota et al. 2005; Moss and Griffin 2006; Griffin 2007). 
In 60% of cases, patients remit uneventfully from measles, however malnutrition and age-
extremes increase the risk of complications caused by the immune suppressive character of 
measles, which renders patients more susceptible to secondary viral and bacterial infections 
(Ota et al. 2005). Pneumonia and diarrhoea are the most common complications with the 
former accounting for 56-86% of measles fatalities (Duke and Mgone 2003). 
Rare but serious complications of measles infection can occur in the central nervous system 
within 2 weeks (Post-measles encephalomyelitis). Measles inclusion body encephalitis 
(MIBE) and subacute sclerosing panencephalitis (SSPE) can occur months and even 5-15 
years, respectively, after acute infection and are caused by persistent MV infection (Moss and 
Griffin 2006). 
2.3. Genome, Proteins and Structure 
Measles virus is a negative sense single strand RNA virus of 100-300 nm diameter, whose 
16,000 nucleotides contain 6 genes encoding 8 proteins: Nucleoprotein (N), the 
transmembrane glycoproteins haemagglutinin (H) and fusion (F), matrix protein (M), 
phosphoprotein (P), large protein (L) as well as 2 non-structural proteins, C and V (Figure 3) 
(Griffin 2007). 
Nucleocapsid protein is first expressed and is the most abundant protein. It self assembles, 
complexes with L and P, and binds the viral RNA to form the nucleocapsid, the replicase 
complex of the virus. Nucleocapsid protein is an omnipresent antigen in infected cells and is 
the first target of the immune response, though antibodies are not neutralising due to it’s 
unavailability at the virus surface (Graves et al. 1984). The viral envelope is formed by matrix 
protein and cellular lipid bilayer containing haemagglutinin and fusion proteins.  
M is a basic protein with several hydrophobic domains and links the nucleocapsid 
ribonucleoproteins with the envelope proteins during virion assembly. M-protein plays an 
important role in virion generation and budding (Griffin 2007) but when it is associated with 
the ribonucleoprotein core, it inhibits transcription (Suryanarayana et al. 1994). 
The F-protein is a type I transmembrane glycoprotein and is the most highly conserved 
protein of MV. It is anchored in the virus membrane via the hydrophobic C-terminal tail and 
plays a role in cell-cell fusion. Fusion can be inhibited by the presence of anti-F antibodies. A 
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Cys rich region (F337-381), conserved throughout the paramyxoviridae family, interacts with 
H-protein facilitating virus-cell fusion (Griffin 2007). 
The haemagglutinin protein is a 617 amino acid long type II transmembrane protein expressed 
on the surface of the virus and infected cells. The N-terminal domain is essential for transport 
to the cell membrane and acts as a membrane anchor. It appears as disulfide linked 
homodimers which associate into tetramers on the cell surface (Hu and Norrby 1994). The C-
terminal ectodomain of H with its 13 highly conserved cysteine residues, binds to receptors on 
the cell surface and constitutes the first step in measles infection (Devaux et al. 1996). This 
event is followed by a functional cooperation with F allowing viral entry into the cell by 
attaching and fusing viral envelope to host cell membrane (Moss and Griffin 2006; Griffin 
2007). Initially CD46, a complement regulatory molecule expressed on all nucleated human 
cells, was identified as a cellular receptor (Naniche et al. 1993). Tatsuo and colleagues also 
identified SLAM (lymphocyte activation molecule; CD150) as an additional receptor (Tatsuo 
et al. 2000). Phylogenetic analysis of MV strains show that wt and vaccine strains both use 
SLAM but that vaccine strains have evolved to use ubiquitously expressed CD46 as well. 
There are suggestions that H-protein is not the only receptor binding protein of measles virus 
and that other MV proteins are also capable of facilitating virus entry (Yanagi et al. 2006). In 
addition in-vitro infection independent of CD46 and SLAM have been reported suggesting the 
role of not yet identified (inefficient) ubiquitous receptors (Andres et al. 2003; Griffin et al. 
2008). 
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Figure 3: Schematic representation of MV 
The core of the measles virus consists of a ribonucleoprotein complex incorporating N-protein encapsulated 
RNA associated with the polymerase complex of phosphoprotein and the large protein. The ribonucleocapsid is 
connected via M-protein to an enveloping lipid bilayer incorporating viral transmembrane glycoproteins F and 
H. 
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2.4. Immune response to MV infection 
The wt virus induces a humoral and cellular response leading to live-long immunity against 
reinfection (Panum 1938; Black and Rosen 1962; Graves et al. 1984). Passive immunisation 
with anti-measles antibodies protects against virus infection suggesting that a humoral 
response is sufficient to avoid infection, as demonstrated by the protection of infants by 
maternally transferred antibodies (Albrecht et al. 1977). However cellular immunity is crucial 
for virus clearance after infection (Kaplan et al. 1992). Children with agammaglobulinaemia 
(a disease state in which B-lymphocytes fail to produce antibodies), are able to recover from 
MV infection while defects in T-lymphocyte function lead to severe or fatal disease (Moss 
and Griffin 2006). 
Specific antibodies can be detected at the onset of rash, with IgM appearing first and lasting 
for about 8 weeks. IgG and IgA are detectable a few days after onset and remain for life. IgG 
antibodies are directed against most viral proteins N, M, F and H, with the majority targetting 
N, the most abundant protein of MV (Graves et al. 1984). Only anti-H and anti-F antibodies 
contribute to the neutralisation of the virus (de Swart et al. 2005) and the highest proportion of 
neutralising antibodies is directed against H–protein (McFarlin et al. 1980; Giraudon and 
Wild 1985). 
The immune response against measles is mediated by CD8+ and CD4+ cells. CD8+ cells are 
activated during the prodrome. CD4+ Th1 response is essential for virus clearance while a 
subsequent Th2 response promotes the induction of protective MV-specific antibodies 
(Griffin 1995). The strong efficient and long lasting immune response against MV is in stark 
contrast to the ensuing immune suppression that can last for several months (Tamashiro et al. 
1987) and increases the susceptibility towards secondary infections. While the exact 
mechanism of immune suppression remains poorly understood, several parts of the immune 
system seem to be involved. 
 
2.5. MV-vaccine 
The first vaccine against measles was developed at the end of the 1950s using the Edmonston 
strain. The virus was passaged in primary kidney and amnion cells followed by chick embryo 
cells and chick fibroblasts (Bellini et al. 1994). This passaged virus induced immunity against 
measles causing no or only mild clinical symptoms. No neurological sideffects, frequently 
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associated with measles infection, were observed after intracerebral inoculation of monkeys 
with the adapted virus (Enders et al. 1960). This first attenuated live vaccine (LAV) 
(Edmonston B) was patented as a vaccine in 1963. Later on, several attenuated vaccine strains 
were developed on the basis of wt Edmonston strain. The majority of these strains are still 
being used as vaccine: the Moraten strain is used primarily in the US whereas Schwarz is used 
throughout the world. Nucleotide analysis of M, N, H and F sequences showed no more than 
0.6% differences between the various vaccine strains derived from Edmonston strain (Redd et 
al. 1999). 
Prior to vaccination an estimated 5-8 million fatalities were attributed annually to measles 
with 80 million infected. This trend was significantly reduced with the joint efforts of 
vaccination, the increased nutritional status and the use of antibiotics against secondary 
bacterial infections. Today the vaccine is routinely injected to 9-15 months old children 
throughout the world, often together with Mumps and Rubella vaccine (MMR-vaccine). The 
vaccine has a high seroconversion rate, induces long-term protection against MV infection 
after a single dose and has an excellent safety record (Redd et al. 1999). As one of the most 
successful and cost-effective medical intervention it has resulted in the interruption of 
indigenous measles circulation in a number of developed countries (Finland (Heinonen et al. 
1998) and US (CDC 1997)). Several developing countries, especially in Latin America and 
southern Africa, have made significant progress towards eliminating measles (de Quadros et 
al. 1998; Biellik et al. 2002). 
Vaccination is generally accepted to result in long lasting immunity, accompanied with the 
standard rate of vaccine failure (Markowitz et al. 1990; Cutts et al. 1999; Redd et al. 1999). 
Observation in isolated insular population like Palau have shown that after 27 years of no 
known re-exposure to measles, antibody waning did not increase the risk of infection of 
vaccinees. But they confirmed that a second administration of vaccine was more protective 
than single doses (Guris et al. 1996). There have however been reports of measles outbreaks 
and subclinical measles in highly vaccinated populations (Gustafson et al. 1987; Pedersen et 
al. 1989; Yeung et al. 2005). 
2.6. Drawbacks of the current measles vaccine 
The success of the current measles vaccine has lead the WHO to target measles for 
eradication. Mathematical models estimate that in developed countries herd immunity is 
likely to be lost and endemic transmission of measles possible when herd immunity drops 
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below 93-95% (Meissner et al. 2004). Despite the advantages mentioned previously, the 
current LAV has some important drawbacks that may make it difficult to achieve such levels 
in the final stages of measles elimination. 
 
1) The common drawback of currently used attenuated measles vaccines is their thermal and 
chemical instability, requiring a continuous cold-chain and protection from sunlight; factors 
hindering deployment in third world countries.  
 
2) Since measles vaccine have to be administered subcutaneously or intramuscularly 
specialised health workers are required and hazardous waste of needles and syringes needs to 
be properly disposed of (Moss and Griffin 2006).  
 
3) Contrary to the high efficacy in adults and children immunisation with LAV of infants is 
coupled with a weak immunogenicity (Albrecht et al. 1977; Markowitz et al. 1990; Redd et al. 
1999). The reduced efficacy is caused by the presence of interfering maternal anti-MV 
antibodies (Albrecht et al. 1977; Osterhaus et al. 1998) and by the immaturity of the immune 
system even in the absence of maternal antibodies (Gans et al. 1998; Gans et al. 2001).  
Maternally transferred antibodies via the placenta during gestation protect infants after birth 
from a variety of infections. The presence of anti-measles maternal antibodies interferes with 
seroconversion during LAV vaccination by in vivo neutralisation prior to vaccine virus 
replication (Hayden 1979). While early vaccination is complicated by low seroconversion, 
delayed vaccination to improve seroconversion leaves an important fraction of infants without 
protection if maternal antibodies wane prematurely, until routine vaccination at 15 months is 
performed. Waning of maternal antibodies has been reviewed (Caceres et al. 2000; Leuridan 
and Van Damme 2007). Premature waning of maternal antibodies leads to a susceptibility gap 
during which infants and children are at an increased risk of measles infection. Studies in 
Nigerian infants showed that less than half remain protected by maternal antibodies at the age 
of 4 months (Oyedele et al. 2005) and that there is a considerable difference between maternal 
antibody waning in Nigerian and German infants, as infants from developed countries 
remained protected for a longer period (Hartter et al. 2000). To compensate for this observed 
earlier loss of protection and the danger posed by circulating MV, infants in developing 
countries are vaccinated at 9 months of age (Fagbule and Orifunmishe 1988). Despite the 
success of elimination programmes in Latin America a large outbreak in 1997 originating in 
São Paulo and spreading through other countries showed that under 1 year old and young 
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adults were most affected (Cutts et al. 1999) A recent study (Martins et al. 2008) suggested 
that a new group of children may already lose protective immunity by maternal antibodies at 
the age of 3-5 months. While the authors admit that their study was relatively small, they 
observed a vaccine efficacy of over 80% in 4.5 month old children. However earlier 
vaccination combined with the observed antibody waning in vaccinated individuals raises 
questions about the durability of immunity (Putz 2004; Kremer et al. 2006b). Infants in the 
developed world are protected by herd immunity and the first vaccine injection is 
administered at 15 months of age. 
 
4) Several studies have shown that remission from measles results in higher antibody titres 
than compared to vaccination (Christenson and Bottiger 1994; Bouche et al. 1998; Damien et 
al. 1998) 
 
5) Antibody titres raised via vaccination wane faster than those from naturally infected 
persons (Krugman 1983; Christenson and Bottiger 1994; Davidkin and Valle 1998). This 
phenomenon is likely to be further accentuated by the lack of boosts from subclinical 
infections (Davidkin and Valle 1998; Bennett et al. 1999) by circulating virus as measles 
incidence is reduced. Kremer and colleagues suggest that contact with circulating wt virus 
plays a role in maintaining antibody levels in late convalescent patients (Kremer et al. 2006a). 
At the same time there are fears that vaccinees with incomplete immunity can transmit 
measles during the subclinical phase (Mossong et al. 1999; Whittle et al. 1999). 
 
6) The widespread distribution of HIV in the developing world has implications on measles 
vaccination. A number of studies have reported a lower level of passively transmitted 
maternal antibodies against MV at birth in infants born to HIV-1 seropositive mothers, thus 
widening the window of susceptibility. These children were at a 3.8 fold higher risk of 
acquiring measles before immunisation at 9 months (Embree et al. 1992; Moss et al. 1999; 
Moss et al. 2007; Scott et al. 2007). HIV-1 infected infants reacted better to vaccine 
administration at 6 months of age than at 12-15 months presumably because at 6 months, 
infants were not yet immunocompromised (Rudy et al. 1994; Arpadi et al. 1996). In light of 
these findings the WHO has recommended vaccination of HIV-1 infected infants at 6 months 
and a second dose at 9 months, yet the unknown status of HIV-1 infection in infants render 
this policy difficult to implement (Scott et al. 2007). 
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Despite initial concerns MMR vaccination had long been recommended for HIV infected 
children and generally considered safe (Onorato et al. 1989) until in 1994 an HIV-infected 21-
year old man with haemophilia A died 10 months after receiving his second dose of measles 
vaccine. Measles vaccine is no longer recommended for severely immunocompromised HIV-
infected patients whose immunological status is defined by age-specific CD4+ T lymphocyte 
counts (Moss et al. 1999). 
 
2.7. The need for a new vaccine – experimental measles vaccines 
The need for high herd immunity will put the current measles vaccine to its ultimate test to 
achieve worldwide elimination of measles. In the final stages, small flaws of the current 
vaccine could potentially have wide ranging negative consequences and so, since the mid–
eighties, new generations of measles vaccines and/or new administration routes have been 
investigated (Putz 2004). A recent comprehensive review of those efforts has been published 
(Putz et al. 2003a). These experimental vaccines have been mostly tested in mice and the 
rhesus macaque model has been used to assess the risk of atypical measles. The large variety 
of experimental vaccines is illustrated in Table 3 and Table 4, and includes recombinant viral 
vectors expressing mostly the H- and F-surface proteins of measles, which lead to neutralising 
and protective antibodies in rodents and primates. The bacterial recombinant vectors mainly 
express the N-protein of measles as it is not dependent on the eukaryotic folding machinery. 
The success of neutralisation and protective activity with these vectors were more limited than 
for viral vectors. H- and F-proteins incorporated into ISCOMS with the Quil-A adjuvant 
component, were virus-neutralising and protective in cotton rats and macaques. Synthetic 
subunit vaccines of H- and F-protein epitopes induced neutralising and protective antibodies 
in mice and will be described in further detail later. 
 
One novel area of measles vaccine research focuses on aerosol vaccination. The use of 
nebulised measles vaccine has been trialled in Mexico and South Africa and follow-up studies 
suggest that vaccination via aerosol is as effective as or more effective than subcutaneous 
injection (Dilraj et al. 2007; Low et al. 2008). The WHO has recently started the Measles 
Aerosol Project (WHO 2005) aimed at licensing nebulisers and vaccines for this novel type of 
delivery which avoids the need for needles and the associated risks (de Swart et al. 2006; 
Cohen et al. 2008). There has also been recent research into the feasibility of using dry 
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powder inhalation of measles vaccine to circumvent the need of a cold-chain and the 
reconstitution of the virus (LiCalsi et al. 2001; de Swart et al. 2007), with the need for further 
improvements. Administration of these whole virus based vaccines is however still limited by 
the presence of neutralising maternal antibodies in young infants (Low et al. 2008).  
In what could be considered a twist of fate MV itself has become a possible viral vector (de 
Vries et al. 2008) and live attenuated MV is known to be oncolytic and is thus used in cancer 
research to specifically target cancer cells (Liniger et al. 2007; Gauvrit et al. 2008). 
 
 
Table 3: Experimental measles vaccines in rodents 
 
Experimental vaccine Mode of delivery Immune response References 
 
ISCOMs i.m., s.c. Neutralising Abs, CTL, protection (Varsanyi et al. 1987; Stittelaar et al. 2000a; Wyde et al. 
2000a; Wyde et al. 2000b) 
Recombinant viral vectors      
· Adenovirus vectors i.n., i.p., p.o. CTL, protection (Fooks et al. 1995; Fooks et al. 1998) 
· Poxvirus vectors (replication-competent) i.n., i.p. Neutralising Abs, CTL, protection (Drillien et al. 1988; Wild et al. 1992; Galletti et al. 1995; 
Etchart et al. 1996; Kovarik et al. 2001) 
· Poxvirus vectors (replication-deficient) i.n., i.p. Neutralising Abs, protection (Weidinger et al. 2001) 
· Avian virus vectors i.m., i.p. Neutralising Abs, CTL, protection (Wyde et al. 2000a; Wyde et al. 2000b; Kovarik et al. 
2001) 
· Vesicular Stomatitis Virus i.n., i.p. Neutralising Abs, protection (Schlereth et al. 2000b) 
· Attenuated parainfluenza virus type 3 i.n. Neutralising Abs (Durbin et al. 2000) 
 
Recombinant bacterial vectors  
· BCG i.p. IgG, protection (Fennelly et al. 1995) 
· Streptococcus gordonii s.c. IgG (Maggi et al. 2000) 
· Salmonella typhimurium i.p., p.o. IgG, CTL, protection (Verjans et al. 1995; Fennelly et al. 1999; Spreng et al. 
2000) 
· Shigella flexneri i.n. IgG, CTL (Fennelly et al. 1999) 
 
Nucleic Acid vaccines gene-gun, i.d., Neutralising Abs, CTL, protection (Cardoso et al. 1996; Fooks et al. 1996; Etchart et al. 
1997; Yang et al. 1997; Fennelly et al. 1999; Torres et al. 
1999; Fooks et al. 2000; Schlereth et al. 2000a; Green et 
al. 2001) 
 
Plant based vaccines i.m., i.p. Neutralising Abs (Huang et al. 2001; Webster et al. 2002; Bouche et al. 
2003; Marquet-Blouin et al. 2003; Bouche et al. 2005) 
 
Epitope based vaccines 
· Synthetic peptides of F protein i.n., i.p. Neutralising Abs, protection (Obeid et al. 1995; Atabani et al. 1997; Partidos et al. 
1997; Hathaway et al. 1998) 
· Synthetic peptides of H-protein i.p., i..n. Neutralising Abs, protection (Verjans et al. 1995; El Kasmi et al. 1998; El Kasmi et al. 
1999b; El Kasmi et al. 2000; Spreng et al. 2000; Putz 
2004; Putz et al. 2004; Halassy et al. 2006)  
· “Recombinant peptides” of F protein p.o. IgG, CTL, protection (Verjans et al. 1995; Spreng et al. 2000) 
· Polyepitopes of H-protein i.p. Neutralising Abs (Bouche et al. 2003; 2005) 
 
A summary of experimental measles vaccines in rodents. i.d.: intradermal; i.m.: intramuscular; i.n.: intranasal; 
i.p.: intraperitoneal; p.o.: oral; s.c.: subcutaneous. Table and references adapted from Putz (2003a). 
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Table 4: Experimental measles vaccines in macaques 
 
Experimental vaccine Mode of delivery Immune response References 
   
ISCOMs i.m. Neutralising Abs, CTL, protection (de Vries et al. 1988; Rimmelzwaan and Osterhaus 1995; van 
Binnendijk et al. 1997; Stittelaar et al. 2000a; Stittelaar et al. 
2002c) 
Recombinant viral vectors      
· Poxvirus vectors (replication-competent) i.d., i.m. Neutralising Abs, CTL, protection (van Binnendijk et al. 1997; Zhu et al. 2000) 
· Poxvirus vectors (replication-deficient) i.m., i.n. Neutralising Abs, CTL, protection (Stittelaar et al. 2000b; Zhu et al. 2000; Stittelaar et al. 2001) 
· Attenuated parainfluenza virus type 3 i.n. Neutralising Abs (Skiadopoulos et al. 2001) 
 
Recombinant bacterial vectors  
· BCG i.d., i.n. IgG, CTL (Zhu et al. 1997)  
 
Nucleic acid vaccines gene-gun, i.d. Neutralising Abs, CTL, protection (Polack et al. 2000; Stittelaar et al. 2002b) 
 
Mucosal delivery of live attenuated virus  
 aerosol,  m.-e. under investigation (LiCalsi et al. 1999; LiCalsi et al. 2001; Stittelaar et al. 2002a) 
 
A summary of experimental measles vaccines in macaques. i.d.: intradermal; i.m.: intramuscular; i.n.: intranasal;, 
m.-e.: micro-encapsulated. Table and references adapted from Putz (2003a). 
 
2.8. Subunit vaccines based on measles specific epitopes 
Neutralising epitopes have been described for the fusion (F) and the haemagglutinin (H) 
surface glycoproteins of MV. 
 
Fusion protein 
 
Since anti-F antibodies have been found to protect mice against measles induced encephalitis, 
several neutralising epitopes of the F-protein were identified. Atabani and colleagues screened 
a panel of 15-mer peptide from MV-F with polyclonal sera from African children with acute 
measles and identified the F388-402 region, which is located in a conserved Cys rich domain 
of the F protein, as immunodominant. Immunisations of mice with the 15-mer induced MV-
crossreactive and neutralising antibodies. Passive transfer of the induced anti-peptide 
antibodies protected susceptible mice against encephalitis by challenge with a rodent adapted 
strain of MV (Atabani et al. 1997). Partidos and colleagues tested the F397-420 BCE for its 
immunogenicity and protective capacity against rodent adapted MV-challenge. The peptide 
was immunogenic in two mice strains and did not require the addition of a TCE. Analysis of 
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the fine specificities of induced antibodies showed strain dependent preferences that targeted 
F408-420 in the case of C57BL/6 mice, whereas BALB/c mice recognised the F407-417 
region specifically. Crossreactivity with MV was demonstrated but sera lacked neutralising 
activity. Despite this, passive transfer (BALB/c) of anti-397-420 peptide antibodies and active 
immunisation (C57BL/6) with F397-420 peptide protected mice against neuroadapted MV-
challenge (Partidos et al. 1997). Several chimeric peptides composed of one F404-414 BCE 
and one or two copies of the promiscuous TCE (F288) of the F-protein were analysed in 
several mouse strains and only peptides with two TCE followed by the BCE were found to 
induce a protective response against MV-challenge (Obeid et al. 1995). Intranasal 
immunisation of the above TTB chimeric peptide with cholera toxin b subunit adjuvant 
induced neutralising and protective immunity in mice (Hathaway et al. 1998). A random 
solid-phase combinatorial peptide library identified an 8-mer mimotope, with structural 
similarities to F153-161, which induced MV-crossreactive antibodies, demonstrating the 
potential of mimotopes (Steward et al. 1995). 
While the above mentioned epitopes and immunisations with peptides are promising, the fact 
that they are recognised by human sera, makes it unlikely that they can resist neutralisation by 
maternal antibodies and are thus not compatible with a PRE-vaccine (Protection by antibody 
Resistant Epitopes) (El Kasmi and Muller 2001). 
 
Haemagglutinin protein 
 
Two sequential B cell epitopes of the haemagglutinin protein have been identified in our 
laboratory by screening overlapping peptides with a panel of neutralising and protective 
monoclonal antibodies: H236-256, termed NE, neutralising epitope (Fournier et al. 1997) and 
H386-400 named HNE, haemagglutinin noose epitope (Ziegler et al. 1996). 
 
Neutralising Epitope 
 
Several mAb, induced by immunisation with Edmonston strain, recognised the NE domain 
with different fine specificities, were able neutralise a range of wt-MV strains in vitro and 
protected mice against a challenge with neuroadapted MV. A Lys242Gly mutation occurring 
in 50% of MV is thought to allow some viruses to escape neutralisation by these mAb. These 
anti-NE mAbs are functionally similar to anti-F antibodies as they seem to inhibit virus/cell 
fusion, yet are not able to block virus/receptor binding. Based on the discrepancy between 
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haemolytic activity and haemagglutination, the location of the NE epitope is suggested to lie 
at the functional and/or topographical interface between the F- and H-proteins (Fournier et al. 
1997). Amino acid Arg243, which is part of the core epitope, is known to play a role in the 
downregulation of CD-46 receptor, further confirming the importance of the NE domain 
(Bartz et al. 1996). Using functional fine-mapping with truncation analogues the H236-256 
epitope was narrowed down to the core sequence of S244ELSQL249. Circular dichroism in 
combination with 3D structure homology modelling suggested an α-helical structure for the 
epitope (Deroo et al. 1998). Chimeric peptides were synthesised incorporating the BCE H236-
255 or H236-250 or the 7-mer core epitope H243-250 and various TCEs with varying copy 
numbers and orientations. Several of these chimera peptides induced crossreactive and 
neutralising antibodies and the binding motif of NE was defined as E245LXQL249 using mAbs. 
This binding motif was confirmed by anti-peptide antibodies with similar fine-specificities (El 
Kasmi et al. 1998; El Kasmi et al. 1999b). Passive immunisation with anti-peptide antibodies 
protected mice against a neuroadapted MV strain and immunisation with the peptide-vaccine 
was successful in the presence of MV-neutralising antibodies. These experiments demonstrate 
the potential of using peptide-based vaccines in the presence of maternally transferred 
antibodies (El Kasmi et al. 1999b). These anti-peptide sera were however only able to 
neutralise vaccine strain and none of the wt-field isolates. Several explanations were brought 
forward, such as the influence of low neutralising titres, differences in uptake mechanisms of 
the used cell lines and the Arg243Gly mutation in some field isolates. A phage display 
technique lead to several mimotopes of the NE core peptide which were used for 
immunisation and neutralisation tests. Surprisingly, the mimotopes which bound much more 
strongly to anti-NE mAb than some BCE peptides (up to 135 times) failed to induce MV-
crossreactive antibodies. Even more surprisingly antibodies induced against several BCE 
peptides and which did not bind to mAb, were able to crossreact with and neutralise MV (El 
Kasmi et al. 1999a). These finding show the inherent difficulty of a rational design of peptides 
(El Kasmi and Muller 2001). Recently Oh and colleagues demonstrated that the 10-mer 
H250-259 was a TCE and induced protective immunity against a challenge with recombinant 
vaccinia virus expressing H- and F-proteins of the Edmonston strain (Oh et al. 2006). 
 
 
 
 
 
 30
Chapter 1: Introduction 
Haemagglutinin Noose Epitope 
 
The HNE is the second sequential epitope identified by mAb screening. Three of these mAbs 
(BH216, BH21 and BH6) reacted with MV under non-reducing conditions, neutralised MV in 
vitro and protected mice from a lethal challenge with a neuroadapted MV strain. These three 
mAbs specifically bound 15-mer peptides forming the H381-400 sequence. This fragment 
contains three Cys residues (Cys381, Cys386 and Cys394) which are conserved in all 
morbilliviruses and the 15-mers are not recognised by anti-MV sera of women of child-
bearing age (Ziegler et al. 1996). Two peptides of the HNE-epitope (H386-400 and H379-
400) containing two and three Cys respectively were combined with one or two copies of 
promiscuous TCE in different combinations and orientations. Peptides with the shorter BCE 
induced crossreactive but non-neutralising antibodies. The longer BCE with three Cys 
residues induced crossreactive sera when combined with two copies of the TCE, and these 
sera were also MV-neutralising. These peptides were still immunogenic even in the presence 
of anti-MV antibodies suggesting that maternal antibodies in infants would not interfere with 
the immune responses of such peptides (El Kasmi et al. 2000). Functional fine-mapping of the 
HNE H379-410 epitope (E379TCFQQACKGKIQALCEN396) was performed by synthesising 
substitution and truncation analogues. With the help of truncation analogues the core epitope 
was reduced to Q384ACKGKIQALCEN396. Binding of mAb to PEPSCAN peptides, where 
each amino acid residue of the H379-410 region was replaced with Ala, Glu, Asn, Gln, Arg 
and Ser, showed that none of these amino acid residues were tolerated in positions Lys387, 
Gly388, Gln391 and Glu395, with the exception of Arg in position 387. Thus the binding 
motif of X7C[KR]GX[AINQ]QX2CEX5 with a disulfide bridge was suggested for these 
protective antibodies BH216, BH21 and BH6. Twenty-one distinct HNE sequences found in 
92.9% of all MV-strains, displayed this binding motif and twenty of them reacted with mAb 
BH216. All, except one, wt-MV isolates, containing the above binding motif, were neutralised 
in vitro by these mAb (Putz et al. 2003b). 
Molecular modelling of the HNE-peptide H384-396 by dynamic simulations at 300 K 
(Kelvin) and 1000 K and superposition of the calculated structures showed an astonishingly 
rigid structure (Figure 4). The peptide is a flat circular structure and the hydrophilic residues 
Gln384, Lys387, Lys389, Gln391 and Glu395 are located at what is suspected to be the 
solvent exposed side. The hydrophobic sidechains of Ala385, Ile390, Ala392 and Lys393 are 
directed to the opposite side, most likely buried inside the protein (Putz 2004). 
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Figure 4: Molecular model of the HNE 
Top view (A) and lateral view (B) of 4 representative conformations (peptide backbone as yellow, red, blue and 
orange ribbon) from simulation runs at 1000 K superposed to a conformation (peptide backbone as green ribbon) 
from the simulation at 300 K. Sidechains of critical contact residues are shown in blue, hydrophilic/charged 
sidechains in green, hydrophobic sidechains in pink, disulfide bridge in yellow, peptide backbone as thick ribbon 
(Putz 2004). 
 
 
The immunogenicity of HNE-peptides conjugated to DT and TT were tested in the presence 
of maternally transferred anti-carrier and anti-peptide antibodies and prior vaccination with 
the carriers. Two injections of HNE-peptide-conjugates in mice previously immunised with 
the carrier protein induced similar levels than in naïve mice, demonstrating a lack of epitopic 
suppression. Maternally transferred anti-carrier and anti-peptide antibodies lead to initial 
suppression of the immune response which could be overcome by additional boosting. In 
addition, immunisation with the HNE-peptide-conjugates did not exclude the development of 
an immune response against administered MV as demonstrated by the appearance of anti-F 
antibodies. These experiments further reinforce the potential of the HNE-peptide-based 
vaccine in the presence of maternal antibodies and a subsequent immunisation with the 
current live attenuated MV vaccine (Putz et al. 2004). 
 
The potential of HNE-peptides to elicit crossreactive and neutralising antibodies was 
demonstrated by a series of high-molecular weight polyepitope constructs produced in 
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transgenic plants. While the crossreactivity and neutralising activity of paired multiple copies 
of NE- and HNE-epitopes combined with promiscuous TCEs was highly dependent on the 
molecular environment in which they were displayed, some constructs correctly displayed the 
BCEs (Theisen et al. 2000). Immunisation with extracts from transgenic carrots expressing a 
tandem 8-mer of four copies of the HNE and four copies of a promiscuous TT derived T cell 
epitope, induced MV crossreactive antibodies in mice. These antibodies were also capable of 
neutralising a wide range field of isolates of MV, even those with mutations in the HNE 
binding motif. This may indicate that, in this construct the epitopes may display different 
conformations and induce a broader range of antibodies which may overcome the genetic 
variability of some MV strains and ensure neutralisation (Bouche et al. 2003; 2005). 
 
A recent investigation into alternative administration routes of an HNE-peptide subunit 
vaccine showed that intranasal immunisation with cholera toxin induced antibody at similar 
levels than via intraperitoneal route. In addition immunisation with DT-conjugated HNE-
peptide protected mice against a challenge with neuroadapted MV. Transcutaneous 
administration was less successful, giving lower anti-peptide titres which were only weakly 
crossreacting with native H-protein (Putz 2004). 
 
2.9. The rationale of a peptide -based vaccine against measles 
The NE- and HNE-epitopes, described above, are potential epitope candidates for a peptide-
based vaccine to close the susceptibility gap in newborns and infants. Infants can develop 
efficient antibody responses against proteins, and antibodies against the surface proteins are 
sufficient to protect infants from measles  (Putz and Muller 2003). As demonstrated earlier, 
and contrary to most experimental vaccines which are based on whole virus, the immune 
response against NE and HNE is not suppressed by pre-existing anti-MV antibodies. By using 
measles unrelated carrier proteins such as TT, or promiscuous TCE, a Th2 priming of measles 
specific T cells can be avoided. An anomalous Th2 response has been linked to atypical 
measles (Polack et al. 2002). Children immunised with formalin inactivated measles vaccine, 
were affected by a severe form of measles after exposure to circulating wt-MV (Fulginiti et al. 
1967). The risk of atypical measles hampered the development of new measles vaccines until 
an animal model for the condition was found (Auwaerter et al. 1999; Polack et al. 1999). 
There are also suggestions that the current live attenuated vaccination is possible after 
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vaccination with a peptide-based vaccine. Such a PRE-vaccine (Protection by antibody 
Resistant Epitopes) could provide transient protection of susceptible infants until routine LAV 
vaccine can be administered and thus act as a supplement to the current vaccination schedule 
(El Kasmi and Muller 2001; Putz and Muller 2003). 
3. Study Objectives 
As described in the previous paragraphs a substantial amount of work has been done in our 
laboratory on defining BCEs of MV surface proteins and the feasibility of a peptide-based 
vaccine against measles. Two epitopes of the haemagglutinin protein were described and 
induced neutralising and protective antibodies in mice. 
 
The current study aims to further characterise the structure and define structurally and 
chemically important residues of the HNE-peptide with the objective to stabilise the peptide 
and to increase its immunogenicity. 
 
In a first part, the structure of the wt-HNE-peptide (KGQQACKGKIQALCEN) and several 
modified peptides will be resolved by Nuclear Magnetic Spectroscopy (NMR) and the 
influence of substitution will be analysed both by structural comparisons and by antigenicity 
tests with monoclonal antibodies. These models will shed more light on the structural 
requirements of the HNE-peptide for antibody binding and complement the current dynamic 
modelling structure of the HNE-peptide. The resolved structures will then be compared to the 
X-ray crystallography structures of MV-H-protein that have been published after our 
structural studies and further explain the differences between free HNE-peptides and the 
constraint HNE–epitope in the protein. 
 
In a second step we will use the acquired information from both our resolved NMR structures 
and the previously defined HNE binding motif and rationally apply some of the current 
strategies to increase the metabolic stability of peptides. The antigenicity of these modified 
peptides will be assessed by anti-HNE monoclonal antibodies. These modified and stabilised 
HNE-peptides will then be used in vivo to determine their immunogenicity. 
 
In collaboration with Cathy Bodé at the University of Ghent we will analyse the stability, 
antigenicity and immunogenicity of a bile acid-conjugated scaffold-peptide construct. 
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Coupling the HNE-peptide via its C- and N-termini to the scaffold will decrease the 
degradation by exopeptidases. The structural constraints of the scaffold will reduce the 
flexibility of the HNE-peptide and limit the number of peptide conformations presented to B 
cells during the immunisation, thus strengthening the immune response. 
 
This study will thus further increase our understanding of the HNE-peptide structure, and the 
relationship between stability, antigenicity and immunogenicity in the context of epitope-
peptide-based vaccines. 
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Chapter 2: Materials and Methods 
Part I: Materials 
1. Chemicals and reagents 
Commonly used chemicals were purchased from Sigma Aldrich (Bornem, Belgium) and 
Merck Schuchardt (Hohenbrunn, Germany). All chemicals were used without further 
purification. All cell culture medium and reagents were purchased Lonza (Basel, 
Switzerland).Solvents used in mass spectroscopy were from of MS grade from Biosolve 
(Valkenswaard, The Netherlands) 
 
Compound     Supplier 
acetonitrile (ACN)    Biosolve (Valkenswaard, The Netherlands) 
Tween 20     Sigma-Aldrich (Bornem, Belgium) 
phosphate substrate    Sigma-Aldrich (Bornem, Belgium) 
sodium-iodoacetate    Sigma-Aldrich (Bornem, Belgium) 
s-NHS/EDC     Pierce (Rockford, IL, USA) 
β-mercaptoethanol    Calbiochem (Merck, Darmstadt, Germany) 
dithiothreitol (DTT)    Sigma-Aldrich (Bornem, Belgium) 
3-Hydroxypicolinic acid (HCCA)  Bruker (Bremen, Germany) 
2,5-Dihydroxybenuoic acid (DHB)  Bruker (Bremen, Germany) 
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2. Peptide synthesis reagents and amino acids 
Reagents 
Reagents used for automated peptide synthesis were of peptide synthesis grade. 
 
Compound     Supplier 
dichloromethane (DMF)   Biosolve (Valkenswaard, The Netherlands) 
N-methylpyrrolidone (NMP)   Merck Schuchardt (Hohenbrunn, Germany) 
N-hydroxybenzotriazole (HOBt)  Sigma-Aldrich (Bornem, Belgium) 
piperidine      Merck Schuchardt (Hohenbrunn, Germany) 
N,N'-diisopropylcarbodiimide (DIC) Fluka/Sigma-Aldrich (Bornem, Belgium) 
phenol      Merck Schuchardt (Hohenbrunn, Germany) 
ethanedithiol     Merck Schuchardt (Hohenbrunn, Germany) 
thioanisole (methyl phenyl sulphide) Merck Schuchardt (Hohenbrunn, Germany) 
 
Amino acids and resin 
All natural L- and D-amino acids were from OrpegenPharma (Heidelberg, Germany). 
 
Compound      Supplier 
β-alanine     Novabiochem (Merck, Darmstadt, Germany) 
pamba      Fluka/Sigma-Aldrich (Bornem, Belgium) 
t-amcha     Fluka/Sigma-Aldrich (Bornem, Belgium) 
gaba      Fluka/Sigma-Aldrich (Bornem, Belgium) 
achca      Fluka/Sigma-Aldrich (Bornem, Belgium) 
aib      Novabiochem (Merck, Darmstadt, Germany) 
cha      Novabiochem (Merck, Darmstadt, Germany) 
Norleucine (Fmoc-Nle)   Novabiochem (Merck, Darmstadt, Germany) 
Norvaline (Fmoc-Nva)   Novabiochem (Merck, Darmstadt, Germany) 
diamnio propionic acid (dap)   Bachem (Bubenhof, Switzerland) 
trimethylated Lys    Bachem (Bubenhof, Switzerland) 
dimethylated Lys    Bachem (Bubenhof, Switzerland) 
Fmoc-Rink amide aminomethyl-  Iris Biotech (Marktredwitz, Germany) 
polystyrene resin     
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3. Antibodies 
Compound     Supplier 
anti-MV-H (BH216, BH21, BH6,   in house produced mAb from hybridomas 
BH195) (Ziegler et al. 1996) 
IgG-AP     Southern Biotechnology (Birmingham, AL, USA) 
anti-2,4-D (clone E2/G2)   (Franek et al. 1994) for Borstel Research Centre 
horseradish-peroxidase-labeled   Vector, (Burlingame, CA, USA) 
streptavidin (SA-HRP)    
FITC-labelled goat anti-mouse IgG   Sigma-Aldrich (Bornem, Belgium) 
(Anti-Mouse IgG (Fc specific)  
F(ab’) fragment-FITC)    
4. Buffers and Solutions 
The water used for the buffers and solutions was purified on an Elga Option 4 instrument 
(Elga Labwater, Ede, The Netherlands) 
 
HPLC     
HPLC Solvent A   HPLC Solvent B
100% H2O  80% ACN 
0.1% TFA  20% H2O 
   0.1% TFA 
    
Oxidation and conjugation    
Borate buffer   Ammonium bicarbonate buffer
50 mM boric acid  0.1 M NH4HCO3
150 mM NaCl  pH 7.8  
pH 7.4     
   MES  
   0.1 M MES 
   0.5 M NaCl 
   pH 6  
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ELISA and FACS    
Carbonate buffer   Washing buffer  
0.1 M Na2CO3  154 mM NaCl 
adjusted to pH 9.6 with  1 mM Trisbase 
0.1 M NaHCO3  1% (w/v) Tween 20 
   pH 8  
     
Blocking buffer   Dilution buffer  
15 mM Trizma-Acetate  0.1% (w/v) Tween 20 
136 mM NaCl  in blocking buffer 
2 mM KCl  pH 7.4  
1% (w/v) BSA    
pH 7.4     
     
Substrate buffer   FACS buffer  
1 mM AMP  0.5% (w/v) BSA 
0.1 M MgCL2.6H2O  0.05% (w/v) NaN3
pH 10.2   in PBS  
     
Proteolytic assays    
PBS (Dulbecco’s Phosphate-buffered 
saline)
 PBST  
2.7 mM KCl  0.05% (w/v) Tween 20 
1.5 mM KH2PO4  in PBS  
136 mM NaCl    
8.1 mM Na2HPO4    
pH 7.3     
     
L-PBS (“Lite” PBS)  SIFT CaCl2 buffer
10 mM sodium phosphate  1 mM CaCl2
10 mM NaCl  0.005% (w/v) Tween 20 
pH 7   in SIF  
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SIF-buffer (simulated intestinal fluid)  protease inhibitor cocktail
4.6 mM K  308 nM aprotinin 
111.3 mM Na  20 µM leupeptin 
101.5 mM Cl  400 µM 4-(2-aminoethyl)  
in 8 mM phosphate buffer   benzenesulfonyl fluoride 
pH 7.2   2 mM EDTA 
according to 
(Lockwood and Randall 1949)  
 in L-PBS  
     
 
5. Immunisation 
Animals 
BALB/cOlaHsd mice purchased from Harlan (AD Horst, The Netherlands). They were fed 
standard food and water ad libitum. and kept in cages connected to an air filtering system 
(Tecniplast, Someren, The Netherlands) under timed 12 h light/dark cycles at 22 ± 2 °C and 
40 ± 5% relative humidity. The mice were acclimatised for one week before the start of the 
immunisation studies. All animal experiments were done in compliance with the rules of the 
European Communities Council Directive of 24 November 1986 (86/609/EEC). 
 
Adjuvants and anaesthesiacs: 
Compound     Supplier 
Complete Freund adjuvant   Sigma-Aldrich (Bornem, Belgium) 
Incomplete Freund adjuvant   Sigma-Aldrich (Bornem, Belgium) 
Montanide ISA50V    Seppic (Paris, France) 
Alhydrogel 2% 30mg/mL   Brenntag-Biosector (Frederikssund, Denmark) 
Quil-A      Brenntag-Biosector (Frederikssund, Denmark) 
Ketaminum hydrochloridum   Merial, (Lyon, France) 
(Imalgene®1000) 
Xylazinum hydrochloridum   Bayer (Brussels, Belgium) 
(Rompun®2%) 
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Part II: Methods 
1. Peptide synthesis 
1.1. Solid-Phase Peptide Synthesis principle 
The general principle of Solid Phase Peptide Synthesis (SPPS) is one of addition of protected 
amino acids residues to a solid insoluble support in repeated deprotection and coupling cycles 
giving rise to a growing peptide chain. SPPS was pioneered by Bruce Merrifield (Merrifield 
1963) and without it modern peptide synthesis would be unthinkable. Indeed its introduction 
was deemed so revolutionary and essential that Merrifield was awarded the Nobel Prize in 
Chemistry in 1984. The SPPS method has been described and reviewed in several publication 
and textbooks (Atherton and Sheppard 1989; Merrifield 1997; Chan and White 2000). 
The widespread use of a solid polymer support in peptide synthesis and by extension in 
organic synthesis can be readily explained by the numerous advantages that the technique 
offers in contrast to liquid phase synthesis. Removal of reaction mixture, excess reagents, 
side-products and repeated washing steps can be easily achieved by filtration, leaving only the 
desired product on the solid support behind with minimal loss of product and hence increased 
yield. The use of excess reagents allows to push the reaction equilibria towards near 
completion. The simplicity of dispensing and filtration allows the use of automated systems 
(synthesising robots) to achieve peptide synthesis with significant savings in times and 
manpower. Since SPPS does not accommodate for intermediate purification steps, reagents 
need to be carefully selected to assure fast and near complete reactions as well as to minimise 
the production of side-products, especially insoluble ones. 
In standard SPPS peptides are synthesised starting with their C-terminal amino acid residue, 
which is either already preloaded to the resin or added in the first step of the synthesis. In 
order to avoid side-reactions all reactive amino acid residue sidechains are protected and the 
protecting groups are insensitive to the reagents used throughout the synthesis. To prevent 
multiple additions of the same amino acid residue on the growing peptide chain, the reactive 
α-amine group of the backbone is temporarily protected by either of two approaches: an acid 
labile t-BOC protection developed by Merrifield (Merrifield 1964) or an base-labile Fmoc-
group (Carpino and Han 1972). Since t-BOC-group is cleaved by TFA and Fmoc-group by 
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piperidine it is obvious that the sidechain protections of BOC-amino acids and Fmoc-amino 
acids as well as the selection of resins need to be adapted accordingly. Each amino acid 
residue is added via the unprotected C-terminal carboxy group to the reactive α-amine group 
of the growing peptide chain (or of the resin if first step) by use of a carbodiimide coupling 
reagent. The most common method employed consists of diisopopylcarboiimide as coupling 
reagent and hydrobenzotriaziole (HOBt) to suppress epimerisation (racemisation) Recently 
the introduction of 1H-benzotriazol-1-yloxy-tris(pyrrolidino)phosphonium hexafluoro-
phosphate (PyBOP) has further reduced reaction time, epimerisation and production of toxic 
side-products. After washing away the excess reagents, the α-Fmoc group of the newly 
coupled amino acid is removed and the next residue is added. These cycles are repeated until 
the peptide sequence is completed, after which the peptide is detached from the resin, the 
conditions of which depend on the α amine protecting group. The peptide can be released with 
its sidechain protecting groups still present in case of combinatorial synthesis, or more 
frequently the sidechain protecting groups are removed concurrently with resin cleavage. 
Peptides are then precipitated from the reaction mixture and ready for further modifications or 
purification. 
 
1.2. Peptide synthesis: reactor method 
Peptides were synthesised by automated solid phase peptide synthesis using standard Fmoc 
chemistry on a Syro II peptide synthesiser controlled via SyroXP software (Multisyntech, 
Witten, Germany). Synthesis was carried out either in 400 µL small scale polypropylene tip 
reactors (Multisyntech, Witten, Germany) on a 96 reactor block or in 2 mL large scale 
polypropylene reactors (Multisyntech, Witten, Germany) on a 48 reactor block at RT. For 
large scale 30 mg (small scale: 5 mg) of Fmoc-Rink amide aminomethyl-polystyrene resin 
with a loading density of 0.5-0.8 mmol/g were used. N-terminal Fmoc-protected amino acids 
were dissolved overnight at 4 °C at a concentration of 0.45 M in a 0.65 M HOBt solution in 
NMP with end-over-end rotation. Resins were washed and swollen in DMF and Fmoc group 
was removed by the addition of 300 µL (small scale: 80 µL) of 40% (v/v) piperidine in DMF 
twice for 10 min, each step was followed by 5 washes with 500 µL (small scale: 200µL) of 
DMF. The coupling reactions were started by adding 50 µL of a 3 M DIC solution 
(DMF:DCM, 1:1, v/v) and 300 µL (small scale: 50 µL) of amino acid solution giving an 8 
fold excess of amino acid to resin loading. Reactions were carried out twice for 90 min each, 
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followed by 5 washing steps each. The coupling step was completed by capping of unreacted 
NH2 groups to terminate chain elongation of incomplete coupling reactions, with 300 µL 
(small scale: 80 µL) of a 10% acetanhydride/5% DIPEA solution (v/v) in DMF for 15 min 
and washed 5 times with DMF. Capping solution was freshly prepared every 12 h. 
After completed synthesis the resin was washed extensively with DMF, followed by three 
washes with 2 mL (small scale: 300 µL) of methanol and diethyl ether for 1 min each. Peptide 
sidechain protection removal and peptide cleavage from resin was achieved by adding 2 mL 
(small scale: 300 µL) of TFA solution with 5% H2O, 15% scavenger K (6.5% (w/v) phenol, in 
thianisole:ethanedithiol (2:1)) and rotating end over end for 4 h. Since resin cleavage is faster 
than sidechain deprotection the reaction mixture was filtered into 50 mL tubes after 2 h 
reaction time to avoid resin disintegration. Peptides dissolved in TFA were precipitated and 
washed 3 times with 40 mL (small scale: 8 mL) ice-cold diethyl ether (-80°C). The dried 
pellet was dissolved in 80% tert-butanol, frozen and lyophilised in an Alpha 2-4 lyophilisator 
(Christ, Osterode am Harz, Germany). 
To avoid low yields with longer peptide sequences due to lack of mixing capability of the 
robot station, coupling reactions were carried out manually after amino acid position 25. 
Reactors were removed from the rack and the same volumes of DIC and Fmoc-amino acid 
solutions as described above were added manually and reactions allowed to proceed at RT 
with end-over-end rotation for 2 h. Deprotection, capping and washing steps were performed 
via the robot as described above. 
 
1.3. Peptide synthesis: SPOT method 
In the context of a collaboration with the Research Center Borstel (Division of Mucosa 
Immunology) peptide libraries were synthesised by Dr. Steffen Bade on a cellulose membrane 
support using standard Fmoc-amino acid protection chemistry as described by Frank (Frank 
1992). Briefly, peptide SPOTs were defined by automated application of a Boc-Lys(Fmoc) 
solution on a proline-derivatised cellulose membrane, establishing a cleavable ε-Lys-Pro 
anchor (Bray et al. 1990). Next, the first label, Fmoc-N-γ-(N-biotinyl-3-(2-(2-(3-
aminopropyloxy)-ethoxy)-ethoxy)-propyl)-L-glutamine (Merck Biosciences, Schwalbach, 
Germany), was applied. The peptide was then assembled in a semiautomated cycle using an 
ASP 222 peptide synthesiser (Intavis AG, Cologne, Germany): (i) acetyl-capping, (ii) Fmoc-
deprotection with 20% (v/v) piperidine in DMF, (iii) bromophenol blue staining for synthesis 
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control, (iv) drying, (v) triplicate automatic application of 0.2 µL of DIC-activated amino acid 
solutions (0.2 M Fmoc-protected amino acid in a 0.35 M HOBt in NMP solution). As the last 
synthesis step, the second label 11-(2-(2,4-dichlorophenoxy)acetylamino)undecanoic acid was 
attached. This marker had been previously synthesised in the Research Center Borstel 
(Patents: (Bade et al. 2007a; Bade et al. 2007b); unpublished results Bade et al). For sidechain 
deprotection and diketopiperazine formation of the ε-lysine-proline anchor the membrane was 
incubated in 50% TFA, washed and dried. The SPOTs were punched out and transferred 
individually to polypropylene tubes. Peptides were cleaved from the membrane in 0.1 M 
triethylammonium acetate, 20% ethanol at 30 °C. Lyophilised peptides were dissolved in 1.5 
mL L-PBS with 0.005% (w/v) Tween 20, snap frozen in liquid N2 and stored at -80 °C. The 
peptides were then analysed for their biostability. 
2. Peptide oxidation 
Two methods were used for the oxidation of lyophilised peptides: (i) Purified peptides were 
dissolved and oxidised at 1 mg/mL in a 20% DMSO solution in borate buffer for 5 h at RT 
with end-over-end rotation (Tam et al. 1991). The oxidised and reduced isoforms were 
immediately separated via RP-HPLC and lyophilised. (ii) Crude linear peptides were oxidised 
using an improved oxidation method adapted from Eichler (Eichler and Houghten 1997): 
peptides were dissolved in ammonium bicarbonate buffer at a concentration of 0.5 mg/mL 
and 5 molar equivalents of 0.3% H2O2 (stock 30% w/w, Sigma-Aldrich, Bornem, Belgium) 
were added. Peptides were oxidised at RT for 1 h with end-over-end rotation, after which the 
reaction mixture was quenched with 10% acetic acid (50% of reaction volume). Solutions 
were frozen, lyophilised and dissolved in HPLC starting buffer and purified via RP-HPLC. 
3. HPLC 
3.1. High Performance Liquid Chromatography-principle 
In order to analyse any molecules in great detail purification is essential. A useful tool in the 
purification and characterisation of peptides and proteins is provided by High Performance 
Liquid Chromatography (HPLC) (Lottspeich and Zorbas 1998). The basis of HPLC is the 
reversible interaction of the sample in a liquid mobile phase with a solid stationary phase. 
These interactions can be the result of either polarity, size, charge etc. and the methods used 
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to separate molecules via these interactions differ accordingly: reverse phase HPLC (RP-
HPLC), gel filtration or ion exchange chromatography, respectively. In the context of this 
work RP-HPLC was used. 
Loading of large sample volumes is possible with RP-HPLC as the sample binds to the non-
polar phase due to hydrophobic interactions as soon as it comes into contact with the solid 
phase. Gel chromatography which separates according to size differs in this respect as 
separation of sample mixture occurs immediately after loading and hence is only suitable for 
small sample volumes. After the sample mixture is loaded on the column, the sample is eluted 
with increasing concentrations of organic solvent (often acetonitrile or methanol) and the 
addition of ion pairing agents (e.g. TFA). The retention times of sample on the column 
depends on the amount of hydrophobic and hydrophilic groups present on the surface of the 
molecule and their strong yet reversible interactions with the solid phase. For RP-HPLC the 
solid phase is usually silica based attached aliphatic chains of variable carbon chain length. In 
addition structural changes such as those induced by the formation of disulfide bridges, 
influence retention times. 
HPLC in this work was used either in an analytical or semi-prep context: 
 
3.2. Analytical HPLC 
To assess peptide purity after peptide synthesis, aliquots of peptides in tert-butanol were taken 
and analytical RP-HPLC runs were performed. These runs were also important in determining 
elution and scouting parameters for large scale semi-prep HPLC runs. Typically solutions 
containing 15-50 µg of peptide were diluted to 100uL 10% solvent B in solvent A and 
injected into a RP-HPLC ÄKTAexplorer 10S system (Amersham Biosciences, Uppsala, 
Sweden). Elution was performed on a C18 silica gel column [Grom™Sil media, length: 250 
mm, diameter: 4 mm, pore diameter: 120 Å, particle size: 5 µm] (Grom, Rottenburg-
Hailfingen, Germany) with a linear gradient of 10-100% solvent B in solvent A over 6 
column volumes with a flowrate of 1 mL/min. C18 columns were equipped with a 0.2 µm 
stainless steel filter (Alltech, Lokeren, Belgium) and a pre-column of the same media as the 
main column to avoid damage to the column from insoluble sample components. Elution was 
monitored at 215 nm, 230 nm and 280 nm using a UV monitor and peptides were collected 
via an F950 fraction collector (Amersham Biosciences, Uppsala, Sweden). Peptide mass and 
oxidative status was confirmed by mass spectroscopy. 
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3.3. Semi-preparative HPLC 
Semi-preparative HPLC was used to purify peptides after peptide synthesis and after 
oxidation to separate linear and disulfide cyclised isoforms. Lyophilised peptides and peptides 
in oxidation reaction mixtures containing DMSO were dissolved in 10%-20% solvent B in 
solvent A at a concentration of 1-2 mg/mL. Peptide solutions were injected into a RP-HPLC 
ÄKTAexplorer 10S system (Amersham Biosciences, Uppsala, Sweden) and run over either 
one of two C18 columns [Grom™Sil media, length: 250 mm, diameter: 8 mm, pore diameter: 
120 Å, particle size: 5 µm or Grom™Sil media, length: 250 mm, diameter: 20 mm, pore 
diameter: 120 Å, particle size: 5 µm] (Grom, Rottenburg-Hailfingen, Germany) typically with 
a linear gradient of 25-65% solvent B in solvent A over 6-8 column volumes with a flowrate 
of 3 mL/min and 7 mL/min, respectively. C18 columns were equipped with a 0.2 µm stainless 
steel filter (Alltech, Lokeren, Belgium) and a pre-column of the same media as the main 
column. Elution was monitored at 215 nm, 230 nm and 280 nm using a UV monitor and 
peaks were collected via an F950 fraction collector (Amersham Biosciences, Uppsala, 
Sweden). Peptide solutions were frozen and lyophilised and peptide masses and oxidative 
status were confirmed by mass spectroscopy. 
 
4. Mass spectroscopy: MALDI-TOF 
After synthesis and oxidation reactions, peptide masses and oxidative status were confirmed 
by mass spectroscopy on an Ultraflex MALDI-TOF/TOF (Bruker, Bremen, Germany). 
Ground steel massive target mictotitre plates (MTP 384 Bruker, Bremen, Germany) were 
either coated with a thin layer matrix of HCCA in acetone or positions were individually 
spotted with 0.2 µL matrix mixture (HCCA, DHB; Bruker, Bremen, Germany) and 0.5 µL 
peptide solution containing 5 pmoles of peptide were deposed on spots. After drying, samples 
were recrystallised with 0.5 µL of 80% acetonitrile solution in H20 with 0.1% TFA to ensure 
proper crystallisation homogeneticity. External calibration was performed using tryptic 
digestion of BSA (Bruker, Bremen, Germany) with calibration points covering peptide mass 
range. Spectra were analysed for mass and isotopic distribution in flexAnalysis 2.4 (Bruker, 
Bremen, Germany). Furthermore peptide sequence was confirmed using MS-MS (MS2) post 
source decay fragmentation. 
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5. Biostability 
5.1. Biostability in serum 
To evaluate peptide biostability, peptide solutions (1mg/mL in H2O) were mixed in a 1:1 ratio 
with mouse serum (Harlan, AD Horst, Netherlands, Species: Mouse female, Stock/Strair: 
BALB/cOlaHsd, frozen commercial stock or freshly prepared) and incubated at 37 °C. 
Aliquots of 15 µL were collected and added to 335 µL H2O 0.1% TFA after 0, 24 and 48 h 
and frozen until analysis. The aliquots were filtered over previously pre-washed 30 kDa 
Microcon filters (Millipore, Billerica, MA, USA) and 300 µL of filtrate were injected into an 
ÄKTAexplorer 10S system (Amersham Biosciences, Uppsala, Sweden) over a Zorbax 
300SB-C3 column [length: 150 mm, diameter: 2.1 mm, pore diameter: 300 Å, particle size: 5 
µm] (Agilent, Diegem, Belgium) and C18 column [GromTMSil, length: 250 mm, diameter: 4 
mm, pore diameter: 120Å, particle size: 5µm] (Grom, Rottenburg-Hailfingen, Germany) with 
a linear gradient of 10-100% solvent B in solvent A over 6 column volumes with a flowrate of 
0.5 mL/min and 1mL/min, respectively. Biostability was expressed as percentage of 
remaining intact peptide determined via automated integration of the area under the curve of 
the corresponding HPLC peak at wavelengths 215 nm, 230 nm and 280 nm where 
appropriate. 
 
5.2. Biostability in intestinal fluid 
Biostability analysis using murine intestinal fluid was performed by Dr Steffen Bade at the 
Research Center Borstel (Division of Mucosa Immunology) using a novel patented method 
(Patent: (Gorris et al. 2007); Publication: (Gorris et al. 2009)). Peptide sequences were 
flanked C- and N-terminally with specific markers. After incubation with a variety of 
proteolytic fluids the peptides bind to to specific monoclonal antibody on a plastic support 
plastic support via the N-terminal marker 11-(2-(2,4-dichlorophenoxy) 
acetylamino)undecanoic acid. After several washes the peptides are incubated with horse 
radish peroxidase coupled to streptavidin which binds to the C-terminal biotin of intact 
peptides and detection is measured using the TMB substrate. By employing this method any 
cuts in the sequence by proteases will result in the separation of the two markers and no signal 
will be observed. 
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Proteolysis reactions were carried out in a 96-well polypropylene microtiter plate. Intestinal 
fluids were harvested from excised murine intestines (unpublished results Bade et al). The 
crude enzyme preparation was serially threefold diluted in 80 µL/well of approximately 67 
pM peptide in SIFT CaCl2 buffer. The sealed microtiter plate was incubated for 90 min at 37 
°C before the enzyme reaction was stopped by addition of 80 µL/well of doubly concentrated 
protease inhibitor cocktail. The microtiter plate was resealed, stored for 10 min on ice, heated 
for 10 min to 90 °C, and cooled on ice. From each cavity, 75 µL of the peptide solution was 
transferred into a corresponding cavity of a high-bind 96-well microtiter plate (Corning, 
Wiesbaden, Germany) which had been coated with 75 µL/well of 30 ng/mL anti-2,4-D 
antibody E2/G2 beforehand. The plate was washed three times with 300 µL/well of PBST, 
blocked with 250 µl/well of 1 % (w/v) casein/PBS for 3-4 h at RT, and again washed four 
times with PBST. After 2 h 30 min incubation at RT the plate was washed four times with 
PBST, and incubated for 60 min at RT with 75 µL/well of 1 µg/ml horseradish-peroxidase-
labeled streptavidin in 1 % (w/v) casein in PBS. After six washes with PBST, plates were 
developed with the 3,3’,5,5’-tetramethylbenzidine (TMB) substrate system (Frey et al. 2000). 
For the data analysis the raw data of the pseudo-first order proteolysis reaction were fitted to 
an exponential function according to Gorris and colleagues (Patent: (Gorris et al. 2007) 
Publication: (Gorris et al. 2009)). Hydrolysis half-lives were calculated by nonlinear-
regression and differences between hydrolysis half-lives were analysed statistically. 
 
6. Conjugation to carrier – peptide-conjugates 
6.1. Principle 
Bioconjugation chemistry involves the covalent coupling of two or more molecules to form a 
novel compound which combines the characteristics of the individual components. The 
benefits of bioconjugation chemistry have affected nearly every discipline in life sciences. 
Two interrelated chemical reactions are the basis of bioconjugation: the reactive functional 
groups on the crosslinking or derivatising reagent and the functional groups available on the 
target molecules to be conjugated, in this case short peptides and macromolecules. Without 
the presence and chemical compatibility of these functional groups bioconjugation cannot be 
achieved. Derivatisation of nonreactive groups to functionally useful groups for one particular 
conjugation strategy is of great interest to researchers. Knowledge of the basic chemistry 
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behind coupling reactions between reactive and target functional groups and the careful 
choice of reagent systems selected on the basis of the available functional groups, form the 
prerequisite of a successful and intelligent conjugation strategy. It is of particular importance 
in the context of vaccine and drug research to preserve the in vitro and in vivo characteristics 
of the molecules involved in the bioconjugation, thus the chosen reagents and conjugation 
should not affect functional groups of critical amino acid residues nor impede structure-
activity relationship. In the context of peptide-protein carriers the most commonly used 
functional groups are primary amines, i.e. the N-terminal α-amine or the ε-amine of Lys 
sidechain; and carboxylate groups, i.e. the C-terminal carboxylate, and β- or γ-carboxylate 
groups of Asp and Glu acid sidechains respectively. The amine and carboxylate group linkage 
coupling reaction employs EDC/NHS chemistry. Alternatively coupling reactions using 
sulfhydryl groups of cysteine sidechains are facilated by SPDP chemistry. Hermanson has 
published an extensive guidebook on bioconjugation techniques (Hermanson 1996). 
 
6.2. Method 
Whole tetanus toxoid (TT) (a generous gift from the Serum Institute of India, Hadaspar, Pune, 
India) was modified and conjugated to HNE-peptides using an adapted protocol (Prodhomme 
et al. 2007). First crude whole TT (150 kDa) was purified by buffer exchange using a 10 kDa 
cut-off Amicon Ultra-4 centrifugal filter (Millipore, Billerica, MA, USA) (3500 g, 20 °C, 15 
min) in PBS buffer. Protein concentration was determined by DC Protein Assay (Biorad 
Laboratories, Hercules, CA, USA) according to manufacturer’s recommendation. The purified 
TT solution was adjusted to 1 mg/mL and reduced by a 200 molar excess of DTT for 20 min 
at 50 °C. The reduced proteins were immediately alkylated by the addition of a 400 molar 
excess of sodium-iodoacetate. After 20 min at RT the modified TT was purified by washing 
with MES buffer [0.1 M MES, 0.5 M NaCl, pH 6] using a 10 kDa cut-off Amicon Ultra-4 
centrifugal filter, the solution was adjusted to 10 mg/mL and stored at 4 °C. 
In a next step the available carboxyl groups of TT were activated and coupled with the zero-
length crosslinking Sulfo-NHS/EDC chemistry (N-hydroxysulfosuccinimide/1-Ethyl-3-[3-
dimethylaminopropyl] carbodiimide hydrochloride) to TT in a two step one-pot reaction. First 
2x103 molar equivalents of Sulfo-NHS in H2O and 1x103 molar equivalents of EDC in H2O 
were added to the solution of modified TT and solution was adjusted with MES buffer to a 
final concentration of 1 mg/mL of TT. Reaction was allowed to proceed at RT with end-over-
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end rotation for 15 min after which β-mercaptoethanol was added in a 4x104 molar excess. 
After 10 min a solution of 300 molar excess peptides in PBS-H2O (1:1) was added and 
coupling reaction of activated carboxyl groups of TT to free primary N-terminal α-amine and 
ε-amine of Lys sidechain was carried out overnight at RT in the dark with end-over-end 
rotation. The conjugates were purified by washing with 3 reaction volumes of 50 mM 
ammonium bicarbonate buffer (pH 7.8) using 10 kDa cut-off Amicon Ultra-4 centrifugal 
filters. Protein concentration was measured as above and solutions were stored at 4° C. 
Coupling of peptides to TT was assessed by ELISA with anti-HNE monoclonal antibodies 
BH216, BH21 and BH6. 
 
7. ELISA 
7.1. Indirect Enzyme Linked Immunosorbent Assay 
The principle of Enzyme Linked Immunosorbent Assay (ELISA) is the recognition by 
enzyme linked antibodies of antigens absorbed onto a specially treated plastic support. 
Binding to the plate occurs via hydrophobic interaction between chemical groups on the 
peptide. In order to avoid any other components from the ELISA reaction to bind to the plate 
and lead to non-specific background noise, all free binding sites are blocked by the addition of 
a blocking reagent (e.g. BSA, Casein etc). The bound antigen is then exposed to a purified 
antibody or serum containing antibodies that may (or may not) recognise the coated antigen. 
After the addition of a secondary antibody covalently linked to an enzyme such as alkaline 
phosphatase, the samples are incubated with a substrate solution containing a chromophore 
which is oxidised by the enzyme on the secondary antibody. The colour change of the 
reaction is measured by a spectrophotometer. This method allows to assess the antigenicity of 
a given antigen with regard to specific antibodies or to assess the immunogenicity of a peptide 
by the amount of induced anti-peptide antibodies in sera. The term indirect ELISA is derived 
from the fact that the antibody bound to antigen is not measured directly but via a secondary 
antibody. 
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7.2. Antigenicity of synthetic peptides by indirect ELISA 
To assess the antigenicity of synthetic peptides by monoclonal anti-H-protein antibodies, 
ELISAs were performed in 96-well plates (Maxisorb, Nalge Nunc, Rochester, NY, USA). 50 
µL of twofold dilutions of peptides (starting concentration: 3.2 µM) in carbonate buffer 
adjusted to pH 9.6 were coated overnight at 4 °C. Plates were washed manually with washing 
buffer and blocked for 2 h with 200 µL blocking buffer at RT. Plates were washed again and 
incubated with 50 µL of monoclonal antibody BH216, BH21 or BH6 (1:1000 dilution in 
dilution buffer) for 90 min at RT. After washing, plates were incubated for 90 min at RT with 
50 µL of goat anti-mouse IgG-AP antibody (1:750 in dilution buffer). After washing, plates 
were incubated at 37 °C with 100 µL of a 1.35 mM phosphatase substrate buffer solution. 
Antibody binding was assessed by measuring the optical density at 405 nm after 60 min on a 
SPECTRAmax PLUS384 microplate reader system (Molecular Devices, Sunnyvale, CA, 
USA). Wells with no coated peptide, omitted primary or secondary antibody, or nonspecific 
primary antibody were used as negative controls. wt-HNE-peptide was used as positive 
controls. 
 
7.3. Anti-peptide reactivity of immunised mice sera by indirect ELISA 
Sera from immunised mice were assayed for the presence of peptide-binding antibodies by 
ELISA. The above protocol was adapted as follows: 50 µL of a peptide solution (1.6 µM) or 
125 ng of H-protein in 50 µL were coated in 96-well plates (Maxisorb, Nalge Nunc, 
Rochester, NY, USA) overnight at 4°C using carbonate buffer adjusted to pH 9.6. Plates were 
washed manually using washing buffer and blocked for 2 h with 200 µL blocking buffer at 
RT. Plates were washed again and incubated with 50 µL of a threefold serial dilution of 
mouse serum in dilution buffer for 90 min at RT. After washing, plates were incubated for 90 
min at RT with 50 µL of goat anti-mouse IgG-AP antibody (1:750 in dilution buffer). After 
washing, plates were incubated at 37 °C with 100 µL of a 1.35 mM phosphatase substrate 
buffer solution. Optical density was read at 405 nm after 60 min on a SPECTRAmax PLUS384 
microplate reader system (Molecular Devices, Sunnyvale, CA, USA). Positive controls 
included monoclonal antibodies BH216, BH21 and BH6. Wells with no peptide coated and 
sera from mice immunised with adjuvant or adjuvant and carrier protein (tetanus toxoid) were 
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used as negative controls. Serum end point titres were calculated at five times the response of 
non-immunised mice using the logit-log plot logarithm. 
 
8. Antigen preparation and in vivo animal experiments 
8.1. Antigen preparation 
Prior to injection into animals the peptide-conjugates were combined with their respective 
adjuvants. For the in vivo animal assays all antigen formulations were prepared just prior to 
use and were not stored thereafter to avoid degradation.  
Freund adjuvant water in oil emulsions were prepared by passing 25 µg of peptide-conjugate 
in 100 µL PBS mixed with 100 µL of adjuvant via two 2 mL glass syringes connected via a 
Luer lock constrictor until the solution emulsified. The priming injection formulation was 
prepared using Complete Freund Adjuvant and booster injections were formulated with 
Incomplete Freund Adjuvant. 
Adjuvant preparation with Montanide was performed according to manufacturer’s 
recommendation: 100 µL of peptide-conjugate solution (containing 25 µg conjugate) was 
added to an equal volume of Montanide ISA50V (a kind gift from Seppic, Paris, France), 
vortexed for 30 s and further mixed with five up and down stroked with a syringe. In order to 
achieve a better emulsion that did not separate within a short time, up to thirty up and down 
strokes had to be performed. 
Absorption of peptide-conjugates onto aluminium hydroxide (Alhydrogel 2% 30 mg/mL) was 
performed by adding peptide-conjugate solution (25 µg) to 500 µg of Alhydrogel in 100 µL 
PBS total reaction volume and rotating end-over-end overnight (20 h) at 4 °C. Prior to 
injection samples were diluted to 200 µL with PBS. 
Quil-A, purchased as purified and lyophilised powder, was dissolved to 10 mg/mL solution in 
PBS. 25 µg of peptide-conjugate were mixed with 25 µg Quil-A and diluted in PBS to a final 
injection volume of 100 µL. 
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8.2. Intraperitoneal and subcutaneous route 
Groups of 5-6 specific pathogen-free 11-12 week old female BALB/cOlaHsd mice were 
injected intraperitoneally with 200 µL prepared antigen-formulations (CFA/IFA, Montanide 
and Aluminium hydroxide) or subcutaneously into the scruff of the neck with 100 µL of 
prepared antigen-formulations (Quil-A according to manufacturer’s recommendation) 
containing 25 µg of peptide-conjugate. Booster injections were administered on day 14, 28 
and 42.  
 
8.3. Blood collection 
Mice were put under general anaesthesia by intraperitoneal injection of 200 µL anaesthetics 
solution containing 2.5 mg Ketaminum hydrochloridum (Imalgene®1000) and 50 µg 
Xylazinum hydrochloridum (Rompun®2%). Blood (200 µL) was collected via retro orbital 
bleeding on day 24, 38 and 52. Sera was separated by incubating whole blood samples at 37 
°C for 30 min, followed by centrifugation for 30 min at 3000 g at RT. 
 
9. Flow Cytometry 
9.1. Principle 
Flow Cytometry is an effective method for the identification and characterisation of 
subpopulations of cells such as lymphocytes or assessing the interaction of fluorescence 
labelled molecules with cells. Cells are diluted in saline solution and pass through a laser 
beam in a fluid stream ideally in single file. Flow cytometers that are equipped with a cell 
counter and separator are called fluorescence-activated cell sorter (FACS). In a first step, cells 
are incubated with specific antibodies or mixtures containing antibodies such as sera, 
followed by the addition of a second antibody with a high affinity for the first antibody 
(similar to ELISA). This second antibody is labelled by a chromophore such as fluorescein 
isothiocyanate (FITC). As each labelled or unlabelled cell passes through the laser beam, the 
scattering of light and changes in the wavelength originating from the fluorophore, are 
measured by a series of detectors located in line with the beam or perpendicular to it (forward 
and side scatter, respectively). Light scattering can give important information on the size of 
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the cell and allows setting the calibration to ignore aggregates formed by dead cells. Specific 
absorption and emission of various fluorophores attached to antibodies provides the 
possibility to discriminate between subpopulations (e.g. in lymphocytes) in a single 
experiment (Shapiro 1993). 
 
9.2. Method 
Flow cytometry was used to determine the crossreactivity of mouse sera immunised with 
peptide-conjugates and was performed on a transfected human melanoma cell line (Mel-JuSo-
H) expressing the H-protein of MV. Mel-JuSo-H and Mel-JuSo-wt cells were kindly provided 
by R.L. de Swart (Erasmus University, Rotterdam, The Netherlands (de Swart et al. 1998)). 
Cell stock was thawed and cultured in BioWhittaker® RPMI-1640 medium supplemented 
with 10% FBS-HI, 1% penicillin-streptomycin and 1% L-glutamine or ultraglutamine at 5% 
CO2. To reduce loss of expression of H-protein in Mel-JuSO-H cells, cells were passaged 
only once. On the day of the experiment cells were washed and resuspended in FACS buffer 
and 50 µL added to 1.2 mL tubes at a concentration of 4x106 cells/ml. 50 µL of serum 
dilution (1:50 or 1:100 dilution in FACS buffer) was added, mixed shortly and incubated on 
ice for 30 min. Cells were washed twice with 1 mL FACS buffer and stained for 15 min on 
ice with 50 µL of a 1:200 diluted FITC-labelled goat anti-mouse IgG. Cells were washed 
again twice with FACS buffer and fixed with 0.4% formol. Five thousand cells were counted 
and the fluorescence was measured by flow cytometry on an Epics Elite ESP instrument 
(Coulter Company, Miami, Florida, USA) or BD FACS Canto (BD Biosciences, San Jose, 
CA, USA) as described previously (Muller et al. 1995). Data are expressed as ratios of 
arbitrary fluorescence units (AFU) of immunised sera on Mel-Juso-H and Mel-JuSo-wt cells 
Histogram overlays were produced using WinMDI 2.8. H-protein expression in Mel-JuSo-H 
cells was confirmed by FITC-labelled H-protein specific BH216 monoclonal antibody and by 
mouse sera immunised with MV-H-protein. Negative controls included pre-immunisation 
sera, sera induced against adjuvant alone or against adjuvant carrier (tetanus toxoid) only, 
irrelevant primary antibody and immunised sera on Mel-JuSo-wt cells. 
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10. NMR 
10.1. History and principles 
The description of the intricate workings and details of NMR, couplings and spectroscopy and 
the physics behind these processes are beyond the context of this work. They are explained in 
detail in several textbooks (Williams and Fleming 1995; Lottspeich and Zorbas 1998) and 
with an increased focus on structure determination in Kurt Wüthrichs “NMR of proteins and 
nucleic acids” (Wüthrich 1986). In this chapter only the basics of NMR will be touched upon 
to illustrate the usefulness of the technique for the determination of structures of peptides and 
proteins. 
 
Limitations and comparison to X-ray 
NMR and X-ray crystallography (or X-ray diffraction) are the two major methods for the 
determination of three-dimensional structures of macromolecules and proteins. The two 
methods can be seen as complementary. X-ray crystallography requires the growing of 
crystals and is thus based on solid state. The obvious disadvantages are the difficulty in 
obtaining crystals for a number of molecules and the fact that solid state structure does not 
necessarily represent the structure of the molecule in a liquid physiological environment. 
NMR on the other hand is measured mostly in solution which has significant implications on 
the data obtained. First of all, solution dynamics allow the peptides to adopt a variety of 
structures and energy transfers from one molecule to the next can easily occur, resulting in 
signal averaging. The dynamics of solution phase NMR also allow for kinetic analysis of 
biological processes with real time observation of appearance product specific peaks or the 
disappearance of starting material specific peaks; a process which is useful in reaction kinetic 
and protein folding studies. The disadvantages of NMR include the need for larger amounts of 
sample and the lack of stereospecific resonance assignment. 
The phenomenon of NMR was first observed in 1946 and during the sixties it became a 
routine technique in organic chemistry. After the introduction of the Fourier transformation 
(FT) in the 1970s the field of NMR has expanded enormously. 
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Magnetisation field, free induction decay and Fourier Transformation 
In order for atoms to be visible in NMR they need to have a nuclear spin. Nuclei with odd 
mass numbers have non integer spins and can thus orient themselves in a magnetic field. The 
most important atoms with nuclear spins are 1H and 13C, which have both spins of ½. When 
exposed to an applied magnetic field (B0) these atoms can either align themselves with the 
magnetic field in a low energy state or they can oppose the magnetic field in a high energy 
state. A broad range of radio frequencies is applied to the system and nuclei can be promoted 
to the higher energy state if the radio frequency matches the required energy (Bulk 
magnetisation - M). When nuclei fall back to the low energy state in a process referred to as 
relaxation, energy is released which is measured. Since the differences in energy levels are 
low, NMR is a relatively insensitive method requiring much larger amounts of analytes than 
other spectroscopy methods. The sensitivity and signal to noise ratio can be improved by 
increasing the number of scans, but a much more effective way is to increase the strength of 
the applied magnetic field. With higher field strength the differences between ground and 
excited state are more significant increasing the energy released by relaxing nuclei and hence 
increasing the signal strength. While NMR machines started out using magnetic fields of 60-
100 MHz, most routinely used machines operate in the 400-600 MHz region and high end 
instruments reach up to 950 MHz.  
A radio frequency signal is applied to magnetic field (B0) at a 90° angle for a short time which 
results in an oscillating magnetic field (B1). A receiver coil along one axis records the 
oscillating signal during the relaxation time. The combined signals of all 1H nuclei in a 
sample constitute the free induction decay (FID) and are recorded as a series of decaying 
cosine waves. The Fourier transformation (FT), a mathematical approach to solving the 
complex mix of waves, converts these into frequencies which are plotted against the signal 
amplitude and give a 1D NMR spectrum (An analogy of this is an orchestra whose music also 
consists of large number of sound waves, which are deciphered by our brains into the 
different musical instruments). In Fourier transform NMR the pulses of radio frequencies are 
applied in multiple and quick succession cancelling out noise and giving average signal 
responses. 
 
Chemical shift 
The term chemical shift refers to the shift in frequencies at which nuclei are observed with 
respect to a reference frequency (usually 1H of TMS – Tetramethylsilane). The chemical shift 
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is defined as the difference between the frequency of the peak of interest and the frequency of 
a reference peak, divided by the operating frequency of the instrument: 
)(
)()(
MHzfrequencyoperating
HzHz refs υυδ −=  
The chemical shift has no units and is expressed as ppm. Since it is related to an internal 
standard it is not influenced by the NMR instrument or operating frequency. The scale of δ is 
written right to left (0-10 for 1H ) with high frequency responses appearing to the left in the 
downfield region and low frequency signals appearing upfield. The chemical shift is 
influenced by the environment of the nuclei: each nucleus is surrounded by circulating 
electrons which produce their own electromagnetic fields opposing the applied field. These 
nuclei are shielded and a stronger field is required to achieve resonance in such cases. In 
addition neighbouring atoms and double bonds also effect the shielding of nuclei. 
 
Coupling and Nuclear Overhauser Effect 
An important feature of NMR is the interaction of spins from adjacent nuclei. The spin of one 
nucleus affects the magnetic environment of an adjacent nucleus by transferring some of its 
energy. This interaction can occur in two ways: scalar coupling (or J-coupling) results from 
transfer of energy of nuclei via bonds. This effect is limited to nuclei distant by up to 3 
chemical bonds. The nuclear Overhauser effect (NOE) on the other hand is the interaction 
between magnetic fields of nuclei through space via dipolar relaxation and is detectable over 
short distances of 2-4 Å. This interaction is physically different from scalar coupling. Both of 
these phenomena are the basis of two dimensional NMR and provide information on the 
distance of nuclei in complex molecular arrangements like peptides and proteins and hence 
their structure. 
2D-NMR spectra 
In order to obtain 2D-NMR spectra an additional experimental step is applied to the 
traditional 1D-NMR experiment. As previously the magnetisation of the system is changed by 
bursts of radio frequencies at 90° angle to the established field. Instead of measuring the 
signals immediately an evolution and mixing time is added during which the spins are 
allowed to influence each other (either through space or through scalar spin-spin coupling). 
After the mixing time another series of 90° pulses are applied and the FIDs are acquired. The 
 57
Chapter 2: Methods 
setup of the instrument is arranged so that either spin-spin coupled or through space 
interactions are recorded and displayed diagonally as crosspeaks on a 2D-NMR (Figure 5).  
NH/α-H
NH/β,γ,δ,ε-H α-H/ β,γ,δ,ε-H
γ,δ,ε-H / γ,δ,ε-H
 
Figure 5: 2D TOSCY spectrum of an HNE-mutant peptide  
1D NMR spectra are shown on the axis and intraresidual crosspeaks are shown as 2D spectrum field. The 
diagonal separates the spectrum into a mirror image. The large peak at the centre is caused by water. The 
relevant regions containing intraresidual crosspeaks are highlighted and labelled. 
 
Three major 2D-NMR spectra are routinely used: 
COSY (COrrelation SpectroscopY) is the 2D representation with crosspeaks originating 
through single scalar coupling only. 
In TOCSY (TOtal Correlation SpectroscopY) the magnetisation is successively transferred 
through the entire spin system via scalar coupling. This allows the differentiation of 
overlapping signals of nuclei originating from different spin systems and specific assignment 
of these resonances to their respective spin system, which is essential in structural studies of 
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peptides and proteins. The advantage of TOCSY is the display of entire spins systems of 
amino acids resulting in characteristic patterns for each amino acid. 
NOESY (Nuclear Overhauser Effect SpectroscopY) is a 2D-NMR experiment which 
incorporates all proton-proton interactions through space and is essential in the determination 
of three dimensional structures. The intensities of crosspeaks between protons with a maximal 
distance of approximately 4 Å are inversely related to the sixth of the power of the distance. 
The main benefit of NOESY is that protons which are located far apart in the primary 
structure can induce crosspeaks due to their arrangement in secondary and tertiary structure. 
Crosspeaks of αH of residue (i) to NH of residue (i+1) are used for sequential assignment. 
Crosspeaks of αH(i) to NH(i+3) and NH(i+4) as well as NH(i) to NH(i+2) are characteristic 
of an α-helix. 310 helices show slightly different crosspeaks since they lack αH(i) to NH(i+4) 
but gain αH(i) to NH(i+2) crosspeaks. β-sheets show none of these crosspeaks and only have 
NH(i) to NH(i+1) and αH(i) to NH(i+1) sequential crosspeaks, whose intensities however are 
inverse of helix crosspeaks in the same region (Figure 6). 
 
 
Figure 6: Summary of sequential and medium range 1H -1H NOEs 
NOE pattern of sequential and medium range NOE expected in the standard secondary structures of parallel and 
antiparallel β-sheets, α-helices, 310-helices, tight turns I, II, I’ and II’, and half-turns. The numbers at the bottom 
represent the residue number in the secondary structure elements. Short 1H -1H distances between two residues 
are shown as bars, the thickness of which represent the crosspeak intensities in NOESY and are proportional to r-
6. Figure from (Wüthrich 1986) 
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10.2. Measurements 
4 mg of peptide were dissolved in 350 µL doubly distilled H2O and 350 µL of TFE-d2 or D2O 
were added to give 700 µL with a ±3 mM concentration. 1H-NMR Spectra were recorded on a 
Bruker Avance DMX 600 NMR spectrometer (Bruker, Rheinstetten, Germany) at 300 K with 
mixing times of 110 ms for TOCSY and 250 ms for NOESY. The spectra were referenced to 
residual water residues at 4.8 ppm or TFE signal at 3.95 ppm. 
 
10.3. NMR spectrum analysis and structure calculations 
NMR spectra were processed using XWin NMR software (Bruker, Rheinstetten, Germany). 
The characteristic crosspeak pattern of each amino acid in 50% TFE-d2 was determined in 
amide proton region of 2D-TOCSY 1H NMR spectra (Figure 7). Amide proton to sidechain 
protons crosspeaks within each amino acid allowed the assignment of NH/αH crosspeak to a 
specific residue (Wüthrich 1986). This assignment does not give any indication about the 
residues position in the sequence. Focusing on the fingerprint region of NH/αH in the NOESY 
spectrum, and superposing it on the corresponding region of the TOCSY, showed additional 
peaks, which were used for sequential residue assignment (Wüthrich 1986). Briefly, NOE 
crosspeaks between αH of one residue (i) coupling with HN of the following residue (i+1) in 
the peptide sequence and allows assignment of each amino acid pattern to the residue number 
in the sequence (Figure 8). For example Gly2 has a horizontal crosspeak with Gln3 (NH of 
Gly2 coupling to αH of Gln3). A vertical line down from this crosspeak will lead to αH of 
Gln3. After assignment of each αH peak, chemical shifts were obtained by using the NOESY 
spectrum. Experimental α-proton chemical shifts were compared to random coil chemical 
shifts (Wüthrich 1986), allowing identification of structural elements. According to Hung and 
Samudrala, 1H α-chemical shifts are higher than for random coil structures (downfield) in 
extended structures (β-sheet) and lower than average (upfield) in helices (Hung and 
Samudrala 2003). 
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Figure 7: Characteristic crosspeak patterns of amino acids in TOCSY 
Cutout of 8.8-7.5 ppm (amide region) and 0.08-5 ppm (sidechain region) of 2D-TOSCY shows amino acid 
specific crosspeak patterns which allow assignment of amide crosspeaks to specific residues. 
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Figure 8: Sequential amino acid assignment in fingerprint NOESY region 
Sequential NOE crosspeaks of αH(i) to NH(i+1) in the NOESY fingerprint region (x-axis: 8.8-7.5 ppm and y-
axis: 3.8-4.8 ppm) allows sequential assignment of amino acids. 
 
Spectra were analysed using the AURELIA software (Neidig and Kalbitzer 1990) (Bruker, 
Rheinstetten, Germany) on a Silicon Graphics work station: Threshold level was set 
arbitrarily, standard peak multiplicity was applied, a peak list was created and additional 
peaks were added manually to the list when not detected by the software. Each peak was 
either unambiguously assigned or removed from list. Peak signal integration was performed 
using side chain NH2 signals of Gln as calibration for distance calculation. For manually 
added crosspeaks distances were obtained by comparison (using topographic lines in spectra) 
to known crosspeaks of similar intensities with calculated distances. Since the interpretation 
of NOESY lacks stereospecific resonance assignment of sidechain protons, a theoretical 
proton located centrally with respect to these protons was added via pseudo-atom corrections 
as described by Wüthrich (Wuthrich et al. 1983). Duplicate signals originating from the peaks 
located diagonally in the NOESY spectrum were averaged. If the difference between the 
intensities of identical peaks was greater than 0.5 Å, signals were analysed for splitting or 
fusion with nearby peaks and corrected accordingly. 
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Structure calculations were performed using the protocol embedded in the CNSsolve software 
1.0 (Brunger et al. 1998) starting with an extended peptide backbone and incorporating the α-
proton chemical shifts and NOE data. Initial calculations were computed for 20 structures and 
NOE with distance violations above 0.5 Å which occurred in 4 or more structures were re-
examined carefully in NOESY and distance corrections were applied if necessary. Several 
rounds of such structure refinement were performed and the cut-off for distance violations 
was lowered to 0.2 Å. In a final step 100 structures were computed using the refined distance 
constraints; these were sorted according to lowest number of 0.2 Å distance violations, 
followed by the lowest ENOE and lowest ETotal. The 20 lowest energy structures were further 
analysed in superposition studies to determine the central structure. Finding an objective and 
optimal fitting region for the 20 structures is essential to determine the structure with the 
lowest overall RMSD. Pairwise RMSD were calculated using the consecutive segment 
method (Blankenfeldt et al. 1996). Short segments of two, three, four and five residues in 
length were compared pairwise for all 20 lowest energy structures by the INTRMS 
programme. For instance, in the case of 3 residue segment length, segments Lys1-Gln4, then 
Gly2-Ala5, Gln3-Cys6 up to Leu13-Asn16 were compared for each structure. The RMSD of 
the backbone atoms calculated for these fragment were assigned to each residue within the 
segment. In the three-residue segment calculations, each residue is present in three segments, 
with the exception of the two C- and N-terminal residues of the sequence. Finally the average 
of each assigned value was attributed to the residue in question and plotted against the 
sequence. The resulting plot was used to determine the best fitting regions for allows a section 
for fitting with an RMSD of 0.2, 0.4 or 0.6 Å (Figure 9). After combining the separate pdb 
files of the 20 structures to a single pdb file with the MOLEMAN2 module (Uppsala Software 
Factory, Sweden), LSQMAN calculation (Uppsala Software Factory, Sweden)(Kleywegt 
1996) was performed to determine the central structure with the lowest RMSD to a 
hypothetical mean of all 20 structures within a defined region, selected by the consecutive 
segment method. The LSQMAN module also calculated RMSD values of each structure to 
the central structure for the fitted region. 
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Figure 9: Mean RMSD for backbone atoms 
Mean RMSD for backbone atoms in each residue are shown, calculated using consecutive segment method (2-5 
amino acid segment length) and plotted against residue number for the 20 lowest energy structures 
 
11. Molecular Modelling 
Visualisation and analysis of pdb structure files was performed using a variety of software 
including BRAGI (Schomburg and Reichelt 1988); Pymol, an open-source projected 
maintained by DeLano Scientific LLC; ViewerLite 4.2 (Accrelys, San Diego, CA, USA) and 
Deepview/Swiss-PdbViewer 3.7 (Guex and Peitsch 1997). All the figures of resolved NMR 
structures in this work have been created with Pymol. Figures of amino acids or chemical 
compounds were created with MDL ISIS™/Draw 2.5 (MDL, San Ramon, CA, USA). 
 
12. Statistical analysis 
Statistical analysis was performed using SigmaStat 3.1 and SigmaPlot 9.0. Serum end point 
titres from ELISA and AFU ratios from flow cytometry experiments were analysed 
individually and plotted in boxplot with average values shown as horizontal line and the box 
area covering 75% data points. Data were analysed by One Way ANOVA logarithm and 
statistical significance was quantified by Student-Newman-Keuls test unless stated otherwise, 
with statistical difference being at least p<0.05. Half-lives from biostability tests with murine 
intestinal fluids were analysed using outlier analysis (extreme studentised deviate method), 
One Way ANOVA and the Bonferroni post hoc test. Statistical and regression analyses were 
performed on GraphPad Prism version 5.01 for Windows (GraphPad Software, San Diego, 
CA, USA). For all statistical analyses a probability of p<0.05 was considered significant.
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Part I: Structures 
1. NMR 
1.1. Measurements and α-proton chemical shifts 
A series of HNE-peptides with substitutions in the epitope core (KGQQACKGKIQALCEN), 
which was previously defined in our laboratory (Putz et al. 2003b), were synthesised. These 
peptides were analysed by NMR and observations of α-chemical shifts highlighted structural 
differences between them and the wt-HNE-peptide, as α-proton chemical shifts are known to 
be dependent of the secondary structure of peptides and proteins. α-protons located in α-
helices experience an upfield shift in four consecutive residues when compared to chemical 
shifts of protons in random coil conformation (Wüthrich 1986). A downfield shift in three 
consecutive residues is indicative of β-sheets (Wishart et al. 1992). Figure 10A shows the 
differences between observed α-proton chemical shifts in 50% TFE-d2 solutions and random 
coil values for each amino acid of HNE-peptides in which Gly8 was substituted with a variety 
of amino acids. The values for the C-terminal region of Gln11-Asn16 of wt and modified 
HNE-peptides were similar. Based on chemical shift structural predictions the α-helix 
observed in the wt-peptide seems to be conserved between Gln11 and Glu15 in all mutants. 
Values for the N-terminal residues (Lys1-Ala5), which have no defined structure, were 
similarly well conserved and no significant difference in secondary structure was expected 
within this region. Substituting Gly8 had not only a direct effect on the chemical shift of the 
amino acid at that position but also lead to significant shifts in adjacent residues, further 
increasing the flexibility of the random coil loop region (Cys6-Ile10). As expected a Gly to 
Pro substitution had the largest effect based on the backbone altering character of Pro. The 
variations in the α-proton chemical shifts observed for the critical contact residues Cys6, Lys7 
and Gly8, indicate that the structure of the antibody binding motif of all HNE Gly8 
substituted peptides differed from the wt-HNE-peptide, which is likely to affect binding 
(Figure 10A). 
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Substitutions of amino acids located within the α-helical region generally show less dramatic 
effects (Figure 10B). Mirroring the results from Gly8 mutant the values for C- and N-termini 
of these helix mutants remain largely unchanged with regard to the reference peptide, 
retaining the N-terminal random coil arrangement and the C-terminal α-helix. One notable 
exception is the Leu13Asn substituted peptide, whose values changed significantly in the C-
terminal region from upfield to downfield shifts, which is likely helix destroying. As 
demonstrated in the case of Gly8 mutants the region located between Cys6 and Ile10 had no 
defined structure and HNE peptide mutants Ile10Ala and Ile10Glu exhibiting the largest 
difference in α-proton chemical shifts in this region. 
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Figure 10: Differences in secondary structure of HNE-peptide based on 1H α-chemical shifts in TFE-d2
Shown are differences between experimental and theoretical chemical shifts of α-protons of HNE-peptides with 
Gly8 substitutions (A) and helix substitutions (B) for each amino acid.  
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Influence of solvent on α-proton chemical shifts and structure 
 
To determine the influence of solvents on α-proton chemical shifts and structure, 1H NMR 
spectroscopy measurements were performed in H2O for wt-HNE-peptide and four substituted 
HNE-peptides (Figure 11A). While α-proton chemical shifts in H2O of residues located within 
the α-helical region were less pronounced and thus the helix was better defined in 50% TFE-
d2 solution, the overall secondary structure remained conserved in H2O in all measured 
peptides (Figure 11B, C and D). 
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Figure 11: Differences in secondary structure of HNE peptide based on 1H α-chemical shifts in H2O and 
50% TFE-d2  
Shown are differences between experimental and theoretical chemical shifts of α-protons for each amino acid of 
wt and modified HNE-peptides with Gly8 substitutions in H2O (A). Direct comparisons between chemical shifts 
in 50% TFE-d2 (filled bars) and H2O (empty bars) of wt-HNE-peptide (B), Gly8Ala mutant (C) and Gly8Val 
mutant (D) are shown. 
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Influence of disulfide bond on the structure of HNE-peptide 
 
NMR measurements were performed in 50% TFE-d2 on both reduced and oxidised Gly8Val 
substituted HNE-peptides, in order to assess the influence of the disulfide bridge on the 
structure. Applying the method of using α-proton chemical shifts as easy and reliable criteria 
for structural domains, the oxidised HNE-peptide formed an α-helix between Lys9 and Cys14 
(Figure 12). While no actual structure was determined for either the reduced or oxidised 
Gly8Val peptide, the reduced isoform showed significant differences in α-proton chemical 
shifts. These were observed as expected for Cys6 and Cys14, since these residues were no 
longer constrained by the disulfide bond. This increase in conformational freedom also altered 
the structure of the loop region between Cys6 and Cys14, with an α-helix now extending N-
terminally up to residue Gln3.  
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Figure 12: Differences in secondary structure of reduced and oxidised HNE-peptide 
Shown are differences between experimental and theoretical chemical shifts of α-protons of reduced (open bars) 
and oxidised (filled bars) HNE-peptide Gly8Val in 50% TFE-d2. 
 
1.2. Biological activity of modified HNE-peptides 
HNE-peptides with substitutions of critical and non-critical contact residues were tested for 
their antigenicity (Figure 13). wt-HNE-peptide reacted strongest with HNE-specific 
monoclonal antibody BH216 while peptides with substitutions of non-critical contact residues 
Leu13Ala and Ile10Ala showed a 2/3 and 1/3 decreased response, respectively, compared to 
wt-HNE-peptide. The other single substituted peptides failed to interact with BH216 mAb in 
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line with previous results obtained for the binding motif (Putz et al. 2003b). A peptide with 
both Ile10Ala and Leu13Ala substitutions showed no reactivity even though Ile10 and Leu13 
are not contact residues and each of these substitutions is allowed separately on their own. 
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Figure 13: Indirect ELISA of Gly8 and α-helix mutants of HNE-peptides with monoclonal antibody 
Wt-HNE-peptide, Gly8 substituted peptides and α-helix substituted peptides were coated and analysed for their 
ability to bind monoclonal antibodies BH216 in indirect ELISA. 
 
1.3. Structure of wt-HNE-peptide 
The structure of the wt-HNE-peptide was determined for our laboratory in collaboration with 
Dr. Karsten Bruns and Prof. Victor Wray of the Helmholtz Research Centre for Infection 
Research (Structural Biology, Research Group Biophysical Analysis) in Braunschweig, prior 
to the start of this work and was essential in developing substitution peptides that were used 
throughout this work. It was in their laboratory, under their guidance and with their help that I 
performed all other NMR structure determinations of peptides mentioned throughout this 
work. 
Nuclear Overhauser effect (NOE) crosspeaks for KGQQACKGKIQALCEN in 50% TFE-d2 
were assigned as described before. The qualitative information obtained from comparison of 
observed α-proton chemical shifts with those from random coil structures, indicated that 
starting from Gln11, the C-terminus has a helical structure. The N-terminus appears largely 
unstructured (Figure 10A). The analysis of short and medium range NOE, showed that the C-
terminus contained significantly more interresidual interactions than the N-terminus (Figure 
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14). A number of these medium range interactions (αH(i) to NH(i+3) and NH(i+4)) are 
characteristic of an α-helical structure. The quantitative NOE data was used as distance 
constraints in molecular dynamics and energy minimisation calculations. A total of 197 NOE 
crosspeaks were assigned unambiguously, composed of 59 intraresidual, 73 sequential, 64 
medium range (up to i-i+4) and 1 long range (over i-i+4) interactions (Figure 15). These NOE 
were used to generate 100 conformations of which the 19 lowest energy conformations were 
used for fitting analysis. The consecutive segment method was applied to these structures, as 
described before, and amino acid sequence of Gln3 to Asn16 showed a backbone RMSD 
below 0.4 Å (Figure 16). This region was selected as fitting region and for central structure 
determination. Fitting of the lowest energy structures highlights regions with well conserved 
structural features and less defined domains (Figure 17), as suggested by qualitative α-proton 
chemical shift data and quantitative NOE. The peptide consists of a well conserved α-helix 
between Ile10 and Asn16 and an N-terminal linkerarm Lys1-Ala5, with pronounced 
flexibility. The critical HNE-motif residues Cys6, Lys7 and Gly8 as determined by Putz 
(2003b) are arranged in an exposed loop held in place by the disulfide bond between Cys6 
and Cys14. The presence of the disulfide bridge was confirmed by NOE of β-H of Cys6 to 
amide proton of Cys14. 
The critical hydrophilic residues of the antibody binding motif (Cys, Lys, Gly, Gln and Glu) 
are located on top of the α-helix (Figure 18). The bottom of the helix is formed by essentially 
hydrophobic uncharged residues (Ile, Ala and Leu), which have no role in binding. Ile10 can 
only be substituted by Ala, Glu and Gln, and plays most likely a structural role, as no direct 
contact with the antibody is expected. The linkerarm and Asn16, none of which are part of the 
binding motif, are directed away from the motif. A number of low energy structures are 
characterised by a backbone torsion around Gly8 causing the linkerarm to point into the 
antibody binding domain (Figure 19). Several Gly8 substituted HNE-peptides were 
synthesised to investigate this backbone flip and the structure of Gly8Ala has been resolved. 
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Figure 14: Structurally important short and medium range NOEs in wt-HNE-peptide 
Summary of observed structurally important sequential and non sequential short and medium range NOEs in the 
wt-HNE-peptide. 
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Figure 15: Total quantitative NOE crosspeaks observed and assigned for wt-HNE-peptide 
Distribution of quantitative NOE observed and assigned to each residue for wt-HNE-peptide and used for 
molecular dynamic calculations. Apart from intraresidual NOE, each interresidual NOE appears twice as both 
residues to which they are assigned are shown. 
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Figure 16: Mean RMSD for backbone atoms of wt-HNE-peptide 
Mean RMSD for backbone atoms in each residue are shown, calculated using consecutive segment method (2-5 
amino acid segment length) and plotted against residue number for the 19 lowest energy structures. 
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Figure 17: Structure of the 19 lowest energy conformations of wt-HNE-peptide 
Superposition of the 19 lowest energy structures calculated for wt-HNE-peptide after alignment of the backbone 
atoms of Gln3 to Asn16. Peptide backbones are shown as tubes. Central structure is shown in green, disulfide 
bridges as yellow lines. (A) Top view, (B) lateral view. 
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Figure 18: Central structure of wt-HNE-peptide 
The critical contact residues of the antibody binding domain are displayed as coloured sticks and labelled. The 
peptide backbone is shown as tube. 
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Figure 19: Backbone torsion around Gly8 of wt-HNE-peptide 
Alignment showing flip of N-terminal linkerarm for 6 structures of the 20-40 lowest energy conformations of 
wt-HNE peptide. Peptide backbones are shown as tubes, disulfide bridge as yellow lines. 
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1.4. Structure of Gly8Ala-HNE-peptide 
The Gly8Ala substituted peptide (KGQQACKAKIQALCEN) was one of several synthesised 
to further determine the characteristics of the HNE-loop and the observed flip in the wt-
structure. NOE crosspeaks in 50% TFE-d2 were assigned as described before. α-proton 
chemical shift data (Figure 10A) and short and medium range couplings (Figure 20) indicate 
the presence of a C-terminal helical structure starting at Gln11 and a relatively unstructured 
N-terminus. A total of 211 NOE unambiguously assigned crosspeaks were composed of 104 
intraresidual, 59 sequential, 45 medium range (up to i-i+4) and 3 long range (over i-i+4) 
interactions (Figure 21) and used as distance constraints in structure modelling. 
After repeated and improved calculation steps, the 20 lowest energy structures of the last 
calculation were selected for structural analysis. Mean backbone RMSD values, obtained by 
the consecutive segment method, showed large backbone variations in the N-terminal domain. 
A mean RMSD below 0.4 Å was observed between residues Ala8 and Glu15 (Figure 22). 
This interval highlights a relatively stable region with a conserved secondary structure in the 
20 lowest energy conformations. The structure with the lowest RMSD to all other 
conformations was selected as the central structure and was used as a template for the 
alignment of the remaining 19 structures between Ala8 and Glu15 (Figure 23). The 
superposition confirmed indications of α-proton chemical shifts and qualitative NOE (Figure 
20) that the C-terminus of the peptide forms an α-helix between residue Gln11 and Glu15. 
Thus the Gly8Ala substitution did not affect the α-helix to any large extent. Disulfide bonds 
between Cys6 and Cys14 were confirmed by long range NOE interactions between Cys6 (βH) 
and Cys14 (NH) as well as Ala5 (βH) - Cys14 (NH) and Ala8 (βH) - Leu13 (γH). The Lys1-
Ala8 region exhibits substantial flexibility as observed for the wt-HNE-peptide structure. The 
structure of the peptide differs significantly from the wt-HNE-peptide with regard to the Gly 
loop and the orientation of the linkerarm. The Gly8Ala structure is more closely related to the 
observed flipped structure of wt-HNE-peptide. This random coil structure shows a preference 
to point upwards, into the antibody binding domain in 19 of the lowest energy conformations, 
with the central structure adopting a conformation in the plane of the α-helix. It is important 
to note that the central structure was determined as such for the fitting region Ala8-Glu15 of 
the backbone atoms, independently of orientation and structure of the Lys1-Lys7 sequence. 
Fitting clearly shows a preference for perpendicular arrangement of the sidearm with regard to 
the α-helix for majority of conformations. 
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Figure 20: Qualitative summary of observed short and medium range NOE in Gly8Ala peptide 
Summary of observed structurally important sequential and non sequential short and medium range NOEs in the 
Gly8Ala substituted HNE-peptide. 
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Figure 21: Total quantitative NOE crosspeaks observed and assigned for Gly8Ala mutant 
Distribution of quantitative NOE observed and assigned to each residue for Gly8Ala mutant and used for 
molecular dynamics calculation. Apart from intraresidual NOE, each interresidual NOE appears twice as both 
residues to which they are assigned are shown. 
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Figure 22: Mean RMSD for backbone atoms of Gly8Ala mutant peptide 
Mean RMSD for backbone atoms in each residue are shown, calculated using consecutive segment method (2-5 
amino acid segment length) and plotted against residue number for the 20 lowest energy structures. 
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Figure 23: Structure of the 20 lowest energy conformations of Gly8Ala mutant 
Superposition of the 20 lowest energy conformations calculated for Gly8Ala mutant after alignment of the 
backbone atoms residues 8 to 15. Peptide backbones are shown as tubes, disulfide bridge as yellow lines. Central 
structure is shown in pink. (A) Top view, (B) lateral view. 
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1.5. Structure of Ile10Ala-HNE-peptide 
The Ile10Ala substituted HNE-peptide is part of a series of peptides with potential α-helical 
stabilising substitutions. α-proton chemical shifts (Figure 10A) and quantitative observations 
of assigned NOE crosspeaks (Figure 24) indicated a C-terminal helical domain and an 
unstructured N-terminus. A total of 154 NOE crosspeaks were assigned unambiguously 
composed of 74 intraresidual, 55 sequential, 26 medium range (up to i-i+4) and 1 long range 
(over i-i+4) interactions (Figure 25). 
After gradual improvements of the NOE data, 100 structures were calculated and the 20 
lowest energy structures were selected for further structural analysis. The consecutive 
segment method was applied to these structures and amino acid sequence of Lys9 to Cys14 
with a backbone RMSD below 0.4 Å was selected as fitting region and central structure 
determination (Figure 26). After pairwise fitting of the 20 lowest structures over the region of 
Lys9-Cys14, the central structure was determined. Alignment of the remaining 19 structures 
to the central structure showed that the α-helical region is well conserved as expected (Figure 
27). The peptide backbone around C-terminal Glu15 and Asn16 residues is considerably more 
flexible and these residues are not part of the α-helix as predicted by qualitative NOE and α-
proton chemical shifts. The α-helix from Ile10 to Glu15 is preceded by a flexible N-terminus 
correlating with the observations from the structures of the wild-type and Gly8Ala substituted 
HNE-peptides. The disulfide bond between Cys6 and Cys14 is confirmed by long range NOE 
interaction of Cys6 (βH) and Gln11 (αH). 
 
 
Figure 24: Qualitative summary of observed short and medium range NOE in Ile10Ala mutant peptide 
Summary of observed structurally important sequential and non sequential short and medium range NOEs in the 
Ile10Ala substituted HNE-peptide. 
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Figure 25: Total quantitative NOE crosspeaks observed and assigned for Ile10Ala mutant peptide 
Distribution of quantitative NOE observed and assigned to each residue for Ile10Ala mutant peptide and used for 
molecular dynamic calculations. Apart from intraresidual NOE, each interresidual NOE appears twice as both 
residues to which they are assigned are shown. 
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Figure 26: Mean RMSD for backbone atoms of Ile10Ala mutant peptide 
Mean RMSD for backbone atoms in each residue are shown, calculated using consecutive segment method (2-5 
amino acid segment length) and plotted against residue number for the 20 lowest energy structures. 
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Figure 27: Structure of the 20 lowest energy conformations of Ile10Ala mutant peptide 
Superposition of the 20 lowest energy structures calculated for Ile10Ala mutant peptide after alignment of the 
backbone atoms residues 9 to 14. Peptide backbones are shown as tubes, disulfide bridges as yellow lines. 
Central structure is shown in blue. (A) Top view, (B) lateral view. 
 
1.6. Structure of Ile10Ser-HNE-peptide 
The structure of KGQQACKGKSQALCEN was resolved to assess the influence of a Ser 
substitution in the α-helix domain of the wt-HNE-peptide. α-proton chemical shifts (Figure 
10A) and quantitative NOE data (Figure 28) suggest that the α-helix was in fact retained but 
the lower number of crosspeaks in the C-terminal domain could be a sign of a weakened 
helix. Structure calculations were performed using a total of 222 unambiguously assigned 
NOE crosspeaks composed of 112 intraresidual, 71 sequential, 35 medium range (up to i-i+4) 
and 4 long range (over i-i+4) interactions (Figure 29). 
The 20 lowest energy structures were selected after structure calculations and the consecutive 
segment method was applied, as described above. Amino acids Lys7 to Cys14 with a 
backbone RMSD below 0.4 Å were selected as fitting region and central structure 
determination (Figure 30). The 19 lowest energy structures were aligned with the central 
structure for the fitting region of Lys7 to Cys14 (Figure 31). Generally the region between 
disulfide bound Cys exposed a well conserved structure in all 20 lowest energy 
conformations. Long range NOEs of β-protons of Cys6 with α and amide protons of Gln11 
and Cys14 respectively, and β-proton of Cys14 with the amide proton of Cys6 confirm the 
presence of a disulfide bond between the two Cys. The C-terminus is characterised by an α-
helix between Gln11 and Glu15, correlating with α-proton chemical shift data and results 
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obtained from the structures of wt-HNE-peptide and other substituted HNE-peptides. It is 
interesting to note that the C-terminus for this structure is considerably more flexible. For 
position Asn16, 11 structures align with the central structure corresponding to the structures 
of wt-HNE-peptide, Gly8Ala and Ile10Ala substituted peptides. However 8 conformations 
exhibit a backbone twist at Glu15 and as a result Asn16 of these structures is moved outside 
the α-helix. More importantly the side chain of Glu15 is directed away from the antibody 
binding site and hidden inside the α-helix. The random coil structure of the N-terminal 
linkerarm displays the expected flexibility and is located in the same plane as the α-helix. 
 
 
Figure 28: Qualitative summary of observed short and medium range NOE for Ile10Ser mutant peptide 
Summary of observed structurally important sequential and non sequential short and medium range NOEs in the 
Ile10Ser substituted HNE-peptide. 
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Figure 29: Total quantitative NOE crosspeaks observed and assigned for Ile10Ser mutant peptide 
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Distribution of quantitative NOE observed and assigned to each residue for Ile10Ser mutant peptide and used for 
molecular dynamic calculations. Apart from intraresidual NOE, each interresidual NOE appears twice as both 
residues to which they are assigned are shown. 
Amino acid sequence
K G Q Q A C K G K S Q A L C E N
R
M
SD
 [Å
]
0.0
0.2
0.4
0.6
0.8
1.0
1.2
 
 
Figure 30: Mean RMSD for backbone atoms of Ile10Ser mutant peptide 
Mean RMSD for backbone atoms in each residue are shown, calculated using consecutive segment method (2-5 
amino acid segment length) and plotted against residue number for the 20 lowest energy structures. 
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Figure 31: Structure of the 20 lowest energy conformations of Ile10Ser mutant peptide  
Superposition of the 20 lowest energy structures calculated for Ile10Ser mutant after alignment of the backbone 
atoms residues 7 to 14. Peptide backbones are shown as tubes, disulfide bridges as yellow lines. Central structure 
is shown in yellow. (A) Top view, (B) lateral view. 
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2. Functional importance and location of disulfide bond in HNE-peptides 
The amino acid sequence of the HNE loop of measles virus H-protein contains three Cys that 
can potentially form disulfide bonds. To assess the location and importance of the disulfide 
bonds and the structural role of each Cys, Cys of full length HNE peptides were 
monosubstituted with amino butyric acid (Cys381B, Cys386B or Cys394B) and a full length 
HNE-peptide sequence with all three substitutions was synthesised as control. Binding of 
these peptides to anti-HNE specific monoclonal antibodies (mAbs) BH216, BH21 and BH6 
was assessed. Monosubstituted Cys386B, Cys394B and trisubstituted (Cys381B, Cys386B, 
Cys394B) peptides failed to bind anti-HNE specific antibodies (Figure 32). Only the oxidised 
peptide Cys381B with a disulfide bond between Cys386 and Cys394 reacted within this 
peptide series. BH216 (Figure 32A) recognises C381B peptide much stronger than the 
oxidised shorter HNE peptide sequence (KGQ383QACKGKIQALCEN396). Binding profiles of 
BH21 with peptides were very similar (data not shown). BH6 shows a different binding 
specificity than BH216 with the same peptides: the importance of the Cys386-Cys394 
disulfide bridge is confirmed and no other substituted peptide reacts with BH6 (Figure 32B). 
This mAb does however exhibit stronger binding to the shortened oxidised HNE-peptide. 
These results, indicating a disulfide bridge between Cys386-Cys394, corroborate observations 
made by Putz (2003b) and were later confirmed by the publications of crystal structures of the 
MV H-protein (Colf et al. 2007; Hashiguchi et al. 2007). 
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Figure 32: Indirect ELISA of mono and trisubstituted full length HNE peptides with monoclonal 
antibodies. 
Each Cys in the full length HNE sequence E379TCFQQACKGKIQALCENPEWA400 was substituted with amino 
butyric acid (Cys381B , Cys386B  or Cys394B , or trisubstituted ) and peptides were coated and analysed 
for their ability to bind mAbs BH216 (A) and BH6 (B) in indirect ELISA. Oxidised shortened wt-HNE-peptide 
 (KGQ383QACKGKIQALCEN396) was included as control. 
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Part II: Stability and antigenicity 
1. wt-HNE-peptide non-recognition by anti-MV sera 
The binding specificities of sera and anti-H-protein mAb to HNE peptide and H-protein were 
assessed in ELISA. Results showed that the shortened wt-HNE-peptide 
KGQ383QACKGKIQALCEN396 was only recognised by BH216 antibody (Figure 33) and 
related mAb BH21 and BH6 (data not shown), which specifically bind the HNE-loop. Sera 
from naturally immunised (late convalescent) and vaccinated individuals showed no reactivity 
with the HNE-peptide. mAb BH195 is known to bind only to reduced full length HNE 
peptides and selectively to the H397-400 region of the denatured H-protein and is routinely 
used as a negative control in ELISA with shortened HNE-peptides. As expected BH195 did 
not bind the HNE-peptide, however some reactivity with H-protein was observed possibly due 
to the presence of some denatured H-protein which exposed the H397-H400 region. The H-
protein was strongly recognised by mAb BH216 and sera from late convalescent and 
vaccinated individuals. MV negative sera did not bind the HNE peptide or the MV H-protein. 
These binding specificities, in particular the binding of the MV neutralising and protective 
BH216 and the absence of binding of human sera to peptide, confirmed the choice of the 
HNE-peptide as a lead peptide for peptide-based vaccine against MV in the presence of anti-
MV antibodies. 
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Figure 33: Differential recognition of H-protein and shortened HNE-peptide 
ELISA responses of human sera from naturally infected (late convalescent), immunised and vaccinated 
individuals and monoclonal anti-HNE antibodies binding to coated H-protein (empty bars) or shortened wt-
HNE-peptide (KGQ383QACKGKIQALCEN396) (filled bars). 
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2. Fine specificities of monoclonal antibodies 
The anti-HNE specific monoclonal antibodies BH216, BH21, BH6 and BH195 used 
throughout this work have different binding specificities to HNE-peptides. Confirming earlier 
results, BH195 binding was negative for both reduced and oxidised forms of the wt-HNE-
peptide (Figure 34A). Even the other anti-HNE mabs showed considerable differences in 
reactivity with the wt-HNE-peptide: BH216 only binds HNE-peptide with cyclised Cys 
residues. The reduced form was only poorly recognised. BH6 on the other hand, while 
predominantly binding the oxidised isoform, had a much higher tolerance for the lack of a 
disulfide bond in the wt-HNE-peptide, with approximately 50% of antibodies also binding the 
reduced isoform. 
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Figure 34: Fine specificities of anti-HNE monoclonal antibodies to shortened HNE-peptide 
HNE-peptide (KGQ383QACKGKIQALCEN396) was coated either in reduced (empty symbols) or oxidised (filled 
symbols) form and binding specificities of monoclonal antibody BH216 (circles) and BH195 (triangles) (A), and 
BH6 (B) were assessed in ELISA. 
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3. Stability of wt-HNE-peptide in serum 
Initially the ELISA technique was assessed for its capacity to analyse peptide stability in 
serum. The method allows monitoring peptide fragments from degradation process for their 
interaction anti-HNE mAb. Peptides were coated on ELISA plates and incubated with serum 
at different time points and degraded peptides were analysed for mAb binding. In an 
alternative approach peptide was incubated with serum and the reaction mixtures were coated 
and standard ELISA protocol was followed thereafter. Both these methods were assessed and 
found to be inadequate. The major drawbacks of these techniques were background noise due 
to serum binding to plastic support and the apparent inability of serum proteases to degrade 
peptide that is coated to the plastic support (data not shown). The ELISA approach to peptide 
stability was abandoned and HPLC based stability tests were developed.  
The HPLC based biostability test of the reference peptide KGQQACKGKIQALCEN in 
mouse serum from the frozen stock revealed a half life of 11.8 hours (Figure 35A). In fresh 
serum the half life was even shorter (8.9 hours, Figure 35B). Frozen commercial mouse serum 
stock was chosen for further biostability tests because of the homogenicity of pooled sera 
compared to freshly prepared serum and thus higher reproducibility of results.  
 
y = 86.058e-0.0462x
R2 = 0.9894
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70 80
Time [h]
In
ta
ct
 p
ep
tid
e 
re
m
ai
ni
ng
 [%
]
t1/2=11.8
y = 78.394e-0.0506x
R2 = 0.9912
0 10 20 30 40 50 60 70 80
Time [h]
t1/2=8.9
 
A B 
Figure 35: Degradation of wt-HNE peptide in mouse serum over a 72 h time span 
Biostability of wt-HNE-peptide was assessed in serum from frozen commercial stock (A) or from freshly 
prepared (B) mouse serum (n=1-2). Trendlines (black) were used to determine half-lives. 
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4. Enhancing the stability of wild-type HNE-peptide 
4.1.  Preliminary peptide synthesis 
 
In a first preliminary peptide synthesis two sets of peptides were produced to assess different 
functional aspects and to establish interesting modifications for further syntheses. 
 
1) In a first set of peptides, the N-terminus of the peptide chain featured a Fmoc protecting 
group on the Lys backbone amine. Prior to immunisation, peptides are generally coupled to 
carrier protein which is likely to block degradation of the peptide N-terminus. The presence of 
the Fmoc protecting group was intended to simulate the carrier protein and at the same time 
facilitate the monitoring of peptide degradation. But the Fmoc group was unable to protect the 
N-terminus against exopeptidase mediated proteolytic degradation, because of spontaneous 
cleavage of the protecting moiety and accelerated peptide degradation (data not shown).  
 
2) Our structures of the wt-HNE-peptide and substitution HNE-peptides have shown that 
amino acids following the C-terminal residue Glu15 are directed away from the antibody 
binding site and are unlikely to affect binding to the critical HNE contact residues. 
The second set of synthesised peptides were part of a library with different C-terminal 
extensions by non-natural amino acids (see Annexe 1), to identify modifications that 
enhanced peptide biostability without affecting its antigenicity. The various extension 
residues included large and modified amino acids and D-amino acids whose sidechains did 
not include functional groups. In contrast to expectations most single additions of non-natural 
amino acids such as pamba (4-(aminomethyl)benzoic acid) and gaba (γ-aminobutyric acid) or 
the additions of one or two D-amino acids had little effect on the stability towards serum 
proteases after 4 hours of incubation or reduced peptide antigenicity (data not shown). In 
contrast the analysis suggested that t-amcha (trans-4-(aminomethyl)cyclohexanecarboxylic 
acid), achca (1-(amino)cyclohexanecarboxylic acid), aib (α-amnioisobutyric acid), D-Phe, D-
Ala, and D-Val amongst others (data not shown), were potentially interesting. 
The combination of different N- and C-termini within the same peptides complicated the 
conclusions drawn from this exploratory peptide synthesis. 
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4.2. C-terminally extended peptides 
 
A new synthesis of peptides with the above mentioned C-terminal extensions or the C-
terminal addition of natural (PEWA) or modified (PEWa and PEWAa) HNE-sequence 
residues, were produced (see fold out page Annexe 2). The N-terminal Lys of all of these 
peptides, including the wt-HNE-peptide, was blocked via acetylation for the stability testing, 
as such a modification is known to stabilise peptides against exopeptidases(Maillère et al. 
1995) and allowed focus on the C-terminus only. The antigenicity measured binding of anti-
HNE mAb, and the biostability, expressed in terms of % of intact peptide remaining after 48 h 
incubation in serum, were plotted against each other. This plot shows peptides with interesting 
mutations in the top right corner (Figure 36). Those modified peptides exhibit increased 
stability and retained antigenicity, while peptides located at the bottom left of the plot contain 
the least favourable modifications. Only a few C-terminal additions such as D-Ala, PEWAa 
and PEWa retained antigenicity and were as stable as the N-acetylated wt-HNE-peptide 
(Figure 36). Unexpectedly, the large majority of modified peptides showed decreased 
biostability compared to the wt-HNE-peptide, although some of these reacted better with anti-
HNE mAbs. The addition of two D-amino acids to the C-terminus inhibited antibody binding, 
presumably because of steric interactions. 
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Figure 36: Biostability-antigenicity correlation plot of C-terminally extended peptides 
The biostability (x-axis) and antigenicity (y-axis) of modified HNE-peptides are plotted against one another. 
Biostability is calculated as % intact peptide and mean values (±SD) of 2 independent experiments are shown. 
Antigenicity is expressed as absorbance in ELISA with BH216 mAb binding to 0.8 µM coated peptide.wt-HNE-
peptide is shown in bold. 
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4.3. Internally and N-terminally modified peptides 
 
Since C-terminal extensions did not increase the biostability of the HNE-peptide, a number of 
peptides with internal modification were synthesised. Substitution studies in the HNE binding 
motif, which were previously done in our laboratories (Putz et al. 2003b), guided the selection 
of acceptable substitution sites. The critical antibody binding residues were left unaltered; 
instead the noncritical Lys9 which is also expected to be a major endopeptidase target was 
substituted with a variety of amino acids. Substitution of Lys9 with Ala, His, Ser and Gln 
produced peptides, which were more stable than the wt-HNE-peptide or as stable as in the 
case of Lys9Asn (Figure 37). However, with the exception of Lys9Ala substitution, their 
antigenicity was reduced or totally lost. 
The N-terminal Lys of the HNE-peptide is important for optimal coupling to the carrier 
protein and was added as a linker to the HNE-sequence during earlier work in our laboratory 
(Putz 2004). Since Lys is a known target of peptidases, modifications of the N-terminus such 
as branching extensions (G4K2KGQQ… and G2KGQQ...) were produced which could 
increase the stability of the peptides.The additional residues were added to the backbone and 
sidechain amine of N-terminal Lys. The increased number of N-terminal amine groups could 
also reduce the risk of coupling via sidechain amines of Lys residues located inside the 
antibody binding domain (Lys7 and Lys9). Coupling via the latter Lys was suggested to 
destroy the critical epitope. While improving the biostability to 48% (from 37%), a reduction 
in reactivity with mAb BH216 was observed for these peptides (Figure 37). The substitution 
of the N-terminal Lys with its D-isomer did not increase the stability, suggesting that the 
responsible aminoexopeptidase is not stereospecific. Thus only the Lys9Ala (peptide 2734) 
mutant showed both improved stability and antigenicity and was selected as the lead 
substitution for further rounds of synthesis. 
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Figure 37: Biostability-antigenicity correlation plot of internally and N-terminally modified peptides 
The biostability (x-axis) and antigenicity (y-axis) of modified HNE-peptides are plotted against one another. 
Biostability is calculated as % intact peptide and mean values (±SD) of 2 independent experiments are shown. 
Antigenicity is expressed as absorbance in ELISA with BH216 mAb binding to 0.8 µM coated peptide. 
Branched peptides: G4 and G2 = Gly coupled to preceding Lys via backbone and sidechain NH2, K2 = Lys 
coupled to preceding Lys via backbone and sidechain NH2,. wt-HNE-peptide is shown in bold 
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4.4. Internally and C-terminally modified peptides 
Based on the results observed for the C-terminal modifications and internal substitutions, a 
synthesis combining these individual changes, was performed. This resulted in peptides 
KGQQACKGAIQALCENPEWa (2741), KGQQACKGAIQALCENa (2744), 
KGQQACKGAIQALCENv (2745) and KGQQACKGAIQALCEN (2751), with better 
stability in mouse serum compared to wt-HNE-peptide KGQQACKGKIQALCEN (2752): 
stabilities increased from 37% to 47%, 54%, 50%, and 53%, respectively (Figure 38). These 
peptides also retained the reactivity with respect to mAb BH216. 
The substitution of Lys7 to D-Lys (peptide 2749) increased stability from 37% to 59% 
compared to wt-HNE-peptide. The addition of a Lys9Ala substitution to this peptide (peptide 
2750) lead to an additional increase in stability to 71%. However peptides whose Lys7 was 
replaced with its D-isomer failed to bind mAb. Substituting Lys with Arg had a destabilising 
effect suggesting that Arg is even more readily cleaved by proteases than Lys. 
It is interesting to note that the consecutive C-terminal extension of D-Val and D-Ala, on a 
peptide with a Lys9Ala substitution, abolished the reactivity of this peptide with BH216 mAb, 
confirming earlier results of loss of antigenicity due to the addition two D-amino acid 
additions. HoweverInstead, the addition of two consecutive D-Ala residues to the C-terminus 
conserved the peptide’s antigenicity. Presumably the steric hindrance with respect to the 
antibody binding domain by two small D-Ala residues is much less pronounced than with 
larger D-amino acids. 
The four peptides with an enhanced biological stability listed above, were singled out for 
immunological studies. 
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Figure 38: Biostability-antigenicity correlation plot of internally and C-terminally modified peptides 
The biostability (x-axis) and antigenicity (y-axis) of modified HNE-peptides are plotted against one another. 
Biostability is calculated as % intact peptide and mean values (±SD) of 2 independent experiments are shown. 
Antigenicity is expressed as absorbance in ELISA with BH216 mAb binding to 0.8 µM coated peptide. 
Underlined peptide sequences were selected for immunisation studies. wt-HNE-peptide is shown in bold. 
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4.5. Further improved internally and C-terminally modified peptides 
Following the immunisation with peptides 2741, 2744, 2745 and 2751 with the Lys9Ala 
mutation and various C-terminal modifications, an additional set of peptides were synthesised 
in an attempt to further stabilise the HNE-peptide. The immunisation results obtained with the 
above peptides directly influenced the selection of the new modifications that were included 
in the new synthesis. In this synthesis the D-Val C-terminal extension was eliminated to 
exclude solubility problems.  
The results obtained for these new peptides with additional modifications in the antibody 
binding motif, shed more light on the structure required for antibody binding, especially with 
respect to Lys7. Substitution with diaminopropionic acid (dap) with a shorter basic sidechain, 
in this position completely abolished antibody binding, whereas norvaline (Nva) and 
norleucine (Nle) preserved antibody binding, despite their lack of a basic sidechain (Figure 
39A). For most peptides with Nle and Nva substitutions no biostability measurements were 
possible: The Nle and Nva substitution peptides bind more strongly to the used cellulose filter 
since the substitution of basic residues by aliphatic ones increased hydrophobicity of the 
peptides. These peptides are thus only plotted on the y-axis showing the antigenicity. Only 
peptides containing at least two Lys (2796 and 2797) gave a reliably increased biostability, 
but their antigenicity was reduced or lost. No peptide stability assays were performed on 
Lys7dap substituted peptides, because they were not recognised by the mAbs. 
Dap was also investigated as a possible replacement of N-terminal Lys. Lys1dap substitution 
in the wt-HNE-peptide increased the stability from 37% to 47% and conserved the 
antigenicity (Figure 39A). When this substitution was combined with additional modifications 
such as Lys9Ala substitution and C-terminal extensions, the stability was further increased 
without compromising the antigenicity compared to wt-HNE-peptide. Peptide 2787 with 
Lys1Dap, Lys9Ala and C-terminal D-Ala modifications was substantially stabilised (to 68%) 
and was one of the most stable peptides that still reacted with BH216 and BH21 mAbs. 
Several Lys7 substitutions lead to peptides with both increased stability and conserved 
antigenicity (Figure 39B). These modified peptides included substitutions of Lys7 with 
sidechain ε-di- or tri-methylated Lys, but their stability was very dependent on additional 
modifications. A simple replacement of Lys7 with di-methylated sidechain Lys (peptide 
2798) did not improve the stability compared to wt-HNE-peptide. However when this 
substitution was combined with Lys9Ala (peptide 2791), or Lys9Ala and C-terminal D-Ala 
addition (peptide 2784), very stable and antigenic peptides were obtained. 
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A similar observation was made when Lys7 was substituted with tri-methylated sidechain 
Lys: this change alone increased the antigenicity of the peptide (peptide 2811) but the stability 
remained unchanged. An additional replacement such as Lys9Ala (peptide 2809) or Lys9Ala 
combined with either PEWa (peptide 2805) or a C-terminal extension with D-Ala (peptide 
2807), lead to some of the most stable and reactive peptides in this synthesis (Figure 39B).  
These further improvements in stability meant that nearly twice as much intact peptide was 
detected after 48 h incubation in serum compared to wt-HNE-peptide. Since the antigenicity 
of these peptides was also further improved, they were selected for immunisation (peptides 
2784, 2787, 2791, 2805, 2807 and 2809). 
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Figure 39: Biostability-antigenicity correlation plot of internally and C-terminally modified peptides 
improvements following results of immunisations 
The biostability (x-axis) and antigenicity (y-axis) of modified HNE-peptides are plotted against one another. 
Biostability is calculated as % intact peptide and mean values (±SD) of 2 independent experiments are shown. 
Antigenicity is expressed as absorbance in ELISA with BH216 mAb binding to 0.4 µM coated peptide. (A) Lys7 
substitutions with L* = Nle, V* = Nva, D* = dap. (B) Lys7 substitutions with K* = di-methylated Lys, K = tri-
methylated Lys. Underlined peptide sequences were selected for immunisation studies. wt-HNE-peptide is 
shown in bold. 
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5. Stability of HNE-peptides in intestinal juice 
A number of peptides selected on the basis of their stability, were further analysed for their 
biostability in intestinal juice, in a collaboration with Dr. Steffen Bade at the Research Center 
Borstel (Research group: Mucosa Immunology). The method is performed on peptides that 
are flanked by 11-(2-(2,4-dichlorophenoxy)acetylamino)undecanoic acid and biotin on the N- 
and C-terminus, respectively. Peptides can be incubated with a variety of different 
physiological fluids (serum, intestinal wash, peritoneal wash etc). These peptides are then 
fixed N-terminally to an ELISA plate coated with the antibody specific for the N-terminal 
residue. The detection step is performed with a horse radish peroxidise coupled to 
streptavidin. This enzyme only detects intact peptides using the biotin/streptavidin interaction 
on the C-terminus. The half-lives of peptides were calculated via a logarithm based on serial 
dilutions of murine intestinal juice from intestinal washes. Wt-HNE-peptide 
KGQ383QACKGKIQALCEN396 had a half-life of 0.8 s and all tested modified peptides were 
more stable (Figure 40). The half-lives of peptides 2741, 2744, 2745 and 2751, which were 
tested in the first round of immunisation, correlate well with the stabilities observed in serum; 
for example peptide 2751 with only a Lys9Ala mutation, showed a 1.4 fold increase in 
stability in both serum and intestinal fluid. The peptides for the second immunisation (2807, 
2784, 2787, 2809 and 2791) were as stable as or more stable than the peptides used in the first 
immunisation. Peptide 2809 with a tri-methylated Lys and Ala substitution of Lys7 and Lys9 
respectively, showed a two fold increase in stability compared to wt-HNE-peptide. Only 
peptide 2805 showed a slight decrease in stability compared to the above peptides, but was 
still 1.3 times more stable than wt-HNE-peptide. Peptides of the second immunisation were 
overall more stable than those used for the first round of immunisation, but the increase in 
stability in intestinal fluid was less pronounced than in serum. An interesting outlier in the 
tested peptides was (dap)GQQACKGAIQALCEN (peptide 2787) whose half-life increased 
by a factor of 8. Peptide 2745, which lacks the dap substitution but is otherwise identical, is 
not stabilised to such an extent. In serum peptide 2787 was nearly twice as stable as wt-HNE-
peptide. These differences between intestinal fluid and serum suggest that exopeptidases with 
different specificities and affinities are present in both media. 
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This novel method for the determination of biostability also allowed the analysis of peptides 
with Lys387Nva and Lys387Nle substitutions, which could not be tested in serum using the 
standard HPLC analysis method because of their absorption on the filter. These peptides 
(2776, 2775, 2783, 2782, 2790, 2789, 2797 and 2796) with an additional Lys9Ala and or C-
terminal extensions, were not more stable than the other modified peptides. 
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Figure 40: Half-lives of selected peptides in murine intestinal juice 
Biostability was tested using a patented procedure (Gorris et al. 2007). Peptides were incubated with murine 
intestinal juice and intact peptide was measured by C-terminal marker specific revelation step. Half-life is 
expressed in s and shown as bars (mean +-SEM; n=6). One Way Anova was applied and significance levels are 
indicated as *** p<0.001 as determined by the Benferroni post hoc test. 
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6. Efficiency of peptide-conjugation to carrier protein 
Peptides with increased stability and conserved antigenicity were coupled to tetanus toxoid 
(TT) using zero-length crosslinking sulfo-NHS/EDC chemistry. Before using these peptide-
conjugates for immunisation, the efficiency of peptide conjugation to TT was confirmed by 
testing the conjugates with mAb BH216 (Figure 41A) and BH6 (Figure 41B) in ELISA. 
BH21 (not shown) and BH216 binding profiles were very similar. Binding of the mAbs to the 
unconjugated carrier TT served as negative control. Constructs segregated into two groups 
according to their binding to BH216: TT-2807, TT-2784 and TT-2787 reacted three times 
better than the other constructs. The same pattern of reactivity was observed with BH21 mAb 
(data not shown). In contrast BH6 bound equally well to all constructs with the exception of 
TT-2805. The differences in binding to BH216 mAb may have suggested lower coupling 
efficiencies for some peptides, however in light of the BH6 results, peptide coupling seems 
similar between the different conjugates. A second batch of conjugates gave the same 
reactivities with BH216, BH21 and BH6 mAb as observed here (data not shown). 
construct concentration [nM]
0 20 40 60 80
Ab
so
rb
an
ce
 [m
O
D
]
0
500
1000
1500
2000
2500
3000
construct concentration [nM]
0 20 40 60 80
 
A B 
 
 TT-2805  TT-2784  TT-2809  TT-2833 (wt-HNE) 
 TT-2807  TT-2787  TT-2791  TT 
 
Figure 41: Antigenicity of TT-peptide-conjugates with BH216 and BH6 mAb 
Prior to immunisation TT-peptide-conjugates were assessed for their coupling efficiency during conjugation 
reaction. TT-conjugates were coated in indirect ELISA and analysed for their ability to bind monoclonal 
antibodies BH216 (A) and BH6 (B). 
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Part III: Immunogenicity 
1. Reactivity of mouse sera against homologous peptides 
 
Table 5: List of peptides used for immunisation 
peptide code sequence1)
2752 / 2833 KGQQACKGKIQALCEN   - wt-HNE 
2741 KGQQACKGAIQALCENPEWa 
2744 KGQQACKGAIQALCENv 
2745 KGQQACKGAIQALCENa 
2751 KGQQACKGAIQALCEN 
2784 KGQQACK*GAIQALCENa 
2787 D*GQQACKGAIQALCENa 
2791 KGQQACK*GAIQALCEN 
2805 KGQQACKGAIQALCENPEWa 
2807 KGQQACKGAIQALCENa 
2809 KGQQACKGAIQALCEN 
  1) D* = diamoni propionic acid (dap) , K* = di-methylated Lys, K = tri-methylated Lys 
 
Antigenic peptides with enhanced stability were selected from the previous experiments. They 
were coupled to TT and the TT-peptide-conjugates were assessed by immunisation. Peptide 
specific antibodies were measured by ELISA after 4 injections with TT-peptide–conjugates 
(Table 5, peptides 2741, 2744, 2745, 2751 and 2752). Median end point titres (EPT) for each 
group showed that similar levels of antibody were induced against TT-2741 and TT-2752 (wt-
HNE- peptide) (Figure 42A). TT-2744 gave significantly lower EPT values compared to TT-
2741 and TT-2752 (p<0.05) despite its increased stability. We assume that the lower 
solubility of peptide 2744 has impaired coupling resulting in reduced peptide binding to the 
carrier. In conclusion, increases in the stability of peptides 2741, 2744, 2745 and 2751 did not 
induce higher levels of antibodies than the wt-HNE-peptide. 
Based on the results obtained from these immunogenicity tests, further stabilising 
substitutions were performed. Selected peptides (Table 3, peptides 2784, 2787, 2791, 2805, 
2807, 2809 and 2833) were conjugated to TT and evaluated for their immunogenicity (Figure 
42C). Peptide-conjugates TT-2787 and TT-2833 (wt-HNE-peptide) induced similar levels of 
antibodies and these levels were higher than those of the other peptide-conjugates. There was 
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little variation in the levels of antibodies raised against TT-2805, TT-2807, TT-2784, TT-
2809 and TT-2791. 
It is interesting to note that the clustering observed during TT-peptide-conjugate quality 
control with BH216 did not lead to the same groups when assessing the levels of antibodies 
induced against these conjugates. BH216 reacted better with peptide-conjugates TT-2807 and 
TT-2784 than with TT-2809 and TT-2791, yet levels of antibodies raised against these 
peptide-conjugates were similar, further suggesting that the difference in reactivity with the 
antibody is related to fine-specificities of anti-HNE mAb binding rather than the quantity of 
peptides conjugated to the carrier. 
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Figure 42: Assessment of anti-peptide specific response after immunisation with peptide-conjugates 
Peptide specific serum end point titres (EPT) after 4 injections of TT-peptide-conjugates were determined in 
ELISA at 5 times OD response of negative sera. The bottom line of the box plot indicates the 25 percentile, the 
top line the 75 percentile. The median is shown as horizontal bar. Sera (n=4-6) were titrated against coated 
homologous peptide alone (not coupled to TT) revealing peptide specific antibodies only. (A) First round of 
immunisation; (C) further modified and stabilised peptides. One Way Anova was applied and significant 
difference is indicated as * p<0.05 as determined by the Student-Newman-Keuls method. (B) and (D) show 
median serum dilution curves of groups of mice (n=4-6) against the corresponding homologous peptide. 
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2. Reactivity of mouse sera against heterologuous wt-sequence 
2.1. wt-HNE-peptide 
All sera from immunised mice were analysed for their crossreactivity with wt-HNE-peptide 
(KGQQACKGKIQALCEN) (Figure 43 top panel). Mice immunised with TT-2741 gave a 
significantly higher antibody titres against wt-HNE-peptide compared to those induced by 
TT-2744 (p<0.05). The low level of crossreacting antibodies induced against TT-2744 could 
be explained by the lower solubility of this peptide. No significant differences in antibody 
titres were observed between TT-2741, TT-2745 and TT-2751, similar to their reactivity with 
the homologous peptide (Figure 42A). 
Evaluation of anti-wt-HNE-peptide antibody levels induced against peptide-conjugates with 
additional modifications, showed that these conjugates form two distinct groups with respect 
to their ability to induce crossreactive antibodies (Figure 43B). Sera from mice immunised 
with constructs TT-2787, TT-2809 and TT-2791 recognised wt-HNE-peptide better than those 
immunised with TT-2805, TT-2807 and TT-2784, with a statistical significance between TT-
2805 and TT-2787 and TT-2809, respectively (p<0.05). There was little difference between 
the various peptide-conjugates within the two groups. The clustering of groups against wt-
HNE-peptide differed from the results observed against homologous peptide where TT-2787 
induced higher levels of antibodies than the other modified HNE-peptide-conjugates. It was 
estimated that a higher proportion of the anti-peptide antibodies induced against TT-2809 and 
TT-2791 crossreacted with wt-HNE-peptide than those induced against the other peptide-
conjugates. Based on these results, peptide-conjugates TT-2787 and TT-2809 were selected to 
analyse the influence of a variety of adjuvants. 
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Figure 43: Assessment of crossreactivity with wt-HNE-peptide induced against different TT-peptide-
conjugates 
wt-HNE-peptide specific serum end point titres after 4 injections of TT-peptide-conjugates were determined in 
ELISA at 5 times OD response of negative sera. The bottom line of the box plot indicates the 25 percentile, the 
top line the 75 percentile. The median is shown as horizontal bar. Sera (n=4-6) were titrated against coated 
heterologous wt-HNE-peptide (KGQQACKGKIQALCEN) alone (not coupled to TT) revealing wt-HNE-peptide 
specific antibodies only. (A) First round of immunisation; (B) further modified and stabilised peptides. One Way 
Anova was applied and significant difference is indicated as * p<0.05 as determined by the Student-Newman-
Keuls method. 
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2.2. recombinant MV-H-protein 
In a further effort to demonstrate the HNE-crossreactivity of induced antibodies, sera from 
mice immunised with the first set of stabilised peptides, were titrated against recombinant H-
protein in ELISA (Figure 44) and showed only weak levels of crossreacting antibodies. 
Immunisation with wt-HNE-peptide-conjugate induced the highest level of antibodies. There 
was no significant difference in the levels of antibodies raised by peptide-conjugates TT-
2741, TT-2745 and TT-2751. Sera from mice immunised with TT-2744 showed the lowest 
crossreactivity with recombinant H-protein compared to wt-HNE-peptide (p<0.05) 
confirming the results obtained throughout the study. 
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Figure 44: Crossreactivity with recombinant MV-H-protein of sera from mice immunised with HNE-
peptide-conjugates. 
H-protein specific crossreactivity after 4 injections of TT-peptide-conjugates were determined in ELISA using 
mouse sera (1:200 dilution) titrated against 125ng of coated recombinant H-protein and are expressed as 
absorbance in mOD. The bottom lines of the box plots indicate the 25 percentile, the top line the 75 percentile. 
The median is shown as horizontal bar. . One Way Anova was applied and significant difference is indicated as * 
p<0.05 as determined by the Student-Newman-Keuls method. 
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3. Effect of adjuvants 
3.1. Reactivity of mouse sera against homologous peptides 
Irrespective of adjuvant used, serum EPT values of mice immunised with peptide-conjugates 
TT-2787 and TT-wt-HNE-peptide (TT-2833) showed no significant difference between each 
other when titrated against coated homologous peptide (Figure 45). In contrast TT-2809 
induced lower anti-peptide antibodies (p<0.001). Immunisation of TT-wt-HNE-peptide 
(2833) with Montanide lead to significantly lower anti-peptide antibody titres compared to 
Alum, Quil-A and Freund adjuvant (p<0.05). Similarly, the combination of TT-2787 with 
Montanide was less potent than the other adjuvants, especially Freund adjuvant (p<0.05). 
When all peptide-conjugates are considered, Montanide induced significantly less antibodies 
than Alum (p<0.01), Freund’s adjuvant (p<0.01) and Quil-A (p<0.05). 
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Figure 45: Assessment of anti-peptide specific response after immunisation with peptide-conjugates using 
different adjuvants 
Anti-peptide specific end point titres (mean ±SD) after 4 injections of TT-peptide-conjugates determined in 
ELISA at 5 times OD response of negative sera. Sera (n = 4-6) were titrated against coated homologous peptide 
alone (not coupled to TT) revealing peptide specific antibodies only. Two Way Anova was applied and 
significant difference is indicated as * p<0.05 and *** p<0.001 as determined by the Student-Newman-Keuls 
method. 
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3.2. Reactivity of mouse sera against heterologuous wt-HNE-peptide 
Irrespective of the adjuvant used, peptide-conjugate TT-2787 induced higher levels of wt-
HNE-peptide crossreactive antibodies than TT-2809 (p<0.01) (Figure 46). TT-2787 peptide-
conjugate worked significantly better than TT-2809 when injected in combination with Quil-
A (p<0.01). The TT-2787 peptide-conjugate showed no difference in antibody levels 
irrespective of the adjuvants used. These data showed that there were significant differences 
between the adjuvants depending on which peptide-conjugate was used. In general Alum was 
the most appropriate universal adjuvant.  
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Figure 46: Assessment of crossreactivity to wt-HNE-peptide induced against different TT-peptide-
conjugates 
wt-HNE-peptide specific crossreactive end point titres (mean ±SD) after 4 injections of TT-2787 and TT-2809 
peptide-conjugates determined in ELISA at 5 times OD response of negative sera. Sera (n = 4-6) were titrated 
against coated heterologous wt-HNE-peptide (KGQQACKGKIQALCEN). Two Way Anova was applied and 
significant difference is indicated as ** p<0.01 as determined by the Student-Newman-Keuls method. 
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4. Flow Cytometry – Facs 
Flow cytometry with Mel-JuSo transfected cell lines expressing the MV-H-protein was 
performed to test the crossreactivity of antibodies with native MV-H-protein after 
immunisation with TT-peptide-conjugates. Sera, immunised with different peptide-conjugates 
recognised native MV-H-protein with varying affinities: Similar to the results with 
recombinant H-protein in ELISA, wt-HNE-peptide-conjugate induced always higher levels of 
crossreactive antibodies compared to TT-2741 (p<0.05), TT-2744 (p<0.001), 2745 (p<0.05) 
and 2751 (p<0.05) (Figure 47A). Peptide-conjugate TT-2741 immunised mice reacted better 
than those injected with TT-2745 and TT-2751. When compared to the antibody binding to 
recombinant H-protein in ELISA, the crossreactivity of TT-2741 to native H-protein is 
increased relative to TT-2745 and TT-2751. TT-2744 immunised mice essentially lacked 
crossreactivity similar to our observations in H-protein ELISA. 
 
Of the second series of peptide-conjugates, TT-2787 (1 out of 6 sera) and TT-wt-HNE-
peptide (3 out of 6) induced crossreactive antibodies with H-protein. None of the stabilised 
HNE-peptides, containing di- and tri-methylated Lys induced antibodies crossreacting with 
the H-protein when coinjected with Freund adjuvant (data not shown). 
 
To assess whether adjuvants could affect the crossreactivity of the antibodies, Montanide, 
Quil-A or Alum were coinjected with TT-2787, TT-2809 or TT-2833 (wt-HNE-peptide) 
conjugate. When TT-2787 and TT-2809 were administered with Montanide, 2 out of 6 or 1 
out of 6 H-protein crossreactive sera were obtained. No crossreactivity was observed when 
TT-2787 and TT-2809 were injected with Quil-A or Alum (data not shown). H-protein 
binding of sera immunised with TT-wt-HNE-peptide-conjugate was observed irrespective of 
the used adjuvants (Figure 47B). The efficacy of adjuvants to induce crossreactive antibodies 
varied with Montanide and Quil-A inducing 4 out of 6 and 5 out of 6 crossreactive sera, 
respectively, whereas in the Alum and Freund adjuvant groups only 2 out of 5 and 3 out of 6 
mice sera were positive, respectively. 
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Figure 47: Crossreactivity with native MV-H-protein of anti-HNE-peptide sera 
Crossreactivity with MV-H-protein of mouse sera after immunisation with TT-peptide-conjugates was measured 
by flow cytometry on Mel-JuSo-H transfected and Mel-JuSo-wt cells. Boxplot bars represent median values of 
AFU ratios (AFU H / AFU wt). The bottom lines of the box plots indicate the 25 percentile, the top line the 75 
percentile. Ratios above 2 are considered positive. (A) 1/50 serum dilution of mice immunised with various TT-
peptide-conjugates (n=4-5); (B) 1/100 serum dilutions of mice immunised with TT-wt-HNE-peptide-conjugate 
(n=5-6) in combination with 4 different adjuvants. One Way Anova was applied and significant difference is 
indicated as * p<0.05 and *** p<0.001 as determined by the Student-Newman-Keuls method. (C-H) Typical 
flow cytometry histograms of crossreactivity with H-protein on Mel-JuSo-H cells (red histogram) and Mel-JuSo-
wt cells (open histogram) TT-2741 (C), TT-2744 (D), TT-2745 (E), TT-2751 (F), TT-2752 (wt-HNE) (G) and 
adjuvant only (H) 
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Part: IV Bile-acid peptide-scaffold analysis 
1. Synthetic pathway 
1.1. Synthesis of scaffold-peptide construct 
In collaboration with Catherine Bodé at the Department of Organic Chemistry at the 
University of Ghent, we have evaluated an HNE-peptide-scaffold construct. We investigated 
the feasibility to restrict the conformation of a the HNE-peptide using a bile-acid based 
scaffold. The detailed description of the chemistry of the scaffold-peptide construct is beyond 
the scope of this thesis (Bodé et al.; Bodé 2007; Bodé et al. 2007) . In the following 
paragraphs only a short summary of the chemical synthesis pathway of the scaffold-peptide 
construct will be described, followed by a more in depth analysis of the biological data 
observed. 
 
An orthogonally protected bile-acid based steroidal scaffold was coupled to a functionalised 
Tentagel resin for SPPS, via a photolabile linker, which allowed easy deprotection and 
chemical analysis of reaction intermediates. Two approaches for the synthesis of the peptide 
on the scaffold were investigated: The two-strand approach is based on convergent solid 
phase peptide synthesis. One part of the peptide was synthesised on the C-12 amine of the 
scaffold linked to the resin. The second part of the peptide sequence was assembled separately 
on another resin. After resin cleavage the sidechain-protected peptide was coupled via the N-
terminus to the C-3 amine of the scaffold via compatible linkers (succinic acid). After 
successful coupling, the two strands were connected via simple backbone cyclisation to yield 
the final product. This two strand approach with convergent SPPS has a clear advantage in the 
synthesis of difficult and/or large peptide sequences. The second peptide sequence can be 
purified prior to coupling to the scaffold, thus reducing the number of by-products. This two 
strand approach was however complicated by several factors including difficulties of coupling 
the second strand to the scaffold. 
The single strand approach is based on the stepwise synthesis of the peptide strand starting 
from Fmoc-protected Gly linker residue coupled to the scaffold. After completion of the 
peptide sequence, the peptide was oxidised to form the disulfide bridge. The peptide strand 
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was coupled to the C-3 amine of the scaffold via the succinic acid linker thus closing the 
peptide loop. The orthogonal sidechain protection groups were removed by TFA and the 
scaffold-peptide construct was cleaved from the resin by UV-irradiation. After purification of 
the scaffold-peptide construct we analysed it in a collaboration for its stability, antigenicity 
and immunogenicity (Figure 48). 
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Figure 48: Synthetic pathway for scaffold-peptide construct 
The synthetic pathway starting with steroidal scaffold, linkage to resin and functionalisation of scaffold, one 
strand peptide synthesis on scaffold, followed by cystine formation, backbone cyclisation, sidechain protection 
group removal and cleavage from resin to yield final scaffold-peptide construct. 
 
1.2. Synthesis of cyclic control peptide 
To assess the influence of the scaffold of the scaffold-peptide construct on biostability, 
antigenicity and immunogenicity, a peptidic control sequence was synthesised. This control 
peptide contains the same peptide sequence as the scaffold-peptide construct including the 
disulfide bridge and merely lacks the scaffold itself. The synthetic pathway started with a 
Fmoc-Glu395-OAll residue which was covalently coupled via its sidechain to chlorotrityl resin 
and the peptide chain was elongated via SPPS until completion of the peptide sequence. The 
intermediate peptide “Fmoc-N-G-Q-A-C-K-G-K-I-Q-A-C-E-(resin)” was oxidised to form the 
disulfide bridge, followed by backbone cyclisation between amine group of N-terminal Asn 
residue and the carboxy group of Glu, to form the cyclised control peptide with a Gly spacer 
between “C-terminal” Glu and “N-terminal” Asn. Cyclisation of the peptide sequence prior to 
cystine formation caused dimerisation of the peptide chains presumably because of the high 
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loading of the resin. In this context it is important to differentiate between cyclic and oxidised 
peptides. Here cyclisation refers to the backbone connection of N- and C-terminal amino 
acids thus forming a cyclic peptide. Peptides such as the HNE-peptide with a disulfide bridge 
in the sequence are referred to as linear oxidised peptides. 
 
2. Biological evaluation 
2.1. Biostability 
Preliminary tests of the biostability of the scaffold-peptide construct and the cyclised control 
peptide indicate that after 24 h incubation in mouse serum, over 75% of the peptides remain 
intact (data not shown). This was a significant improvement in comparison with the natural 
wt-HNE-peptide which was degraded to 25% within the same time. Despite these 
improvements neither the scaffold nor the cyclisation increased the peptide stability to the 
same extent as our internal and C-terminal modifications. 
 
2.2. Antigenicity 
The cyclic peptide and scaffold-peptide construct were tested for their reactivity with anti-
HNE mAb BH216, BH21 and BH6. Binding patterns of BH216 and BH21 were similar, 
showing that binding to scaffold-peptide construct was stronger (Figure 49A) than binding to 
linear oxidised wt-HNE-peptide (KGQQACKGKIQALCEN). The cyclic control peptide gave 
a much weaker binding. Binding patterns to BH6 were predictably different: the linear 
oxidised control peptide gave the highest binding followed by the scaffold-peptide construct 
and cyclic peptide. It is interesting to note that the cyclic peptide gave much better binding 
with BH6 than it did with BH216 (Figure 49B). No binding of peptides to negative control 
BH195 were observed, which specifically recognises the PEWA region of denatured H-
protein. 
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Figure 49: Antigenicity of scaffold-peptide construct and cyclic control peptide tested with anti-HNE 
monoclonal antibodies. 
Scaffold-peptide construct (open circle) and cyclic control peptide (triangle) were analysed for their ability to 
bind monoclonal antibodies BH216 (A) and BH6 (B) in indirect ELISA in relation to wt-HNE-peptide 
(KGQQACKGKIQALCEN) (closed circle). 
 
2.3. Immunogenicity 
The chemistry of the scaffold-peptide construct and of the cyclic peptides did not allow 
covalent coupling to tetanus toxoid. The only available reactive amine and carboxy groups 
were located on sidechains and coupling would likely destroy the epitope. Thus peptides were 
merely mixed with TT in immunisation tests. Following the same immunisation schedule with 
Freund adjuvant described previously we injected 20 µg of each peptide either alone or mixed 
with 20 µg TT. After 3 injections sera of immunised mice were analysed for the presence of 
anti-peptide antibodies (Figure 50). The scaffold-peptide construct and the cyclic peptide 
induced high and comparable titres when coinjected with TT. In the absence of TT, the 
scaffold-peptide construct induced a much lower antibody titre and cyclic peptide was 
essentially non-immunogenic, demonstrating the benefit of additional T cell epitopesof TT. 
In order to establish the crossreactivity of the induced antibodies, sera of mice immunised 
against scaffold-peptide construct were titrated against coated cyclic control peptide in ELISA 
(data not shown). Poor binding was observed for scaffold-peptide construct mixed with TT 
and scaffold-peptide construct injected alone showed no crossreactivity. This poor binding 
can be explained either by the fact that most antibodies raised against the scaffold-peptide 
construct targeted the scaffold only, or more likely, that the structure of the cyclic peptide 
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differs substantially from the one adopted by the same peptide sequence constrained by the 
scaffold. 
Neither the scaffold-peptide construct nor the cyclic peptide induced sera crossreacting with 
recombinant MV-H-protein or with the native MV-H-protein expressed by Mel-JuSo-H cells 
assessed by ELISA and flow cytometry, respectively (data not shown) 
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Figure 50: Assessment of anti-peptide specific response after immunisation with scaffold-peptide construct 
and cyclic peptide with or without TT 
Serum dilution curves of mice (n=6) after three injections of scaffold-peptide construct mixed with TT (A), 
scaffold-peptide construct alone (B), cyclic peptide mixed with TT (C) and cyclic peptide alone (D) in ELISA 
against coated scaffold-peptide construct (A,B) and coated cyclic peptide (C,D). 
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Chapter 4: Discussion 
1. Role of Cysteine bridges and of the HNE 
The recent publication of two X-ray crystallography structures of the measles H-protein (Colf 
et al. 2007; Hashiguchi et al. 2007) has allowed us to put our structure of the wt- HNE-peptide 
into the context of the native H-protein. So far only few models were available: (1) a 3D 
structure obtained by homology modelling on the basis of the crystal structure of influenza 
virus neuramidase (Langedijk et al. 1997). After the publication of the crystal structure of the 
haemagglutinin-neuraminidase (HN) protein of Newcastle disease virus (NDV) (Crennell et 
al. 2000) the model of MV-H-protein was refined: (2) A new model of the H-protein based on 
the HN-protein of NDV was proposed (Vongpunsawad et al. 2004). (3) A second model with 
NDV as a template using sequence homology, secondary structure prediction and protein 
folding was created (Masse et al. 2004). (4) A fourth structure was predicted by concerted use 
of homology modelling, fold recognition and de novo folding techniques also based on the 
crystal structure of the HN-protein of NDV (Damien et al unpublished). 
While these models gave a good indication on the location of protruding accessible loops of 
the H-protein, the structure of these loops was not well defined and the proposed Cys bridges 
remained a matter of debate for some time. The importance of the Cys in the structure and 
function of the H-protein has been recognised early on (Hu and Norrby 1994) and this is 
reflected in the conservation in number and position of the Cys in all MV isolates. The Cys 
pattern is not limited to MV but Cys are also conserved in the H-protein of rinderpest virus 
(Tsukiyama et al. 1987), canine (Curran et al. 1991), phocine (Kovamees et al. 1991) 
distemper viruses and all other morbilliviruses (Ziegler et al. 1996). However there has been 
conflicting data on which Cys bridges are important in the structure of the HNE. Hu and 
Norrby suggested that Cys381, Cys394 and Cys494 are essential for the function of the H-
protein and that Cys386 is most likely unpaired (Hu and Norrby 1994). Cys381 was suggested 
to form a disulfide bond with Cys494. The model by Langedijk on the other hand predicts the 
disulfide bridges Cys381-Cys386 and Cys394-Cys494. Earlier work within our laboratory by 
Ziegler could only show a functional importance for Cys394 and El Kasmi found that the 
presence of all three HNE Cys in peptides were necessary for the induction of MV-
neutralising antibodies (Ziegler et al. 1996; El Kasmi et al. 2000). More recent work by Putz 
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demonstrated that peptides containing only the Cys386-Cys394 bridge induced MV-
neutralising sera (Putz et al. 2003b). In this study we have also confirmed by Cys substitution 
of full length HNE peptides, the recognition of peptides with a Cys386-Cys394 bridge by 
anti-HNE mAbs. The importance of the Cys386-Cys394 disulfide bridge was also confirmed 
by the two crystal structures of the H-protein; both of them predict Cys bridges between 
Cys386-Cys394 and Cys381-Cys494. The structure of the loop and Cys positions preclude the 
formation of both Cys381-Cys386 and Cys381-Cys394 bridges, since Cys381 is locked in an 
α-helix pointing in the opposite direction of Cys 386 and Cys394 (Figure 51). 
While it seems that the crystal structures and our results contradict the data by Hu and 
colleagues, these data could represent different states of the H-protein: The disulfide bridges 
in a native protein are the end result of a process of oxidation, reduction and isomerisation of 
disulfide bonds by enzymes such as protein disulfide isomerase (Creighton et al. 1995), 
suggesting that different disulfide bridge arrangements may exist in the H-protein at different 
stages of its life cycle. It has also been reported that reduction and rearrangement of disulfide 
bridges in native proteins act as switches for biological functions (Hogg 2003). For example 
cleavage of various disulfide bonds within the bound complex of CD4 immune cell receptor 
and gp120 surface protein of HIV-1 has been reported to be essential for virus entry and cell-
cell fusion (Fenouillet et al. 2001; Gallina et al. 2002; Matthias et al. 2002). Even though such 
an effect has never been directly suggested in the case of MV-H it cannot be excluded that 
disulfide bridges undergo functional rearrangements. 
Disulfide bridges are important for stabilising the conformation of proteins by lowering the 
entropy of the unfolded state by restricting the degrees of freedom (Sternberg 1997). They 
also ensure the structural integrity of proteins and can protect them against oxidants and 
proteolytic cleavage (Arolas et al. 2006). In the HNE the disulfide bond between Cys386 and 
Cys394, located in two distinct α-helices, stabilises a turn between these two α-helices. The α-
proton chemical shift data obtained for the reduced Gly8Val substituted peptide suggests an 
elongation of the α-helix in the absence of disulfide link induced loop. This structural change 
may be responsible for the lack of reactivity of anti-HNE mAb with reduced HNE-peptides. It 
is however unknown whether a lack of disulfide bonds in the HNE would lead to the same 
structural change in the H-protein. This seems unlikely since the HNE is more constrained 
within the H-protein compared to the flexible free peptide. The disulfide bridge in the HNE-
peptides is essential for maintaining a structure able to mimic the HNE arrangement of the H-
protein. 
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The actual role of the HNE and its conserved Cys residues remains unclear. Since the HNE-
antibody binding motif is conserved in most known MV isolates (Putz et al. 2003b) and the 
Cys located within the HNE are conserved in all known morbilliviruses it very likely that this 
region has a very important but unknown function. 
It has been known for some time that the H-protein of wt-MV preferentially binds SLAM 
(CD150) and not CD46 (Yanagi et al. 2006). Mutational studies have shown that Pro486 and 
Ile487 are critical for H-protein binding to CD46 (Vongpunsawad et al. 2004) and 
substitutions in the vaccine strains (Asn390Ile, Asn481Tyr) further enable CD-46 binding 
(Bartz et al. 1996; Tahara et al. 2007). Residue 390 is located in the HNE, and the other 
amino acids are located in the opposite loop, which is kept in close proximity to the HNE by 
the Cys381-Cys494 disulfide bridge. It is thus possible that the HNE, with its proposed 
Cys386-Cys394 and Cys381-Cys494 disulfide bonds may stabilise the secondary structure 
required for CD46 binding and retain the function of regions located further away or possibly 
support conformational changes after binding which play a role in cell-cell fusion. 
Hashiguchi showed that although N-linked sugars hide several H-protein domains, the 
receptor binding sites and the HNE-loop remain exposed. A role in receptor binding would 
explain the relative conservation of the HNE-sequence (Hashiguchi et al. 2007). This would 
also explain the neutralising capacity of our HNE-targeting mAbs (BH216, BH21 and BH6). 
Cys394
Cys386
Cys381
Cys494
 
Figure 51: HNE cysteine residues 
The crystal structure of H-protein (Hashiguchi et al. 2007) is shown as cartoon type, HNE region 
(E379TCFQQACKGKIQALCENPEWA400) is coloured in blue, HNE Cys residues are labelled and disulfide 
bridges between Cys381-Cys494 and Cys386-Cys394 are shown in yellow. 
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2. HNE-peptide structures 
Comparisons of observed α-proton chemical shifts with literature values of random coil 
structures provided qualitative information on the position and nature of secondary structure 
elements in the modified HNE-peptides, without the need to resolve complete structures. It 
was thus shown that the majority of substitutions of Gly8, Ile10 and Leu13 of the wt-HNE-
peptide (KGQQACKGKIQALCEN) did not lead to an apparent loss of α-helical structure of 
the C-terminus. Notable exceptions were Gly8Pro, which due to the backbone twist affected 
the loop around Gly8, and Leu13Asn. Asn is known to be strongly helix-destructive and the 
α-proton chemical shifts confirm that the helix formation was inhibited and the whole peptide 
adopted a random coil structure (Pace and Scholtz 1998). N-terminal Asn may also account 
for the break in the α-helix observed in both our HNE-peptides and the HNE of the H-protein. 
We observed that some modified and wt-HNE-peptide retained most of their secondary 
structure in water even if the helix was weakened. This is surprising since short peptides 
usually do not adopt a secondary structure in water (Shepherd et al. 2005). We suspect that 
the disulfide bridge between Cys6 and Cys14 can account for this high stability. At the same 
time we showed that a Gly8Val substitution and a break in the disulfide bond increased the α-
helical content of the modified HNE-peptide, further confirming the tendency of this region to 
adopt such a secondary structure. 
 
2.1. wt-HNE-peptide 
Peptides can adopt a multitude of structures when they are removed from the constraints of 
the protein of which they are part. This effect was also obvious in our NMR structures. 
Comparisons of the crystal structure of the HNE region 
(E379TCFQQACKGKIQALCENPEWA400) of the H-protein (Hashiguchi et al. 2007) and our 
NMR structure of the wt-HNE-peptide (K1GQQACKGKIQALCEN16) clearly show that the 
structure of the flexible N-terminal linkerarm region observed in the HNE-peptide does not 
correlate to the structure of the N-terminal HNE in the H-protein (Figure 52). In the H-protein 
the amino acids preceding the loop around Gly8 form an α-helix keeping the critical contact 
residue Lys 7 in a more constrained conformation compared to the free peptide. In addition 
the N-terminal linkerarm in the free HNE-peptide adopts an orientation that would not be 
allowed in the protein because of steric hindrance from other structural domains. The helical 
region with the critical contact residues for antibody binding (BH216) on the other hand is 
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conserved in the free HNE-peptide, indicating that the structural informations for the α-helix 
are contained in the Ile10 to Asn16 sequence, independent of protein environment. The N-
terminal region Lys1-Lys7 requires other structural features of the H-protein to keep it in a 
helical conformation. It is also possible that the Lys1-Gly2 extension prevents helix 
formation. Gly has a greater conformational freedom because of its lack of sidechain 
(Sternberg 1997) and breaks the α-helix as shown by Gly8 in the HNE-peptide and Gly388 in 
the H-protein. 
Our resolved NMR structure of the wt-HNE-peptide was considerably more accurate than the 
molecular model of the HNE-peptide (QACKGKIQALCEN) previously generated by 
dynamic simulations (Putz 2004). The critical and non-critical residues were correctly located 
in opposite planes however that model did not predict the α-helix that we observed in the 
NMR structure. The relative positions of the critical residues were significantly different 
between the model and the NMR structure. This indicates that a purely dynamic modelling, 
based on force-fields, cannot give a correct representation of the structure of small peptides. 
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Figure 52: Superposition of H-protein and wt-HNE-peptide structures 
Crystal structure of H-protein (orange) and central structure wt-HNE-peptide (green) superposed by alignment of 
residues 390 to 395/10 to 15. Peptide backbones are shown as tubes and critical contact residues Lys387/7, 
Gln391/11 and Glu395/15 are shown as sticks. 
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2.2. Structure of Gly8Ala 
The superposition of the structures calculated for HNE-peptide mutants gave important clues 
about the effects of certain amino acid substitutions on the peptide structure, effects that are 
difficult to predict. Together with the results of the ELISA with mAb BH216 of HNE-
peptides these changes could shed light on the biological results and especially on the 
structural requirements for sustained antigenicity of the HNE-peptide. 
The Gly8Ala substituted peptide was part of a series of Gly8 mutants synthesised to 
investigate the importance and structure of the Gly loop formed by disulfide bond in the 
HNE-peptide structure and to further investigate the orientation of the N-terminal linkerarm 
observed in some of the wt-HNE-peptide conformations. Alignment of Gly8Ala to wt-HNE-
peptide was somewhat complicated by the peculiar conformation of the central structure. As 
seen in Figure 23, the orientation of the linkerarm of the central conformation did not align 
with those of the other 19 low energy conformations, while the the structural features of the 
loop between Cys6 and Cys14 are conserved in all these conformations. Comparisons 
between wt-HNE-peptide and Gly8Ala peptide showed that the position and orientation of the 
critical contact residues Gln11 and Glu15 sidechains within the helix are well conserved 
(Figure 53). The loop distortion caused by the substitution of Gly to Ala has severe effects on 
the position of Lys7 which is moved out of the plane formed by the contact residues in the wt-
HNE-peptide. This shift together with the tendency of the linkerarm to point into the binding 
domain explains the absence of interaction of mAb BH216 with this peptide. These results are 
confirmed by comparisons with the structure of the H-protein. Superposition of the central 
structure of Gly8Ala (Figure 54) and the twenty lowest energy conformations of Gly8Ala 
mutant (Figure 55) with H-protein confirmed the loop distortion between Cys6 and Cys14 and 
linkerarm orientation into the antibody binding domain. The lack of binding of mAb BH216 
to Gly8Ala peptide could be explained by comparison to both the HNE-peptide NMR 
structure as well as the H-protein crystal structure. The linkerarm orientation observed after 
Gly8Ala substitution may be caused by steric hindrance of the Ala sidechain with the 
backbone of the neighbouring residues, which causes a distortion of the Gly loop and a 
rearrangement of the peptide into an energetically preferred conformation. These results 
explain why no substitution of Gly8 is allowed without abolishing antigenicity.  
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Figure 53: Superposition of wt-HNE-peptide and Gly8Ala mutant peptide structures 
Central structures of wt-HNE-peptide (green) and Gly8Ala mutant peptide (pink) superposed by alignment of 
residues 10 to 15. Peptide backbones are shown as tubes and critical contact residues Lys7, Gln11 and Glu15 are 
shown as sticks. 
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Figure 54: Superposition of H-protein and Gly8Ala mutant peptide structures 
Crystal structure of H-protein (orange) and central NMR structure of Gly8Ala mutant peptide (pink) superposed 
by alignment of residues 390 to 395/10 to 15. Peptide backbones are shown as tubes and critical contact residues 
Lys387/7, Gln391/11 and Glu395/15 are shown as sticks. 
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Figure 55: Superposition of H-protein and 20 lowest energy conformations of Gly8Ala mutant peptide 
Crystal structure of H-protein (orange) and 20 lowest NMR energy conformations of Gly8Ala mutant peptide 
(coloured) superposed by alignment of residues 390 to 395/10 to 15. Peptide backbones are shown as tubes, 
central structure of Gly8Ala is in pink. 
 
2.3. Structure of Ile10Ala 
To increase the reactivity of the wt-HNE-peptide with mAbs we tried to reduce the flexibility 
of the α-helix in the peptide (Gurunath et al. 1995). While Ile10Ser lost antibody binding, the 
Ile10Ala substitution preserved some of the reactivity with mAb BH216 (Putz et al. 2003b). 
Since Ala is at the top of the propensity scale and thus the most preferred amino acid in α-
helices (Chou and Fasman 1974), the helix is well conserved in comparison to the wt-HNE-
peptide (Figure 56). Despite its distant location, the Ile10Ala substitution still influenced the 
linkerarm orientation with Lys7 pointing much further towards the antibody binding region. 
This would explain the partial loss in reactivity with mAb in the ELISA. The comparison of 
the Ile10Ala peptide with the H-protein shows that both align very well (Figure 57). There is a 
much better superposition of Lys7 of the Ile10Ala substituted peptide with Lys387 of H-
protein than there is of wt-HNE-peptide Lys7 and the H-protein Lys387 residue. Thus, in 
principle Ile10Ala should react better with BH216 than the wt-HNE-peptide. However, the 
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reduced reactivity with BH216 is probably again linked to the orientation of the linkerarm of 
the peptide. The linkerarm in the wt-HNE-peptide points in the opposite direction of the 
binding domain and is thus less likely to sterically interfere with an approaching antibody 
than the linkerarm of the Ile10Ala mutant which is located in the same plane as the antibody 
binding domain. The small position shift of Lys7 observed for the wt-HNE-peptide may be 
compensated by induced fit, thanks to the inherent flexibility of the peptide, by a slight 
distortion of the loop between Cys6 and Cys14, which would superpose the two Lys and 
allow antibody binding. 
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Figure 56: Superposition of wt-HNE-peptide and Ile10Ala mutant peptide structures 
Central structures of wt-HNE-peptide (green) and Ile10Ala mutant peptide (blue) superposed by alignment of 
residues 10 to 15. Peptide backbones are shown as tubes and critical contact residues Lys7, Gln11 and Glu15 are 
shown as sticks. 
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Figure 57: Superposition of H-protein and Ile10Ala mutant peptide structures 
Crystal structure of H-protein (orange) and central structure of Ile10Ala mutant peptide (blue) were superposed 
by alignment of residues 390 to 395/10 to 15. Peptide backbones are shown as tubes and critical contact residues 
Lys387/7, Gln391/11 and Glu395/15 are shown as sticks. 
 
2.4. Structure of Ile10Ser 
As demonstrated by Putz (2003b), an HNE-peptide with an Ile10Ser mutation lost the ability 
to react with anti-HNE mAb. This may seem surprising since Ile10 is not a contact residue but 
most likely plays a structural role. Negative effects on the α-helix of the HNE-peptide and 
consequently antibody binding were not expected since Ile and Ser are situated midfield on 
the propensity scale with 0.41 and 0.5 kcal/mol, respectively. The scale ranges from 0 
kcal/mol for Ala which is the amino acid most preferred in α-helices, to 1 kcal/mol for Gly, 
the least preferred residue (Pace and Scholtz 1998). Comparisons between the Ile10Ser 
mutant and wt-HNE-peptide and the HNE-epitope in the H-protein confirm that the α-helix 
together with the position and orientation of the critical contact residue Gln11 remain fairly 
well conserved (Figure 58A, Figure 59). As previously shown, the C-terminal region of the 
helix is more flexible compared to the rest of the HNE-peptide structures and the twists seen 
for Glu15 are expected to account for some of the reduced reactivity with antibodies. Ser also 
has a major influence on the structure of the loop between the two Cys residues. The loop 
appears more elongated compared to the wt structures (HNE-peptide and H-protein) resulting 
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in a significant shift of Lys7 (Figure 58B). In addition the flexible linkerarm tends to lie in the 
same plane as the Lys7 / Lys387 sidechain of the HNE and is likely to block access to the 
antibody (Figure 58A, Figure 59).  
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Figure 58: Superposition of wt-HNE-peptide and Ile10Ser m
Central structures of wt-HNE-peptide (green) and Ile10Sser mu
residues 10 to 15. Peptide backbones are shown as tubes and cr
shown as sticks. Lateral view (A), top view (B). 
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3. Stability and antigenicity 
The half-life of wt-HNE-peptide was the benchmark to which peptides modified for enhanced 
stability would be compared to. The stability of the peptides was tested in mouse serum, 
which is commercially available and known to represent a high protease activity, even if 
immunisations are not done by intravenous route but by intraperitoneal injection. 
Intraperitoneal fluid is rarely available and collection cannot be easily standardised. The use 
of serum is therefore generally accepted as a useful fluid to assess the stability of peptides to 
be used in a clinical setting (Brinckerhoff et al. 1999). For instance, degradation experiments 
comparing peptide stabilities in human serum and synovial fluid found no difference between 
the two (Powell et al. 1992). Thus as a model, serum was an appropriate choice for stability 
testing of peptides and given the context of the experimental settings, serum from mice was 
chosen. 
 
Analysis of the wt-HNE-peptides revealed a number of factors known to stabilise peptides: (i) 
the C-terminal amide stabilises peptides against exopeptidase degradation (Maillère et al. 
1995; Brinckerhoff et al. 1999; Marschütz et al. 2002) and has been used throughout our 
study. (ii) Disulfide bridges stabilise peptide conformations and to some extent also block 
peptidase activity (Tugyi et al. 2005a). (iii) Prior to immunisation HNE-peptide was coupled 
to tetanus toxoid, which acted as carrier and provided important T cell epitopes to induce an 
immune response. The conjugation, via the N-terminal amine groups, blocked the HNE-
peptide N-terminus from aminoexopeptidases specifically. 
 
Our NMR studies have helped our understanding of the structural effects of amino acid 
substitutions on peptide antigenicity. Initial modifications of the HNE-peptide to increase the 
stability without compromising its reactivity with the antibodies, focused on the extension of 
the C-terminus, because even substitutions of non-critical residues of the α-helix had negative 
effects on antigenicity. Previous work in our laboratory (Putz 2004) established that residues 
N396PEWA400 could be replaced with any number of residues without interfering with 
antibody binding. Our NMR structure of the wt-HNE-peptide has shown that the C-terminus 
following Glu15 points away from the antibody binding site and therefore C-terminally 
extended amino acids were not expected to severely influence antigenicity. The orientation of 
the backbone was also confirmed in later publications of the X-ray crystal structures of the 
native H-protein (Colf et al. 2007; Hashiguchi et al. 2007). 
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To simulate the carrier protein and hopefully block degradation via aminoexopeptidases, the 
N-terminal Fmoc protection group was assessed. Blocking the N-terminus would have 
allowed us to focus only on carboxypeptidases and endopeptidases which are the only 
peptidases that can degrade N-terminally conjugated HNE-peptides. However, our studies 
have shown that due to premature cleavage in serum, the Fmoc group was not suitable and 
acetylation was more appropriate. N-terminal acetylation has previously been shown to 
protect synthetic peptides against N-terminal degradation (Maillère et al. 1995; Brinckerhoff 
et al. 1999). In fact, in eukaryotes many proteins are protected against N-terminal degradation 
by acetylation (Bell and Strauss 1981; Bradshaw et al. 1998). 
To protect the C-terminus against degradation, candidate residues for C-terminal modification 
were selected from the literature as well as based on structural considerations (see Annexe 1). 
D-amino acids and modified natural amino acids, amongst others, were considered for this 
purpose. A limitation was the commercial availability of Fmoc-protected amino acids 
required for peptide synthesis. Candidate amino acids should not add additional functional 
groups which would potentially influence the peptide structure and affect the interaction with 
the antibody. At the same time they must be structurally different enough from natural amino 
acids to reduce peptide susceptibility towards peptidases. 
Surprisingly the variety of non-natural amino acids failed to significantly improve the 
biostability of peptides. β-amino acids have been reported to increase the stability of peptides 
(Steer et al. 2002; Hook et al. 2004) without loss of biological activity (Frackenpohl et al. 
2001; Sagan et al. 2003). A methyl insertion into the peptide backbone increases peptide 
flexibility (DeGrado et al. 1999; Beke et al. 2006). In our hands this did not adversely affect 
antibody binding since β-Ala was C-terminal and outside the binding domain, however the 
increase in stability was only minimal (data not shown). 
Despite their often unusual structures, nonnatural amino acids such as trans-4-
(aminomethyl)cyclohexane carboxylic acid (t-amcha), 1-amino-cyclohexane carboxylic acid 
(achca) and 4-(aminomethyl)benzoic acid (pamba; data not shown) failed to increase the 
stability of peptides, although antigenicity was conserved as expected. 
D-amino acid residues added C-terminally included the small D-Ala and D-Val and the larger 
D-Phe and D-Leu. As observed with the other non-natural residues, no stabilisation was 
achieved by single amino acid extensions. Only the peptide with a C-terminal D-Ala was as 
stable as wt-HNE-peptide in serum. While several studies have reported increased stabilities 
using one or more D-amino acids at the C-terminus of core epitopes, these were either in 
combination with other N-terminal modifications (Brinckerhoff et al. 1999) or have consisted 
 125
Chapter 4: Discussion 
of D-isomer substitutions of L-amino acids already present in the core peptide sequence 
(Hong et al. 1999). Here additions and not substitutions of residues to the peptide sequence 
were analysed and results are comparable to those obtained by Tugyi and colleagues who 
substituted three C-terminal L-amino acids and observed lower peptide stability (Tugyi et al. 
2005b). More surprisingly the addition of two D-amino acids without other modifications, 
failed to stabilise peptides and all permutations of the above four D-amino acids, with the 
exception of 2 D-Ala residues, reduced or even abrogated antibody binding (amongst others 
peptides: 2711, 2712, 2723, 2742, and 2743; other data not shown). It is thought that the 
second amino acid, regardless of its nature, is located too close to the antibody binding 
domain and therefore reduces antigenicity. 
Extending the peptide by the natural sequence in the H-protein (P397EWA400) generated 
peptides with a stability that was similar to that of wt-HNE-peptide only when combined with 
a D-Ala addition (PEWAa and PEWa). Presumably the increase in stability by D-Ala is 
negatively compensated by the presence of additional cleavage sites. 
The failure to design more stable peptides solely by introducing C-terminal modifications 
suggested that carboxypeptidases play a less important role in degradation than 
aminopeptidases (Hong et al. 1999; Galati et al. 2003). Nevertheless this cannot explain the 
failure to improve stability and even the decrease in stability for certain C-terminal additions. 
While these terminal modifications can protect the peptide against exopeptidases, they have 
no protective effect against endopeptidases. In fact, similar to our findings, Marchütz and 
colleagues have also observed an increased susceptibility of terminally modified peptides 
towards endopeptidases. It was suggested that terminal modifications alter the peptide 
structure, thus exposing endopeptidase susceptible amide bonds (Marschütz et al. 2002). Thus 
C-terminal modifications may gain from combinations with amino acid substitutions within 
the core epitope (Webb et al. 2003). 
To investigate this synergic effect and to increase the biostability of modified peptides, 
several internal substitutions were performed. Based on the fine-mapping work of the epitope 
by Putz (2003b) Lys9 was an interesting substitution site since it could be replaced by a 
variety of amino acids without loss of antibody binding. As a basic residue it is also a 
preferred cleavage site of peptidases. While the stability of the HNE-peptides with Lys9 
substituted by several amino acids (Lys9Ala, Lys9Asn, Lys9Ser, Lys9His, Lys9Gln) were 
markedly increased compared to the wt-HNE-peptide, only the Lys9Ala substitution did not 
compromise antibody binding. Thus this substitution was further used in subsequent stability 
studies. The reduced reactivity with mAb BH216 of the other Lys9 substituted peptides does 
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not necessarily question the validity of the established binding motif, but may indicate that the 
shorter HNE-peptide would be more sensitive to a change in the proximity of the binding 
motif than the full length HNE-peptides, which were used in the fine-mapping studies. 
 
In an effort to further increase the stability and immunogenicity of modified peptides, the 
number of Lys in the peptide sequence was reduced. The hypothesis is that endopeptidases 
would be deprived of their cleavage sites. At the same time coupling to the carrier protein via 
ε-amine groups of Lys in the antibody binding domain would be reduced, thus increasing the 
number of N-terminally coupled and biologically active molecules in peptide-protein-
conjugates. Substitutions of Lys7 without loss of antibody binding were expected to be 
difficult since Lys7 is a critical part of the binding motif. D-Lys substitution of Lys7 showed a 
2 fold increased stability, but the loss of antibody binding suggested that the paratope of 
BH216 is stereospecific. Similarly Hong and Na observed a loss of activity of an 
antimicrobial peptide after D-Lysine substitution in the core epitope (Hong et al. 1999; Na et 
al. 2007). This observation is in line with the structural NMR data of the HNE-peptide and the 
H-protein crystal X-ray crystal structure. The sidechain of D-Lys is likely to point further into 
the antibody binding domain and the loop around Gly8 is expected to be distorted to 
accommodate the new sidechain orientation, thus reducing antibody binding.  
 
Methylation of basic amino acid sidechains has been known for some time to be an important 
post-transcriptional modification in a large number of proteins and can occur as mono-, di- or 
tri-methylation. The most well known Lys methylation is that reported in histones, which is 
important for gene regulation (Bannister et al. 2002; Paik et al. 2007). Methylation of Lys 
residues in the heparin-binding haemagglutinin adhesion protein in mycobacteria was 
reported to render the protein resistant to proteolysis (Pethe et al. 2002). Tri-methylation of 
Lys115 in calmodulin has been shown to inhibit ubiquitin mediated proteolysis (Gregori et al. 
1987). Na and colleagues increased the stability of an antimicrobial peptide using mono-
methylated Lys (Na et al. 2007). In our study substitution of Lys7 of the HNE-peptide showed 
that generally tri-methylated Lys are slightly more stable and more antigenic than di-
methylated Lys substituted peptides. Most surprisingly substitutions with di- and tri-
methylated Lys only increased the stability of HNE-peptides compared to wt-HNE-peptide 
when used in combination with further modifications (such as Lys9Ala substitutions), 
suggesting a synergic effect with respect to the additional modification. It is suspected that the 
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methylation of Lys7 on its own actually increases susceptibility of Lys9 towards 
endopeptidases via steric changes in the peptide structure. 
Norvaline- and norleucine-substitution in position 7 conserved or lowered antigenicity with 
mAb BH216 depending on the other substitutions in the same peptide. These data show that 
the binding pocket of the antibody can accommodate a variety of residues at position 7, and is 
relatively independent of functional sidechains since substitution by methylated Lys, 
norleucine and norvaline gave the best results in that order. The binding pocket does, 
however, show selectivity with respect to sidechain orientation (as demonstrated by D-Lys) as 
well as size: diamino propionic acid (dap) with its shorter sidechain loses all reactivity with 
the antibody while the simple addition of one methyl as in norvaline reverses that effect. 
These data showed that an increase in stability is possible but the conservation of antigenicity 
is much more delicate. Overall, our results show that substitutions of Lys7 with methylated 
Lys are interesting since they manage to tread the thin line between not fitting into the 
peptidase active site and yet preserving good interaction with the antibody paratope. 
 
An additional point of interest was the N-terminal linker Lys-Gly, which increased the 
probability of a correct N-terminal coupling to the carrier by adding an additional N-terminal 
amine group and thus reducing peptide coupling via Lys (7 and 9) in the binding motif. This 
additional Lys, however, increased the susceptibility towards exopeptidases in vitro and 
possibly endopeptidases in vivo after coupling to the carrier. Branched peptides in which Lys 
sidechain amine groups were used to couple additional amino acids, were more stable than the 
wt-HNE-peptide but exhibited reduced antigenicity. We hypothesise that the substantial 
increase in size of the linkerarm can sterically hinder the accessibility of the antibody or 
influence the coating efficacy during ELISA. Similar problems were observed with other N-
terminal substitutions or deletions. A possible approach in further tests could be to use biotin 
for N-terminal coating of the peptide in the streptavidin-ELISA system. In the case of 
branched peptides this may in fact strengthen binding compared to wt-HNE-peptide as a result 
of the increased number of N-terminal amine groups. Despite these problems with the current 
experimental setup, dap proved useful as N-terminal Lys replacement since it conserved 
antigenicity and increased peptide stability. 
 
Biostability analysis of a number of stabilised peptides in murine intestinal juice gave results 
that were comparable to those in murine serum. All peptides tested were more stable than the 
wt-HNE-peptide in both serum and intestinal juice. The increased stability of peptides used in 
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the second immunisation following further modification, was also confirmed by the latter. 
Surprisingly peptide 2787 with a dap substitution of N-terminal Lys was significantly more 
stable in intestinal juice than in serum. The reasons for this observation are still under 
investigation. This may be explained by differences in exopeptidase activity in serum and 
intestinal juice. The observation that the stability of peptide 2787 was increased by 8 fold in 
intestinal juice yet did not lead to a similar increase in anti-peptide titres would support this 
hypothesis. Even after only 2 injections with the TT-2787 conjugate there was no significant 
increase in anti-peptide antibody titres compared to other less stable peptides (data not 
shown). Further testing in vitro and in vivo of wt-HNE-peptide with a dap substitution, would 
provide more information on the exact effect of this substitution. 
 
4. Immunogenicity 
During the course of this work we have iteratively combined various peptide modifications 
that increase the stability against the peptide without losing the antigenicity of the parent wt-
HNE-peptide. The antigenicity, based on the interaction with the anti-HNE mAbs, specifically 
BH216, is an interesting tool to determine the effects of substitutions and modifications on 
peptide structure. Antigenicity, the capacity of a molecule to be recognised by antibodies, is 
however only a first step on the road to immunogenic peptide-based vaccines. 
Immunogenicity, the capacity of an antigen to induce an immune response, and specifically 
crossreactive immunogenicity, i.e. the reactivity with the protein from which the peptide is 
derived, are further critical properties. Here we investigated whether modified peptides induce 
antibodies that crossreact with the parent wt-HNE-peptide and with the native H-protein. 
 
Most peptides tested in vivo induced antibodies levels against the homologous peptide that 
were comparable with the wt-HNE-peptide, showing that in most cases the conserved 
antigenicity correlates with immunogenicity. Only peptides with di- and tri-methylated Lys in 
position 7, gave slightly lower titres compared to the two peptides with the natural Lys. We 
suspect that while these peptides bound anti-HNE antibodies to a high degree by induced fit, 
their largely modified sidechains may slightly reduce immunogenicity. The considerable 
increases in stability that were achieved with our modifications did, however, not induce an 
increase in antibody titres compared to the wt-HNE-peptide. Peptide 2787 was as stable in 
serum as other peptides, but in murine intestinal juice the peptide showed a significant 
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increase in stability. It was the only modified peptide with such a discrepancy between serum 
and intestinal juice. This peptide showed a slight increase in anti-peptide antibody titres 
compared to wt-HNE-peptide, but to a lesser extent than the increase in stability in intestinal 
fluid (8 fold). 
While the levels of anti-peptide antibodies are similar between the different peptide-
conjugates, the extent of crossreactivity is much more variable. In the first immunisation 
experiments KGQQACKGAIQALCENPEWa (2743) conjugated to TT induced higher levels 
of antibodies crossreacting with the wt-HNE-peptide than the other peptide-conjugates. 
Crossreactivity with the recombinant H-protein or H-protein expressed on the cell surface of 
Mel-JuSo-H cells was on the other hand more similar to the other peptide-conjugates. 
Putz found that antibodies induced against full length HNE-peptides predominantly 
recognised the C-terminal PEWA residues (Putz 2004). We have shown that conjugates with 
peptides KGQQAC(KMe3)GAIQALCENPEWa (2805) and KGQQAC(KMe3)GAIQALCEN 
(2809), which differ only by their C-terminal extension, induce similar levels of anti-peptide 
antibodies, but KGQQAC(KMe3)GAIQALCEN (2809) has a significantly higher 
crossreactivity with wt-HNE-peptide. This finding confirms that the majority of antibodies 
induced against the former peptide targeted the C-terminus and little or none targeted the core 
epitope. Based on additional C-terminal extensions we further suggest that any addition to the 
C-terminus after C14E15N16 is more immunogenic than the epitope core (i.e. the antibody 
binding motif). Peptides KGQQAC(KMe3)GAIQALCENa (2807) and 
KGQQAC(KMe2)GAIQALCENa (2784) induced similar levels of anti-peptide antibodies 
than their homologues without the C-terminal D-Ala residue KGQQAC(KMe3)GAIQALCEN 
(2809) and KGQQAC(KMe2)GAIQALCEN (2791). Crossreactivity with wt-HNE-peptide on 
the other hand shows that the peptides with an unmodified C-terminus induced more 
antibodies against the epitope core of the wt-HNE-peptide than the C-terminally modified 
peptides. There is an apparent contradiction with peptide 2809 with an unmodified C-terminus 
and 2787 with a D-Ala C-terminus: Immunisation with 2809 induced antibodies that 
crossreacted to a lesser degree with wt-HNE-peptide when combined with several adjuvants, 
than those induced against 2787. However we speculate that the increased complexity of the 
epitope core of 2809 with a tri-methylated Lys at position 7 and a Lys9Ala substitution leads 
to a structure that differs too much from that of the the wt-HNE-peptide and peptide 2787, 
which has only a Lys9Ala substitution in the antibody binding domain. Hence peptide 2787 
could induce higher levels of crossreactive antibodies despite the immunodominant C-
terminus.  
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A rapidly advancing field of vaccinology is the development of adjuvants since currently only 
few adjuvants (e.g. aluminium hydroxide) are licensed for human use. Here we have assessed 
the immunopotentiating efficacy of three different adjuvants: Montanide, Alum and Quil-A 
compared to Freund adjuvant. Due to its toxicity and side-effects Freund adjuvant is not 
allowed for human use and the use in animals is under scrutiny. After intraperitoneal injection 
with Freund adjuvants (complete and incomplete), mice showed signs of abdominal 
discomfort such as arched back and fluffy fur. No such side-effects were observed with any 
other tested adjuvant. Montanide induced lower levels of anti-peptide antibody titres, but 
levels of crossreactive antibody titres were similar to those induced by Freund adjuvant. Thus 
we can only partially confirm the results obtained by other groups which found Montanide 
equally effective as Freund adjuvant both for peptides and proteins (Martinez et al. 1996; 
Halassy et al. 2006). Nevertheless thanks to the absence of major side-effects Montanide 
remains an interesting alternative to Freund adjuvant, if an oil-based adjuvant with Th1 
dominated Th response is desired.  
In our tests Alum adjuvant was the most promising adjuvant. In addition to the absence of 
visual side-effects and discomfort on mice, Alum was the only adjuvant to induce wt-HNE-
peptide crossreactive antibody levels when formulated with TT-2809, and these were 
comparable to those of TT-2787. The use of Alum adjuvant is however not straightforward: 
The reproducibility of antigen absorption onto aluminium hydroxide gel and desorption later 
on, remain issues that can significantly affect in vivo results (O'Hagen 2000). Alum adjuvants 
can be injected subcutaneously (s.c.), intraperitoneally (i.p.) and intramuscularly (i.m.) and 
predominantly induce a Th2 biased Th response, which makes them particularly useful in 
peptide-vaccines where only an antibody response is required.  
Quil-A, a saponin based adjuvant, is also commonly used in ISCOMS (immunostimmulating 
complexes) inducing mainly Th1 immune responses. In our hands Quil-A reacted equally well 
as Alum and Freund’s adjuvant. The low titre of crossreactive antibody observed when used 
in combination with TT-2809 is more likely related to the general tendency of TT-2809 to 
give lower responses and not due to the efficacy of Quil-A, as demonstrated by the levels 
induced by Freund and Montanide. Compared to the other adjuvants, Quil-A is easy to use: a 
solution of Quil-A is simply mixed to the antigen and injected. There are however limitations 
with regard to injection sites and methods. Quil-A is recommended for s.c. injections since i.p 
injections induce chemical peritonitis and fibrous adherences between various organs in the 
body cavity. (Dr. Erik B. Lindblad; personal communication), although use of Quil-A in i.p. 
(Lee et al. 2007) and i.m. (Jackson and Opdebeeck 1995) has been reported. We have 
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observed only slight skin irritation after s.c. injection of 25 µg of Quil-A into the scruff of the 
neck. These side-effects may be even lower when purified varieties of saponin derived 
adjuvants such as QS-21 are used (Powell and Newman 1995; O'Hagen 2000). 
 
5. Fine-specificities of binding of HNE mAbs 
Throughout this work we have shown that anti-HNE monoclonal antibodies BH216, BH21 
and BH6, produced by distinct hybridomas (Ziegler et al. 1996), exhibit different fine-
specificities towards modified HNE-peptides. Our and previous experiments have confirmed 
that the three mAb bind to the HNE-epitope only when C386 and C394 form a disulfide 
bridge. BH6 is less stringent with respect to the oxidation of the disulfide bond and shows 
some reactivity with the reduced peptide while BH216 and BH21 do not. The Cys substituted 
peptides also showed that BH6 preferentially binds shortened HNE-peptide 
(KGQQACKGKIQALCEN) rather than full length HNE-peptide (ETBFQQACKGKIQA-
LCENPEWA). 
Analysis of the peptide coupling efficiency to tetanus toxoid carrier lead to the clustering of 
peptides-conjugates into two distinct groups, when these conjugates were tested with BH216: 
Peptide-conjugates TT-2807, TT-2784 and TT-2787, with a C-terminal D-Ala reacted three 
times stronger than peptides with the “PEWa” extension or no extension. In contrast BH6 
bound equally well to all peptide-conjugates irrespective of the different C-terminal 
modifications. It is therefore unlikely that the differences in binding observed for BH216 are 
caused by differences in the coupling efficiency to the carrier protein. The preference of 
BH216 for peptides with a C-terminus extended by a single amino acid was also observed for 
unconjugated modified HNE-peptides during the antigenicity tests, irrespective of the 
additional amino acid. 
We conclude that (i) BH6 is less stringent with respect to oxidation of the peptide, (ii) 
preferentially binds to shorter HNE-peptides and (iii) is essentially insensitive to C-terminal 
extensions. BH216 and BH21 on the other hand have a preference for the oxidised HNE-
peptides. The amino acid sequence data by Dr Fred Fack (unpublished results) further 
substantiate these findings. Sequence alignments of the complementarity determining regions 
(CDR) of the heavy chains of BH216, BH21 and BH6 to a germ-line sequence showed that 
BH216 and BH21 cluster differently than BH6 (Figure 60A). BH6 shows several mutations 
compared to BH216 and BH21 in CDR H2 and H3 as well as frameworks regions 2 and 3. 
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The alignment of the amino acid sequence of the kappa light chains with a germ-line sequence 
indicated that BH216 and BH6 clustered together (Figure 60B). But most of the substitutions 
in the kappa light chains were conservative replacements, where amino acids were substituted 
with residues of similar structure or property (polarity, basicity, acidity). A structure of the 
BH216 heavy and kappa light chains based on homology modelling with an anti-influenza H-
protein antibody shows that some of these mutations are solvent exposed and may play a role 
in epitope binding (data not shown). It is unclear what influence the framework region 
mutations may have on this binding. 
 
In the context of a collaboration with Prof Yanagi (Department of Virology, Faculty of 
Medicine, Kyushu University, Japan), work is currently underway to crystallise and 
structurally resolve the BH216 antibody/H-protein complex. This will shed more light on the 
antibody paratope and the residues interacting with the HNE-epitope of H-protein. The X-ray 
structure will also be important in determining the effects of the mutations observed in the 
heavy chains of BH6 and the consequences these may have on the antibody binding fine 
specificity.  
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Figure 60: Amino acid sequence alignment of heavy and light chains of three anti-HNE antibodies with 
germ-line sequences 
Amino acid sequences of heavy (A) and kappa light chains (B) of BH216, BH21 and BH6 aligned with germ-
line sequences. Conserved residues are marked with a dot, deletions with a hyphen. Framework regions are 
labelled as FR, heavy and light region CDRs are marked as H and L. (Figure adapted from and with kind 
authorisation by Dr. Fred Fack) 
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6. Bile-acid peptide scaffold 
In fulfilment of her PhD thesis Cathy Bodé (University of Ghent) synthesised a backbone 
cyclised peptide and a scaffold-peptide construct, incorporating the HNE sequence 
QACKGKIQALCEN with a C-terminal Gly spacer. Biological testing of these constructs 
confirmed their antigenicity with respect to the three anti-HNE mAbs. We could again show 
the differences in fine-specificities between BH6 on one hand and BH216 and BH21 on the 
other hand, with BH6 being less selective. The antibody binding profiles showed that the 
scaffold-peptide construct mimics the structure of the HNE more closely than the same 
peptide after end to tail cyclisation. 
The biostability data of the cyclic and scaffold-peptide construct suggest that both scaffold 
and the backbone cyclisation increased the peptide stability in vitro compared to the oxidised 
wt-HNE-peptide (KGQQACKGKIQALCEN). This is in line with the results from various 
groups showing that cyclised peptides are more resistant to proteolytic degradation than linear 
peptides (Clark et al. 2005; Tugyi et al. 2005a). The stability of these constructs however was 
not higher than the stability observed using our internal and terminal substitution strategies. 
This also confirms our previous results that blocking exopeptidases alone does not prevent 
peptide degradation to the same extent as by preventing endopeptidase attack by substitution 
of susceptible residues in the peptide core. 
In immunisation assays these peptides induced high levels of anti-peptide antibodies. 
Antibodies raised against the scaffold-peptide construct reacted only weakly with the cyclic 
peptide. It is not yet clear if the majority of anti-scaffold-peptide construct antibodies targeted 
mainly the scaffold-peptide interface instead of the core epitope, or whether the structural 
differences between the two peptides is too important. Antibodies induced against both cyclic 
control peptide and scaffold-peptide construct did not crossreact with the H-protein. We 
hypothesise that both peptides adopt conformations that can still bind the monoclonal 
antibodies by induced fit, but that are too distant from the natural conformation to induce 
crossreactive antibodies. 
 
It may be possible to improve the structure of these peptides by varying the length of the 
scaffold-bound peptide, or by reducing the disulfide bridge, giving the peptide more 
conformational freedom to adopt an energetically more favourable structure (Bodé 2007). 
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7. Concluding remarks and perspectives 
In this study we analysed the relationship between stability, antigenicity and immunogenicity 
of modified HNE-peptides and provided new information on the structural requirements of 
the HNE-epitope for antibody binding. The data obtained from our NMR structures guided 
our strategy to further improve peptide stability and to understand antibody binding in the 
antigenicity studies. We show that Lys387 plays a crucial role in this regard. 
Our study is one of only few that analysed the substitution by D-amino acids in flanking 
regions of epitope cores (Tugyi et al. 2005b; Manea et al. 2008). Our efforts to stabilise 
peptides based on a rational iterative approach and the NMR structures of HNE-peptides, 
have lead to the synthesis of several peptides with significantly increased stability without 
loss of antigenicity. These peptides induced strong antibody titres, showing that they also 
retained immunogenicity. The failure of these antibodies to strongly crossreact with the 
natural MV-H-protein confirms that antigenicity does not guarantee crossreactive 
immunogenicity. It is important to recognise that there may be large discrepancies between 
antigenicity and immunogenicity. Increased stability against degradation by peptidases was 
achieved by modifying amino acid sidechains. Alternatively a steroidal scaffold-system 
blocked degradation by exopeptidases. By restricting peptide flexibility, the scaffold limited 
the number of possible conformations that are presented during the immunisation process to 
the cell surface immunoglobulins of B cells. The preferred peptide conformations resulting 
from these modifications were still antigenic and bound the antibody via induced fit. They 
may however not be the conformations that are closest to the native protein structure, thus 
reducing crossreactive immunogenicity. Earlier studies in our laboratory demonstrated that 
some antigenic peptides failed to induce crossreactive antibodies, whereas some peptides 
which lacked antigenicity even induced neutralising antibodies (El Kasmi et al. 1999a). But 
the successful protection against FMDV and canine parvovirus of swine and dogs, 
respectively, using peptide-based vaccines demonstrated the feasibility of vaccination with 
peptides (Langeveld et al. 1994; Wang et al. 2002). 
An important question throughout this study was to what extent the wt-HNE-peptide could be 
further stabilised by chemical and conformational approaches, before crossreactive 
immunogenicity started to decrease. Especially a shorter peptide is less likely to accommodate 
amino acid substitutions without a change in its structure. In principle, most increases in 
biostability were penalised by changes in peptide structure and thus a reduction of 
crossreactive immunogenicity. We conclude that stability against degradation may not be the 
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most important factor in peptide-based vaccines and that the correct conformation of a peptide 
compensates to some extent the lower stability. 
The knowledge obtained from the peptide modifications and the NMR structures provide a 
blueprint for a more focused approach to modifying and coupling of the peptide to the 
steroidal scaffold. It would be possible that moderate internal modifications such as a 
Lys9Ala substitution can increase the biological stability of the scaffold-bound HNE-peptide. 
Changing the spacer amino acid residues to better conserve the loop structure of the peptide 
would be another step to improve the structure within the scaffold-system. A combination of 
the two approaches could create a construct with a more stable and yet structurally conserved 
peptide, able to induce a stronger crossreactive immune response. 
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1. Table of non-natural amino acids 
single letter 
code 
common 
abbreviation full name structure 
K* K(Me)2 di-methylated lysine 
N
H
O
O
N
CH3
CH3
R''
R'
 
K K(Me)3 tri-methylated lysine 
N
H
O
O
N
CH3
CH3
CH3
R''
R'
 
L* Nle norleucine 
N
H
O
CH3
O
R''
R'
 
V* Nva norvaline 
N
H
O
CH3
O
R''
R'
 
D* dap diamino propionic acid 
N
H
O
O
NH2
R''
R'
 
 β-Ala β-alanine N
H
NH2
O
R'
 
 pamba 4-(aminomethyl)benzoic acid 
N
H
NH2
O
R'
 
 t-amcha trans-4-(aminomethyl)cyclohexane carboxylic acid N
H
NH2
O
R'
 
 gaba γ-aminobutyric acid NH
NH2
O
R'  
 achca 1-amino-cyclohexane carboxylic acid 
N
H
O
NH2R'
 
B aib α-aminoisobutyric acid NH2
O
CH3CH3
N
H
R'
 
 cha β-cyclohexyl-L-alanine 
O
NH2
N
H
R'
 
+ 
R’ = N-terminal peptide sequence extension 
R’’ = C-terminal peptide sequence extension 
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2. Table of synthesised peptides 
code C-terminally extended peptides    
     
2711 KGQQACKGKIQALCENlv  2721 KGQQACKGKIQALCENPEWA 
2712 KGQQACKGKIQALCENfa  2722 KGQQACKGKIQALCENPEWa 
2715 KGQQACKGKIQALCENv  2723 KGQQACKGKIQALCENva 
2716 KGQQACKGKIQALCEN(achca)  2724 KGQQACKGKIQALCENa 
2717 KGQQACKGKIQALCEN(t-amcha)  2725 KGQQACKGKIQALCENf 
2718 KGQQACKGKIQALCEN(aib)  2726 KGQQACKGKIQALCEN     wt-HNE 
2720 KGQQACKGKIQALCENPEWAa    
     
code internally and N-terminally modified peptides  
     
2729 G4K2KGQQACKGKIQALCEN  2735 KGQQACKGNIQALCEN 
2730 NH2-G4K2KGQQACKGKIQALCEN  2736 KGQQACKGSIQALCEN 
2731 G2KGQQACKGKIQALCEN  2737 KGQQACKGHIQALCEN 
2732 NH2-G2KGQQACKGKIQALCEN  2738 KGQQACKGQIQALCEN 
2733 kGQQACKGKIQALCEN  2739    GQQACKGKIQALCEN 
2734 KGQQACKGAIQALCEN  2726 KGQQACKGKIQALCEN     wt-HNE 
     
code internally and C-terminally modified peptides  
  
2740 KGQQACKGAIQALCENPEWAa  2748 KGQQACRGAIQALCEN 
2741 KGQQACKGAIQALCENPEWa  2749 KGQQACkGKIQALCEN 
2742 KGQQACKGAIQALCENva  2750 KGQQACkGAIQALCEN 
2743 KGQQACKGAIQALCENaa  2751 KGQQACKGAIQALCEN 
2744 KGQQACKGAIQALCENv  2752 KGQQACKGKIQALCEN    wt-HNE 
2745 KGQQACKGAIQALCENa  2753    GQQACKGAIQALCEN 
2747 KGQQACRGKIQALCEN    
     
code Further improved internally and C-terminally modified peptides 
     
2775 KGQQACL*GAIQALCENPEWa  2794 D*GQQACKGAIQALCEN 
2776 KGQQACV*GAIQALCENPEWa  2795 KGQQACLGAIQALCEN 
2777 KGQQACK*GAIQALCENPEWa  2796 KGQQACL*GKIQALCEN 
2780 D*GQQACKGAIQALCENPEWa  2797 KGQQACV*GKIQALCEN 
2781 KGQQACLGAIQALCENPEWa  2798 KGQQACK*GKIQALCEN 
2782 KGQQACL*GAIQALCENa  2801 D*GQQACKGKIQALCEN 
2783 KGQQACV*GAIQALCENa  2802 KGQQACLGKIQALCEN 
2784 KGQQACK*GAIQALCENa  2805 KGQQACKGAIQALCENPEWa 
2787 D*GQQACKGAIQALCENa  2807 KGQQACKGAIQALCENa 
2788 KGQQACLGAIQALCENa  2809 KGQQACKGAIQALCEN 
2789 KGQQACL*GAIQALCEN  2811 KGQQACKGKIQALCEN 
2790 KGQQACV*GAIQALCEN  2833 KGQQACKGKIQALCEN     wt-HNE
2791 KGQQACK*GAIQALCEN    
L* = Nle, V* = Nva, D* = dap, K* = di-methylated Lys, K = tri-methylated Lys. 
Changes compared to wt-HNE-peptide sequence are marked red. Peptides used for immunisations are 
highlighted yellow. 
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